

Scientific and Technical Information Center

Requester's Full Name: Dwayne C. Jones Examiner #: 71244 Date: 23 APR 03
 Art Unit: 1614 Phone Number 30 8-1604 Serial Number: 101076197
 Mail Box and Bldg/Room Location: 2007, CM1 Results Format Preferred (circle): PAPER DISK E-MAIL
2003, CM1 2

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: see attached sheet

Inventors (please provide full names): 11

Earliest Priority Filing Date: 15 FEB 2001

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Please search claims 1 and 4
 also cross these compounds
 w/ ~~methods~~ methods of
 treating - Neuropathic pain (claim 1)
 - Bladder Irritation (claim 2)
 - Overactive Bladder (claim 3)

Point of Contact:
 Barb O'Brien
 Technical Information Specialist
 STIC CM1 6A05 308-4291

STAFF USE ONLY

STAFF USE ONLY	Type of Search	Vendors and cost where applicable
Searcher: <u>BDB</u>	NA Sequence (#) _____	STN <u>400</u>
Searcher Phone #: _____	AA Sequence (#) _____	Dialog _____
Searcher Location: _____	Structure (#) <u>1</u>	Questel/Orbit _____
Date Searcher Picked Up: _____	Bibliographic _____	Dr. Link _____
Date Completed: <u>5-6-03</u>	Litigation _____	Lexis/Nexis _____
Searcher Prep & Review Time: <u>45</u>	Fulltext _____	Sequence Systems _____

This Page Blank (uspto)

=> fil reg; d stat que 13; fil capl; d que nos 14; fil uspatfu; d que nos 17
FILE 'REGISTRY' ENTERED AT 10:33:08 ON 06 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 5 MAY 2003 HIGHEST RN 510776-00-8
DICTIONARY FILE UPDATES: 5 MAY 2003 HIGHEST RN 510776-00-8


TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
PROPERTIES for more information. See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

L1 STR



VAR G1=12/13/14
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE
L3 225 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED 898 ITERATIONS
SEARCH TIME: 00.00.01

(225 ANSWERS)

FILE 'CAPLUS' ENTERED AT 10:33:08 ON 06 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is

Searched by Barb O'Bryen, STIC 308-4291

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 May 2003 VOL 138 ISS 19
FILE LAST UPDATED: 5 May 2003 (20030505/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

L1 STR
L3 225 SEA FILE=REGISTRY SSS FUL L1
L4 43 SEA FILE=CAPLUS ABB=ON L3

FILE 'USPATFULL' ENTERED AT 10:33:08 ON 06 MAY 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 6 May 2003 (20030506/PD)
FILE LAST UPDATED: 6 May 2003 (20030506/ED)
HIGHEST GRANTED PATENT NUMBER: US6560778
HIGHEST APPLICATION PUBLICATION NUMBER: US2003084495
CA INDEXING IS CURRENT THROUGH 6 May 2003 (20030506/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 6 May 2003 (20030506/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2003
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2003

>>> USPAT2 is now available. USPATFULL contains full text of the <<<
>>> original, i.e., the earliest published granted patents or <<<
>>> applications. USPAT2 contains full text of the latest US <<<
>>> publications, starting in 2001, for the inventions covered in <<<
>>> USPATFULL. A USPATFULL record contains not only the original <<<
>>> published document but also a list of any subsequent <<<
>>> publications. The publication number, patent kind code, and <<<
>>> publication date for all the US publications for an invention <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<
>>> enter this cluster. <<<
>>> <<<
>>> Use USPATALL when searching terms such as patent assignees, <<<
>>> classifications, or claims, that may potentially change from <<<
>>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate substance identification.

L1 STR
L3 225 SEA FILE=REGISTRY SSS FUL L1
L4 15 SEA FILE=USPATFULL ABB=ON L3

=> dup rem 14,17

FILE 'CAPLUS' ENTERED AT 10:33:11 ON 06 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 10:33:11 ON 06 MAY 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
PROCESSING COMPLETED FOR L4
PROCESSING COMPLETED FOR L7


L9 51 DUP REM L4 L7 (7 DUPLICATES REMOVED)
ANSWERS '1-42' FROM FILE CAPLUS
ANSWERS '43-51' FROM FILE USPATFULL

=> d ibib abs hitstr 1-51; fil cao; d que nos 18; fil hom

L9 ANSWER 1 OF 51 CAPLUS COPYRIGHT 2003 ACS DUPLICATE 1
ACCESSION NUMBER: 2000:548722 CAPLUS
DOCUMENT NUMBER: 133:150459
TITLE: Preparation of isatin derivatives as
acetylcholinesterase inhibitors and analgesics
INVENTOR(S): Shimshock, Stephen J.; Chesson, Susan M.; Mutlib,
Abdul E.
PATENT ASSIGNEE(S): Aventis Pharmaceuticals Inc., USA
SOURCE: U.S., 5 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6100276	A	20000808	US 1997-806012	19970224
PRIORITY APPLN. INFO.:			US 1996-112005P	P 19960412
OTHER SOURCE(S):		MARPAT 133:150459		

GI




AB The title compds. [I; R = H, alkyl, hydroxyalkyl; X = H, OH, alkoxy, etc.; Y = H, halo], useful for the treatment of memory dysfunction characterized by decreased cholinergic function, and for analgesia, were prepd. Thus, treatment of N-propyl-N-(pyridin-4-yl)-N-1H-indolyl-1-amine with thallium(III) nitrate trihydrate in MeOH afforded I [R = Pr; X, Y = H]. Compds. I are effective as analgesics at 10-50 mg/kg/day.


IT 119257-33-9 119257-34-0
RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of isatin derivs. as acetylcholinesterase inhibitors and analgesics)

RN 119257-33-9 CAPLUS
CN 1H-Indol-1-amine, N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119257-34-0 CAPLUS
CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)





REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 51 CAPLUS COPYRIGHT 2003 ACS DUPLICATE 2
ACCESSION NUMBER: 1998:471468 CAPLUS
DOCUMENT NUMBER: 129:122574
TITLE: Preparation of (un)substituted N-(pyrrol-1-yl)pyridinamines as anticonvulsants
INVENTOR(S): Huger, Francis Parker; Smith, Craig Paul; Kongsamut, Sathapana; Tang, Lei
PATENT ASSIGNEE(S): Hoechst Marion Roussel, Inc., USA
SOURCE: U.S., 28 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US-5776955	A	19980707	US 1996-676608	19960708
			US 1996-676608	19960708

PRIORITY APPLN. INFO.: MARPAT 129:122574
OTHER SOURCE(S):
GI



AB The title compds. [I; R = H, C1-6 alkyl, C2-6 alkenyl, etc.; R1, R2 = H, halo, C1-6 alkyl; R1R2 together with the carbons to which they are attached form (un)substituted benzene ring fused to the pyrrole ring; R3 = H, halo, C1-6 alkyl; R4 = H, halo, NH2, C1-6 alkyl; n = 0-1], useful in treating a patient in need of relief from convulsions, were prepd. Thus, reaction of 1H-indol-1-amine with 3,4-dichloropyridine.HCl in iPrOH afforded II.HCl which showed IC50 of 14 .mu.M against [3H]batrachotoxin binding.


IT 119229-38-8P 119229-43-5P 119229-46-8P
 119229-50-4P 119229-57-1P 119229-58-2P
 119257-32-8P 119257-33-9P 119257-38-4P
 119257-43-1P 145660-10-2P 159732-16-8P
 159732-18-0P 173341-09-8P 173677-77-5P
 188028-92-4P 188028-98-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of (un)substituted N-(pyrrol-1-yl)pyridinamines as anticonvulsants)


RN 119229-38-8 CAPLUS

CN 1H-Indole-3-carboxaldehyde, 1-(methyl-4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 119229-43-5 CAPLUS


CN 1H-Indol-1-amine, 3-ethenyl-N-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119229-46-8 CAPLUS
CN 1H-Indol-1-amine, 5-chloro-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119229-50-4 CAPLUS
CN 1H-Indol-1-amine, 5-bromo-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119229-57-1 CAPLUS
CN 1H-Indol-1-amine, 5-nitro-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119229-58-2 CAPLUS

CN 1H-Indol-1-amine, N-methyl-5-nitro-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119257-32-8 CAPLUS

CN 1H-Indol-1-amine, N-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119257-33-9 CAPLUS


CN 1H-Indol-1-amine, N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119257-38-4 CAPLUS
CN 1H-Indol-1-amine, N-ethyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119257-43-1 CAPLUS
CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 145660-10-2 CAPLUS
CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 159732-16-8 CAPLUS
CN 1H-Indole-3-carboxaldehyde, 1-(propyl-4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 159732-18-0 CAPLUS
CN 1H-Indol-1-amine, 3-ethenyl-N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 173341-09-8 CAPLUS
CN 1H-Indol-1-amine, 3-chloro-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 173677-77-5 CAPLUS
CN 1H-Indole-3-carboxaldehyde, 1-(propyl-4-pyridinylamino)-, oxime (9CI) (CA
INDEX NAME)



RN 188028-92-4 CAPLUS
CN 1H-Indole-3-acetonitrile, 1-(4-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 188028-98-0 CAPLUS
CN 1H-Indol-1-amine, N-(5-chloro-3-pyridinyl)- (9CI) (CA INDEX NAME)




IT 119229-37-7P 119229-39-9P 119229-40-2P
119229-41-3P 119229-44-6P 119229-45-7P
119229-47-9P 119229-48-0P 119229-49-1P
119229-51-5P 119229-52-6P 119229-53-7P
119229-54-8P 119229-55-9P 119229-56-0P
119229-59-3P 119229-60-6P 119229-61-7P
119229-62-8P 119229-63-9P 119229-64-0P
119229-65-1P 119229-68-4P 119229-69-5P
119257-34-0P 119257-35-1P 119257-36-2P
119257-37-3P 119257-39-5P 119257-40-8P
119257-41-9P 141287-61-8P 141287-62-9P
141287-65-2P 141287-68-5P 141287-69-6P
141287-72-1P 159732-08-8P 159732-09-9P
159732-10-2P 159732-11-3P 159732-12-4P
159732-13-5P 159732-14-6P 159732-15-7P
159732-17-9P 159732-19-1P 159732-20-4P
159732-21-5P 159732-22-6P 159732-23-7P
159732-24-8P 159732-25-9P 159732-26-0P
159732-27-1P 159732-28-2P 159732-29-3P
159732-30-6P 159732-31-7P 159732-32-8P
159732-33-9P 159732-34-0P 159732-35-1P
159732-36-2P 159732-37-3P 159732-38-4P
159732-39-5P 159732-40-8P 159732-41-9P
159732-42-0P 159732-43-1P 159732-44-2P

173341-10-1P 173341-11-2P 173341-12-3P
188028-65-1P 188028-69-5P 188028-74-2P
188028-77-5P 188028-84-4P 188028-89-9P
188028-95-7P 188029-00-7P 188029-02-9P
188029-52-9P 188029-56-3P 210237-01-7P
210237-02-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of (un)substituted N-(pyrrol-1-yl)pyridinamines as anticonvulsants)

RN 119229-37-7 CAPLUS

CN 1H-Indol-1-amine, 5-methoxy-N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119229-39-9 CAPLUS

CN 1H-Indole-3-carboxaldehyde, 1-(methyl-4-pyridinylamino)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119229-38-8

CMF C15 H13 N3 O




CM 2


CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 119229-40-2 CAPLUS
CN 1H-Indole-3-carboxaldehyde, 1-(ethyl-4-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 119229-41-3 CAPLUS
CN 1H-Indole-3-carboxaldehyde, 1-(ethyl-4-pyridinylamino)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 119229-40-2
CMF C16 H15 N3 O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.




RN 119229-44-6 CAPLUS
CN 1H-Indol-1-amine, 3-ethenyl-N-methyl-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119229-43-5

CMF C16 H15 N3




CM 2


CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



RN 119229-45-7 CAPLUS
CN 1H-Indol-1-amine, 3-ethyl-N-methyl-N-4-pyridinyl-, monohydrochloride (9CI)
(CA INDEX NAME)




● HCl

RN 119229-47-9 CAPLUS

CN 1H-Indol-1-amine, 5-chloro-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1


CRN 119229-46-8
CMF C13 H10 Cl N3




CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.




RN 119229-48-0 CAPLUS
CN 1H-Indol-1-amine, 5-chloro-N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119229-49-1 CAPLUS
CN 1H-Indol-1-amine, 5-chloro-N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 119229-48-0
CMF C16 H16 Cl N3




CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.

RN 119229-51-5 CAPLUS
CN 1H-Indol-1-amine, 5-bromo-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)


CM 1

CRN 119229-50-4
CMF C13 H10 Br N3


CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.




RN 119229-52-6 CAPLUS
CN 1H-Indol-1-amine, 5-bromo-N-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119229-53-7 CAPLUS
CN 1H-Indol-1-amine, 5-bromo-N-methyl-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 119229-52-6
CMF C14 H12 Br N3




CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.




RN 119229-54-8 CAPLUS
CN 1H-Indol-1-amine, 5-bromo-N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119229-55-9 CAPLUS
CN 1H-Indol-1-amine, 5-bromo-N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 119229-54-8
CMF C16 H16 Br N3




CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 119229-56-0 CAPLUS
CN 1H-Indol-1-amine, 5-nitro-N-4-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 119229-59-3 CAPLUS
CN 1H-Indol-1-amine, N-methyl-5-nitro-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 119229-58-2
CMF C14 H12 N4 O2




CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.




RN 119229-60-6 CAPLUS
CN 1H-Indol-1-amine, 3-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119229-61-7 CAPLUS
CN 1H-Indol-1-amine, 3-methyl-N-4-pyridinyl-, ethanedioate (1:1) (9CI) (CA
INDEX NAME)


CM 1

CRN 119229-60-6
CMF C14 H13 N3




CM 2

CRN 144-62-7
CMF C2 H2 O4




RN 119229-62-8 CAPLUS
CN 1H-Indol-1-amine, 3-methyl-N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119229-63-9 CAPLUS
CN 1H-Indol-1-amine, 3-methyl-N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 119229-62-8
CMF C17 H19 N3




CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.




RN 119229-64-0 CAPLUS
CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl-N-propyl-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 119229-65-1 CAPLUS
CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl-N-propyl- (9CI) (CA
INDEX NAME)




RN 119229-68-4 CAPLUS
CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-N-propyl-, monohydrochloride
(9CI) (CA INDEX NAME)




● HCl

RN 119229-69-5 CAPLUS
CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-N-propyl- (9CI) (CA INDEX


NAME)



RN 119257-34-0 CAPLUS
CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119257-35-1 CAPLUS
CN 1H-Indol-1-amine, 3-ethyl-N-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119257-36-2 CAPLUS
CN 1H-Indol-1-amine, N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119257-33-9
CMF C13 H11 N3




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 119257-37-3 CAPLUS

CN 1H-Indol-1-amine, N-methyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 119257-32-8

CMF C14 H13 N3




CM 2

CRN 110-16-7

CMF C4 H4 O4


Double bond geometry as shown.



RN 119257-39-5 CAPLUS
CN 1H-Indol-1-amine, N-ethyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1


CRN 119257-38-4
CMF C15 H15 N3



CM 2

CRN 110-16-7
CMF C4 H4 O4


Double bond geometry as shown.



RN 119257-40-8 CAPLUS
CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 119257-34-0
CMF C16 H17 N3




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 119257-41-9 CAPLUS

CN 1H-Indol-1-amine, 5-methoxy-N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119229-37-7

CMF C17 H19 N3 O




CM 2


CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 141287-61-8 CAPLUS
CN 1H-Indol-5-ol, 1-[(3-fluoro-4-pyridinyl)propylamino]-, monohydrochloride
(9CI) (CA INDEX NAME)




● HCl

RN 141287-62-9 CAPLUS
CN 1H-Indol-5-ol, 1-[(3-fluoro-4-pyridinyl)propylamino]- (9CI) (CA INDEX
NAME)




RN 141287-65-2 CAPLUS
CN 1H-Indol-5-ol, 3-methyl-1-(4-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 141287-68-5 CAPLUS

CN 1H-Indol-5-ol, 3-methyl-1-(propyl-4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 141287-69-6 CAPLUS

CN 1H-Indol-5-ol, 3-methyl-1-(propyl-4-pyridinylamino)-, ethanedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 141287-68-5


CMF C17 H19 N3 O




CM 2

CRN 144-62-7


CMF C2 H2 O4




RN 141287-72-1 CAPLUS
CN 1H-Indol-5-ol, 1-[(3-fluoro-4-pyridinyl)propylamino]-3-methyl- (9CI) (CA INDEX NAME)




RN 159732-08-8 CAPLUS
CN 1H-Indol-1-amine, 2-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 159732-09-9 CAPLUS
CN 1H-Indol-1-amine, N-(3-methyl-4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 159732-10-2 CAPLUS
CN 1H-Indol-1-amine, N-(3-methyl-4-pyridinyl)-N-propyl- (9CI) (CA INDEX NAME)



RN 159732-11-3 CAPLUS
CN 1H-Indol-1-amine, N-(3-methyl-4-pyridinyl)-N-propyl-, ethanedioate (1:1)
(9CI) (CA INDEX NAME)


CM 1

CRN 159732-10-2
CMF C17 H19 N3




CM 2

CRN 144-62-7
CMF C2 H2 O4




RN 159732-12-4 CAPLUS
CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-, monohydrochloride (9CI) (CA
INDEX NAME)




● HCl

RN 159732-13-5 CAPLUS
CN 1H-Indol-1-amine, N-(3-chloro-4-pyridinyl)-, monohydrochloride (9CI) (CA
INDEX NAME)




● HCl

RN 159732-14-6 CAPLUS
CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-2-methyl-, (9CI) (CA INDEX
NAME)



RN 159732-15-7 CAPLUS
CN 1H-Indol-1-amine, N-(3-chloro-4-pyridinyl)-3-methyl-, monohydrochloride
(9CI) (CA INDEX NAME)




● HCl

RN 159732-17-9 CAPLUS
 CN 1H-Indole-3-carboxaldehyde, 1-(propyl-4-pyridinylamino)-,
 (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 159732-16-8
 CMF C17 H17 N3 O



CM 2

CRN 110-16-7
 CMF C4 H4 O4


Double bond geometry as shown.



RN 159732-19-1 CAPLUS
 CN 1H-Indol-1-amine, 3-ethenyl-N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate
 (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 159732-18-0
CMF C18 H19 N3




CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.




RN 159732-20-4 CAPLUS
CN 1H-Indol-1-amine, 3-ethyl-N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 159732-21-5 CAPLUS
CN 1H-Indol-1-amine, 3-ethyl-N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 159732-20-4
CMF C18 H21 N3




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.



RN 159732-22-6 CAPLUS

CN 1H-Indol-1-amine, N-butyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 159732-23-7 CAPLUS

CN 1H-Indol-1-amine, N-butyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 159732-22-6



CMF C17 H19 N3



CM 2


CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.

RN 159732-24-8 CAPLUS
CN 1H-Indol-1-amine, N-2-propynyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)RN 159732-25-9 CAPLUS
CN 1H-Indol-1-amine, N-2-propynyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 159732-24-8
CMF C16 H13 N3




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.



RN 159732-26-0 CAPLUS

CN 1H-Indol-1-amine, N-(2-methylpropyl)-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 159732-27-1 CAPLUS

CN 1H-Indol-1-amine, N-(2-methylpropyl)-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 159732-26-0



CMF C17 H19 N3



CM 2


CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.

RN 159732-28-2 CAPLUS
CN 1H-Indol-1-amine, N-pentyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)RN 159732-29-3 CAPLUS
CN 1H-Indol-1-amine, N-pentyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 159732-28-2
CMF C18 H21 N3




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.



RN 159732-30-6 CAPLUS

CN 1H-Indol-1-amine, N-(1-methylpropyl)-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 159732-31-7 CAPLUS

CN 1H-Indol-1-amine, N-(1-methylpropyl)-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 159732-30-6



CMF C17 H19 N3



CM 2


CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.

RN 159732-32-8 CAPLUS
CN 1H-Indol-1-amine, N-(1-methylethyl)-N-4-pyridinyl- (9CI) (CA INDEX NAME)RN 159732-33-9 CAPLUS
CN 1H-Indol-1-amine, N-(1-methylethyl)-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 159732-32-8
CMF C16 H17 N3




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.



RN 159732-34-0 CAPLUS

CN 1H-Indol-1-amine, 2-methyl-N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 159732-35-1 CAPLUS

CN 1H-Indol-1-amine, 2-methyl-N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 159732-34-0



CMF C17 H19 N3



CM 2


CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.

RN 159732-36-2 CAPLUS
CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl-N-2-propenyl-,
monohydrochloride (9CI) (CA INDEX NAME)


● HCl

RN 159732-37-3 CAPLUS
CN 1H-Indol-1-amine, N-(3-chloro-4-pyridinyl)-N-propyl-, monohydrochloride
(9CI) (CA INDEX NAME)




● HCl

RN 159732-38-4 CAPLUS
CN 1H-Indol-1-amine, N-(3-chloro-4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 159732-39-5 CAPLUS
CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-N-2-propynyl-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 159732-40-8 CAPLUS
CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl-N-2-propynyl-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 159732-41-9 CAPLUS
CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-2-methyl-N-propyl- (9CI) (CA
INDEX NAME)



RN 159732-42-0 CAPLUS
CN 1H-Indol-1-amine, N-(3-chloro-4-pyridinyl)-3-methyl-N-propyl- (9CI) (CA
INDEX NAME)




RN 159732-43-1 CAPLUS
CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-N-2-propenyl-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 159732-44-2 CAPLUS
CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-N-2-propenyl- (9CI) (CA INDEX NAME)



RN 173341-10-1 CAPLUS
CN Benzoic acid, 2-hydroxy-, compd. with 3-chloro-N-4-pyridinyl-1H-indol-1-amine (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 173341-09-8
CMF C13 H10 Cl N3




CM 2


CRN 69-72-7
CMF C7 H6 O3



RN 173341-11-2 CAPLUS
CN 1H-Indol-1-amine, 3-chloro-N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 173341-12-3 CAPLUS
CN 1H-Indol-1-amine, 3-chloro-N-propyl-N-4-pyridinyl-, monohydrochloride
(9CI) (CA INDEX NAME)




● HCl

RN 188028-65-1 CAPLUS
CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl-N-2-propenyl- (9CI)
(CA INDEX NAME)




RN 188028-69-5 CAPLUS
CN 1H-Indol-1-amine, N-(3-chloro-4-pyridinyl)-N-propyl- (9CI) (CA INDEX NAME)




RN 188028-74-2 CAPLUS

CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-N-2-propynyl- (9CI) (CA INDEX NAME)




RN 188028-77-5 CAPLUS

CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl-N-2-propynyl- (9CI) (CA INDEX NAME)




RN 188028-84-4 CAPLUS

CN 3,4-Pyridinediamine, N4-1H-indol-1-yl- (9CI) (CA INDEX NAME)




RN 188028-89-9 CAPLUS

CN 1H-Indole-3-methanamine, 1-(propyl-4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 188028-95-7 CAPLUS


CN 1H-Indole-3-ethanamine, 1-(4-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 188029-00-7 CAPLUS
CN 1H-Indol-1-amine, N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 188029-02-9 CAPLUS
CN 1H-Indol-1-amine, N-2-pyridinyl- (9CI) (CA INDEX NAME)



RN 188029-52-9 CAPLUS
CN 1H-Indole-3-carboxaldehyde, 1-(propyl-4-pyridinylamino)-, oxime,
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 173677-77-5
CMF C17 H18 N4 O




CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 188029-56-3 CAPLUS
CN 1H-Indole-3-methanamine, 1-(propyl-4-pyridinylamino)-, dihydrochloride
(9CI) (CA INDEX NAME)




● 2 HCl

RN 210237-01-7 CAPLUS
CN 1H-Indole-3-ethanamine, 1-(4-pyridinylamino)-, (2Z)-2-butenedioate (1:2)
(9CI) (CA INDEX NAME)

CM 1


CRN 188028-95-7
CMF C15 H16 N4




CM 2

CRN 110-16-7
CMF C4 H4 O4


Double bond geometry as shown.




RN 210237-02-8 CAPLUS
CN 1H-Indol-1-amine, N-(3-chloro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX
NAME)




IT 119229-75-3 141287-59-4 141287-64-1
141287-66-3 141287-71-0 188029-86-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of (un)substituted N-(pyrrol-1'-yl)pyridinamines as
anticonvulsants)
RN 119229-75-3 CAPLUS
CN 1H-Indol-1-amine, 5-methoxy-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 141287-59-4 CAPLUS
CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-5-(phenylmethoxy)-N-propyl-
(9CI) (CA INDEX NAME)



RN 141287-64-1 CAPLUS
CN 1H-Indol-1-amine, 3-methyl-5-(phenylmethoxy)-N-4-pyridinyl- (9CI) (CA
INDEX NAME)




RN 141287-66-3 CAPLUS

CN 1H-Indol-1-amine, 3-methyl-5-(phenylmethoxy)-N-propyl-N-4-pyridinyl- (9CI)
(CA INDEX NAME)


RN 141287-71-0 CAPLUS

CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl-5-(phenylmethoxy)-N-propyl- (9CI) (CA INDEX NAME)




RN 188029-86-9 CAPLUS

CN 1H-Indol-1-amine, N-(3-nitro-4-pyridinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 51 CAPLUS COPYRIGHT 2003 ACS DUPLICATE 3
ACCESSION NUMBER: 1997:484922 CAPLUS
DOCUMENT NUMBER: 127:103810
TITLE: Anti-obsessional and antidepressant profile of besipirdine
AUTHOR(S): Klein, J. T.; Turk, D. J.; Dileo, E. M.; Effland, R. C.; Huger, F. P.; Kongsamut, S.; Giovanni, A.; Szewczak, M. R.; Rush, D. K.; Martin, L. L.
CORPORATE SOURCE: Neuroscience Research, Hoechst Marion Roussel, Inc., Bridgewater, NJ, 08807-0800, USA
SOURCE: CNS Drug Reviews (1997), 3(1), 1-23
CODEN: CDREFB; ISSN: 1080-563X
PUBLISHER: Neva Press
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review with 103 refs.
IT 119257-34-0, Besipirdine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-obsessional and antidepressant profile of)
RN 119257-34-0 CAPLUS
CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



L9 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2003 ACS DUPLICATE 4
ACCESSION NUMBER: 1995:951498 CAPLUS
DOCUMENT NUMBER: 124:145914
TITLE: Preparation of N-alkyl-N-pyridinyl-1H-indol-1-amines via arylation of 1-amino-3-haloindoles with halopyridines followed by alkylation and dehalogenation
INVENTOR(S): Lee, Thomas B.; Goehring, Keith E.
PATENT ASSIGNEE(S): Hoechst-Roussel Pharmaceuticals Inc., USA
SOURCE: U.S., 7 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5459274	A	19951017	US 1994-242395	19940513
EP 683165	A2	19951122	EP 1995-106921	19950508
EP 683165	A3	19970115		

EP 683165 B1 20000802
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE
AT 195120 E 20000815 AT 1995-106921 19950508
ES 2152342 T3 20010201 ES 1995-106921 19950508
AU 9517997 A1 19951123 AU 1995-17997 19950511
AU 697090 B2 19980924
CA 2149286 AA 19951114 CA 1995-2149286 19950512
JP 07304768 A2 19951121 JP 1995-114468 19950512
US 5644062 A 19970701 US 1995-455468 19950531
US 6512125 B1 20030128 US 1995-455469 19950531
PRIORITY APPLN. INFO.: US 1994-242395 A 19940513
OTHER SOURCE(S): CASREACT 124:145914; MARPAT 124:145914
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB A process is claimed for the prepn. of memory enhancing, analgetic, and antidepressant N-alkyl-N-pyridinyl-1H-indol-1-amines I wherein R is hydrogen, loweralkyl, loweralkoxy or trifluoromethyl; R1 is hydrogen or loweralkyl; R2 is loweralkyl; R3 is hydrogen, loweralkyl, loweralkoxy or trifluoromethyl; and m is 1 or 2, which comprises the steps of: (a) reacting a compd. of the formula II wherein R, R1 and m are as above with an N-X-succinimide wherein X is bromo, chloro or iodo to provide a compd. of the formula III wherein R, R1, X and m are as above; (b) reacting the compd. obtained in step (a) with a compd. of the formula H2NOSO3H to provide a compd. of the formula IV wherein R, R1, X and m are as above; (c) reacting a compd. obtained in step (b) with a compd. of the formula V wherein R3 is as above and Y is chloro, bromo or iodo to provide a compd. of the formula VI wherein R, R1, R3, X and m are as above; (d) reacting a compd. obtained in step (c) with a compd. of the formula R2Z wherein R2 is as above and Z is bromo or chloro to provide a compd. of the formula VII wherein R, R1, R2, R3, X and m are as above; (e) reacting a compd. obtained in step (d) with formic acid in the presence of a metal catalyst; and (f) isolating the product. The following reaction sequence was provided: (a) indole + N-chlorosuccinimide .fwdarw. 3-chloroindole (92.9%); (b) 3-chloroindole + hydroxylamine-O-sulfonic acid .fwdarw. 3-chloro-1H-indol-1-amine (86%); (c) 3-chloro-1H-indol-1-amine + 4-chloropyridine.HCl .fwdarw. 3-chloro-N-4-pyridinyl-1H-indol-1-amine salicylate (48.4%); (d) 3-chloro-N-4-pyridinyl-1H-indol-1-amine salicylate + 1-bromopropane .fwdarw. 3-chloro-N-propyl-N-4-pyridinyl-1H-indol-1-amine hydrochloride (87.6%); (e) dehalogenation of 3-chloro-N-propyl-N-4-pyridinyl-1H-indol-1-amine hydrochloride with NEt3, 5% Pd/C, and formic acid to afford N-propyl-N-4-pyridinyl-1H-indol-1-amine (79.5%); (f) conversion to the HCl salt (88.6%).

IT 173341-09-8P, 3-Chloro-N-4-pyridinyl-1H-indol-1-amine
173341-10-1P 173341-11-2P, 3-Chloro-N-propyl-N-4-pyridinyl-1H-indol-1-amine 173341-12-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of N-alkyl-N-pyridinyl-1H-indol-1-amines via arylation of 1-amino-3-haloindoles with halopyridines followed by alkylation and dehalogenation).

RN 173341-09-8 CAPLUS


CN 1H-Indol-1-amine, 3-chloro-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 173341-10-1 CAPLUS
CN Benzoic acid, 2-hydroxy-, compd. with 3-chloro-N-4-pyridinyl-1H-indol-1-amine (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 173341-09-8
CMF C13 H10 Cl N3




CM 2


CRN 69-72-7
CMF C7 H6 O3



RN 173341-11-2 CAPLUS
CN 1H-Indol-1-amine, 3-chloro-N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 173341-12-3 CAPLUS
CN 1H-Indol-1-amine, 3-chloro-N-propyl-N-4-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT 119257-34-0P, N-Propyl-N-4-pyridinyl-1H-indol-1-amine


130953-69-4P

RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of N-alkyl-N-pyridinyl-1H-indol-1-amines via arylation of 1-amino-3-haloindoles with halopyridines followed by alkylation and dehalogenation)


RN 119257-34-0 CAPLUS

CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 130953-69-4 CAPLUS

CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L9 ANSWER 5 OF 51 CAPLUS COPYRIGHT 2003 ACS

DUPLICATE 5

ACCESSION NUMBER: 1995:227443 CAPLUS

DOCUMENT NUMBER: 122:23863

TITLE: Preparation and use of N-(pyridinyl)-1H-indol-1-amines for the treatment of obsessive-compulsive disorder

INVENTOR(S): Kongsamut, Sathapana; Smith, Craig P.; Woods, Ann T.


PATENT ASSIGNEE(S): Hoechst-Roussel Pharmaceuticals Inc., USA

Searched by Barb O'Bryen, STIC 308-4291

SOURCE: U.S., 12 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5356910	A	19941018	US 1993-92848	19930719
EP 635269	A1	19950125	EP 1994-110875	19940713
EP 635269	B1	19991103		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AT 186215	E	19991115	AT 1994-110875	19940713
ES 2138017	T3	20000101	ES 1994-110875	19940713
AU 9467531	A1	19950127	AU 1994-67531	19940715
AU 673747	B2	19961121		
CA 2128312	AA	19950120	CA 1994-2128312	19940718
NO 9402695	A	19950120	NO 1994-2695	19940718
JP 07053376	A2	19950228	JP 1994-165280	19940718
JP 2807633	B2	19981008		
ZA 9405236	A	19950228	ZA 1994-5236	19940718
HU 69709	A2	19950928	HU 1994-2124	19940718
HU 217063	B	19991129		
RU 2164795	C2	20010410	RU 1994-26084	19940718
CZ 288593	B6	20010711	CZ 1994-1730	19940718
			US 1993-92848	A 19930719


PRIORITY APPLN. INFO.:
 OTHER SOURCE(S): MARPAT 122:23863
 GI



AB Method is disclosed for alleviating obsessive-compulsive disorders (OCD) which comprises administration of an effective amt. of I (m = 1, 2; R = H, halo, lower alkyl, lower alkoxy, hydroxy, nitro, etc.; R1, R2 = H, lower alkyl; R3 = H, halo, lower alkyl). Prepn. of compds. of the invention is included. The effect of N-(3-fluoro-4-pyridinyl)-N-propyl-3-methyl-1H-indol-1-amine and N-(4-pyridinyl)-N-propyl-1H-indol-1-amine-HCl on polydipsia in rats (for evaluation of serotonin reuptake inhibitors with potential efficacy in treating OCD) was detd.


IT **119229-65-1P 130953-69-4P**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of N-(pyridinyl)-1H-indol-1-amines for the treatment of obsessive-compulsive disorder)

RN 119229-65-1 CAPLUS
 CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl-N-propyl- (9CI) (CA INDEX NAME)



RN 130953-69-4 CAPLUS

CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT 119229-60-6 119257-43-1 145660-10-2

159732-08-8 159732-16-8 159732-18-0


159732-38-4

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of N-(pyridinyl)-1H-indol-1-amines for the treatment of
obsessive-compulsive disorder)


RN 119229-60-6 CAPLUS

CN 1H-Indol-1-amine, 3-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119257-43-1 CAPLUS


CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 145660-10-2 CAPLUS
CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 159732-08-8 CAPLUS
CN 1H-Indol-1-amine, 2-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 159732-16-8 CAPLUS
CN 1H-Indole-3-carboxaldehyde, 1-(propyl-4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 159732-18-0 CAPLUS

CN 1H-Indol-1-amine, 3-ethenyl-N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 159732-38-4 CAPLUS

CN 1H-Indol-1-amine, N-(3-chloro-4-pyridinyl)- (9CI) (CA INDEX NAME)




IT 119229-37-7P 119229-38-8P 119229-39-9P
119229-40-2P 119229-41-3P 119229-43-5P
119229-44-6P 119229-45-7P 119229-46-8P
119229-47-9P 119229-48-0P 119229-49-1P
119229-50-4P 119229-51-5P 119229-52-6P
119229-53-7P 119229-55-9P 119229-56-0P
119229-57-1P 119229-59-3P 119229-61-7P
119229-62-8P 119229-63-9P 119229-64-0P
119229-68-4P 119229-69-5P 119257-32-8P
119257-33-9P 119257-34-0P 119257-35-1P
119257-36-2P 119257-37-3P 119257-38-4P
119257-39-5P 119257-40-8P 119257-41-9P
159732-09-9P 159732-11-3P 159732-12-4P


159732-13-5P 159732-14-6P 159732-15-7P
159732-17-9P 159732-19-1P 159732-21-5P
159732-23-7P 159732-25-9P 159732-27-1P
159732-29-3P 159732-31-7P 159732-33-9P
159732-35-1P 159732-36-2P 159732-37-3P
159732-39-5P 159732-40-8P 159732-41-9P
159732-42-0P 159732-43-1P 159732-44-2P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-(pyridinyl)-1H-indol-1-amines for the treatment of obsessive-compulsive disorder)

RN 119229-37-7 CAPLUS
CN 1H-Indol-1-amine, 5-methoxy-N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119229-38-8 CAPLUS
CN 1H-Indole-3-carboxaldehyde, 1-(methyl-4-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 119229-39-9 CAPLUS
CN 1H-Indole-3-carboxaldehyde, 1-(methyl-4-pyridinylamino)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119229-38-8
CMF C15 H13 N3 O




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.



RN 119229-40-2 CAPLUS

CN 1H-Indole-3-carboxaldehyde, 1-(ethyl-4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 119229-41-3 CAPLUS

CN 1H-Indole-3-carboxaldehyde, 1-(ethyl-4-pyridinylamino)-, (Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119229-40-2

CMF C16 H15 N3 O




CM 2


CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 119229-43-5 CAPLUS
CN 1H-Indol-1-amine, 3-ethenyl-N-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119229-44-6 CAPLUS
CN 1H-Indol-1-amine, 3-ethenyl-N-methyl-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119229-43-5
CMF C16 H15 N3




CM 2


CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 119229-45-7 CAPLUS

CN 1H-Indol-1-amine, 3-ethyl-N-methyl-N-4-pyridinyl-, monohydrochloride (9CI)
(CA INDEX NAME)

● HCl

RN 119229-46-8 CAPLUS


CN 1H-Indol-1-amine, 5-chloro-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN	119229-47-9	CAPLUS
CN	1H-Indol-1-amine, 5-chloro-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI)	
	(CA INDEX NAME)	

CM 1


CRN 119229-46-8
CMF C13 H10 Cl N3




CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.




RN	119229-48-0	CAPLUS		
CN	1H-Indol-1-amine, 5-chloro-N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)			



RN 119229-49-1 CAPLUS
CN 1H-Indol-1-amine, 5-chloro-N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 119229-48-0
CMF C16 H16 Cl N3




CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.




RN 119229-50-4 CAPLUS
CN 1H-Indol-1-amine, 5-bromo-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119229-51-5 CAPLUS
CN 1H-Indol-1-amine, 5-bromo-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1


CRN 119229-50-4
CMF C13 H10 Br N3




CM 2.

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.




RN 119229-52-6 CAPLUS
CN 1H-Indol-1-amine, 5-bromo-N-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119229-53-7 CAPLUS
CN 1H-Indol-1-amine, 5-bromo-N-methyl-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 119229-52-6
CMF C14 H12 Br N3



CM 2

CRN 110-16-7
CMF C4 H4 O4


Double bond geometry as shown.



RN 119229-55-9 CAPLUS
CN 1H-Indol-1-amine, 5-bromo-N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1



CRN 119229-54-8
CMF C16 H16 Br N3



CM 2


CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.

RN 119229-56-0 CAPLUS
CN 1H-Indol-1-amine, 5-nitro-N-4-pyridinyl-, monohydrochloride (9CI) (CA
INDEX NAME)

● HCl


RN 119229-57-1 CAPLUS
CN 1H-Indol-1-amine, 5-nitro-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119229-59-3 CAPLUS
CN 1H-Indol-1-amine, N-methyl-5-nitro-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 119229-58-2
CMF C14 H12 N4 O2



CM 2

CRN 110-16-7
CMF C4 H4 O4


Double bond geometry as shown.





RN 119229-61-7 CAPLUS
CN 1H-Indol-1-amine, 3-methyl-N-4-pyridinyl-, ethanedioate (1:1) (9CI) (CA
INDEX NAME)

CM 1

CRN 119229-60-6
CMF C14 H13 N3




CM 2

CRN 144-62-7
CMF C2 H2 O4RN 119229-62-8 CAPLUS
CN 1H-Indol-1-amine, 3-methyl-N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)RN 119229-63-9 CAPLUS
CN 1H-Indol-1-amine, 3-methyl-N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119229-62-8
CMF C17 H19 N3




CM 2


CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 119229-64-0 CAPLUS

CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl-N-propyl-,
monohydrochloride (9CI) (CA INDEX NAME)

● HCl


RN 119229-68-4 CAPLUS

CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-N-propyl-, monohydrochloride
(9CI) (CA INDEX NAME)




● HCl


RN 119229-69-5 CAPLUS
CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-N-propyl- (9CI) (CA INDEX NAME)




RN 119257-32-8 CAPLUS
CN 1H-Indol-1-amine, N-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119257-33-9 CAPLUS
CN 1H-Indol-1-amine, N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119257-34-0 CAPLUS
CN 1H-Indol-1-amine, N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119257-35-1 CAPLUS
CN 1H-Indol-1-amine, 3-ethyl-N-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119257-36-2 CAPLUS
CN 1H-Indol-1-amine, N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119257-33-9
CMF C13 H11 N3




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 119257-37-3 CAPLUS

CN 1H-Indol-1-amine, N-methyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 119257-32-8

CMF C14 H13 N3




CM 2


CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 119257-38-4 CAPLUS
CN 1H-Indol-1-amine, N-ethyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119257-39-5 CAPLUS
CN 1H-Indol-1-amine, N-ethyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1


CRN 119257-38-4
CMF C15 H15 N3



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.




RN 119257-40-8 CAPLUS
CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI)

(CA INDEX NAME)

CM 1

CRN 119257-34-0

CMF C16 H17 N3




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 119257-41-9 CAPLUS
CN 1H-Indol-1-amine, 5-methoxy-N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119229-37-7

CMF C17 H19 N3 O




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.



RN 159732-09-9 CAPLUS

CN 1H-Indol-1-amine, N-(3-methyl-4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 159732-11-3 CAPLUS

CN 1H-Indol-1-amine, N-(3-methyl-4-pyridinyl)-N-propyl-, ethanedioate (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 159732-10-2


CMF C17 H19 N3



CM 2


CRN 144-62-7

CMF C2 H2 O4




RN 159732-12-4 CAPLUS

CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 159732-13-5 CAPLUS
CN 1H-Indol-1-amine, N-(3-chloro-4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 159732-14-6 CAPLUS
CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-2-methyl- (9CI) (CA INDEX NAME)



RN 159732-15-7 CAPLUS
CN 1H-Indol-1-amine, N-(3-chloro-4-pyridinyl)-3-methyl-, monohydrochloride
(9CI) (CA INDEX NAME)




● HCl

RN 159732-17-9 CAPLUS
CN 1H-Indole-3-carboxaldehyde, 1-(propyl-4-pyridinylamino)-,
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 159732-16-8
CMF C17 H17 N3 O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.




RN 159732-19-1 CAPLUS
CN 1H-Indol-1-amine, 3-ethenyl-N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate

(1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 159732-18-0
CMF C18 H19 N3



CM 2

CRN 110-16-7
CMF C4 H4 O4


Double bond geometry as shown.



RN 159732-21-5 CAPLUS
CN 1H-Indol-1-amine, 3-ethyl-N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 159732-20-4
CMF C18 H21 N3



CM 2

CRN 110-16-7
CMF C4 H4 O4


Double bond geometry as shown.



RN 159732-23-7 CAPLUS
CN 1H-Indol-1-amine, N-butyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1


CRN 159732-22-6
CMF C17 H19 N3



CM 2

CRN 110-16-7
CMF C4 H4 O4


Double bond geometry as shown.



RN 159732-25-9 CAPLUS
CN 1H-Indol-1-amine, N-2-propynyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1)
(9CI) (CA INDEX NAME)

CM 1


CRN 159732-24-8
CMF C16 H13 N3




CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.

RN 159732-27-1 CAPLUS
CN 1H-Indol-1-amine, N-(2-methylpropyl)-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 159732-26-0
CMF C17 H19 N3

CM 2

CRN 110-16-7
CMF C4 H4 O4


Double bond geometry as shown.



RN 159732-29-3 CAPLUS
CN 1H-Indol-1-amine, N-pentyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1


CRN 159732-28-2
CMF C18 H21 N3



CM 2

CRN 110-16-7
CMF C4 H4 O4


Double bond geometry as shown.



RN 159732-31-7 CAPLUS
CN 1H-Indol-1-amine, N-(1-methylpropyl)-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 159732-30-6
CMF C17 H19 N3




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 159732-33-9 CAPLUS
CN 1H-Indol-1-amine, N-(1-methylethyl)-N-(4-pyridinyl)-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 159732-32-8

CMF C16 H17 N3




CM 2

CRN 110-16-7

CMF C4 H4 O4


Double bond geometry as shown.



RN 159732-35-1 CAPLUS
CN 1H-Indol-1-amine, 2-methyl-N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 159732-34-0
CMF C17 H19 N3




CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.




RN 159732-36-2 CAPLUS
CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl-N-2-propenyl-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 159732-37-3 CAPLUS
CN 1H-Indol-1-amine, N-(3-chloro-4-pyridinyl)-N-propyl-, monohydrochloride
(9CI) (CA INDEX NAME)




● HCl

RN 159732-39-5 CAPLUS
CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-N-2-propynyl-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 159732-40-8 CAPLUS

CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl-N-2-propynyl-,
monohydrochloride (9CI) (CA INDEX NAME)


● HCl

RN 159732-41-9 CAPLUS


CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-2-methyl-N-propyl- (9CI) (CA
INDEX NAME)

RN 159732-42-0 CAPLUS

CN 1H-Indol-1-amine, N-(3-chloro-4-pyridinyl)-3-methyl-N-propyl- (9CI) (CA
INDEX NAME)




RN 159732-43-1 CAPLUS
CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-N-2-propenyl-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 159732-44-2 CAPLUS
CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-N-2-propenyl- (9CI) (CA INDEX
NAME)




L9 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1990:478182 CAPLUS
DOCUMENT NUMBER: 113:78182
TITLE: N-heteroaryl-4-quinolinamines as cholinergic agents
INVENTOR(S): Effland, Richard C.; Klein, Joseph T.; Davis, Larry;

DUPLICATE 6


Searched by Barb O'Bryen, STIC 308-4291

PATENT ASSIGNEE(S): Olsen, Gordon E.
 SOURCE: Hoechst-Roussel Pharmaceuticals, Inc., USA
 U.S., 18 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4916135	A	19900410	US 1989-348937	19890508
EP 397040	A2	19901114	EP 1990-108409	19900504
EP 397040	A3	19910502		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
ZA 9003396	A	19910227	ZA 1990-3396	19900504
AU 9054691	A1	19901108	AU 1990-54691	19900507
AU 623766	B2	19920521		
CA 2016214	AA	19901108	CA 1990-2016214	19900507
NO 9002003	A	19901109	NO 1990-2003	19900507
HU 54139	A2	19910128	HU 1990-2693	19900507
HU 207726	B	19930528		
JP 03047179	A2	19910228	JP 1990-115936	19900507
PRIORITY APPLN. INFO.:			US 1989-348937	19890508
OTHER SOURCE(S):	CASREACT 113:78182; MARPAT 113:78182			
GI				



I



II


AB The title compds. [I; R = (substituted) pyrrolyl, indolyl, carbazoyl, piperidinylmethyl; R1 = null, H, alkyl, CH2C.tplbond.CH, morpholinobutynyl, piperazinylbutynyl; R2 = null, alkyl CH2C.tplbond.CH; X = H, alkyl, alkoxy, halo, CF3; Y = null, H; YY = (CH2)4; dotted lines = optional bonds], were prepd. Thus, 4-chloro-7-(trifluoromethyl)quinoline and 1H-pyrrolyl-amine were refluxed in Me2CHOH contg. Et2O/HCl to give pyrrolylaminoquinoline II as the hydrochloride which at 20 mg/kg s.c. in mice gave 48% inhibition of phenylquinone-induced writhing.

IT 128546-05-4P 128546-06-5P 128546-07-6P
 128546-08-7P 128546-09-8P 128546-10-1P
 128546-12-3P 128546-13-4P 128546-15-6P
 128546-16-7P 128546-17-8P 128546-23-6P
 128546-24-7P 128546-25-8P 128569-88-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, as analgesic and for treatment of memory dysfunction)

RN 128546-05-4 CAPLUS


CN 4-Quinolinamine, N-1H-indol-1-yl- (9CI) (CA INDEX NAME)



RN 128546-06-5 CAPLUS
CN 4-Quinolinamine, N-1H-indol-1-yl-, (2Z)-2-butenedioate (1:1) (9CI) (CA
INDEX NAME)

CM 1


CRN 128546-05-4
CMF C17 H13 N3




CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.




RN 128546-07-6 CAPLUS
CN 4-Quinolinamine, N-(3-methyl-1H-indol-1-yl)-, monohydrochloride (9CI) (CA
INDEX NAME)



● HCl


RN 128546-08-7 CAPLUS

CN 4-Quinolinamine, N-(3-methyl-1H-indol-1-yl)- (9CI) (CA INDEX NAME)



RN 128546-09-8 CAPLUS

CN 4-Quinolinamine, 7-chloro-N-1H-indol-1-yl-N-propyl- (9CI) (CA INDEX NAME)




RN 128546-10-1 CAPLUS

CN 4-Quinolinamine, 7-chloro-N-1H-indol-1-yl-N-propyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 128546-09-8

CMF C20 H18 Cl N3




CM 2


CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 128546-12-3 CAPLUS

CN 9-Acridinamine, 1,2,3,4-tetrahydro-N-1H-indol-1-yl-, monohydrochloride
(9CI) (CA INDEX NAME)


● HCl

RN 128546-13-4 CAPLUS


CN 9-Acridinamine, 1,2,3,4-tetrahydro-N-1H-indol-1-yl- (9CI) (CA INDEX NAME)




RN 128546-15-6 CAPLUS
CN 9-Acridinamine, 1,2,3,4-tetrahydro-N-(3-methyl-1H-indol-1-yl)- (9CI) (CA INDEX NAME)




RN 128546-16-7 CAPLUS
CN 9H-Carbazol-9-amine, N-4-quinolinyl- (9CI) (CA INDEX NAME)




RN 128546-17-8 CAPLUS
CN 9-Acridinamine, 1,2,3,4-tetrahydro-N-(2-methyl-1H-indol-1-yl)- (9CI) (CA INDEX NAME)



RN 128546-23-6 CAPLUS
CN 9-Acridinamine, 1,2,3,4-tetrahydro-N-(3-methyl-1H-indol-1-yl)-N-propyl-
(9CI) (CA INDEX NAME)




RN 128546-24-7 CAPLUS
CN 9-Acridinamine, 1,2,3,4-tetrahydro-N-(3-methyl-1H-indol-1-yl)-N-propyl-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 128546-25-8 CAPLUS
CN 9H-Carbazol-9-amine, N-propyl-N-4-quinolinyl- (9CI) (CA INDEX NAME)



RN 128569-88-0 CAPLUS

CN 9H-Carbazol-9-amine, N-4-quinolinyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L9 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2003 ACS

DUPLICATE 7

ACCESSION NUMBER: 1990:138914 CAPLUS

DOCUMENT NUMBER: 112:138914

TITLE: Preparation of N-pyridinyl-9H-carbazol-9-amines as analgesics, anticonvulsants, antidepressants, and drugs for memory dysfunction

INVENTOR(S): Effland, Richard C.; Klein, Joseph T.; Davis, Larry; Olsen, Gordon E.

PATENT ASSIGNEE(S): Hoechst-Roussel Pharmaceuticals, Inc., USA

SOURCE: U.S., 9 pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4868190	A	19890919	US 1988-289887	19881227
EP 376155	A1	19900704	EP 1989-123612	19891221
EP 376155	B1	19920805		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 79118	E	19920815	AT 1989-123612	19891221
ES 2044043	T3	19940101	ES 1989-123612	19891221
CA 2006529	AA	19900627	CA 1989-2006529	19891222

DK 8906621	A	19900628	DK 1989-6621	19891222
NO 8905222	A	19900628	NO 1989-5222	19891222
AU 8947203	A1	19900705	AU 1989-47203	19891222
AU 623205	B2	19920507		
JP 02247173	A2	19901002	JP 1989-335256	19891226
JP 07025749	B4	19950322		
ZA 8909904	A	19910227	ZA 1989-9904	19891227
PRIORITY APPLN. INFO.:			US 1988-289887	19881227
			EP 1989-123612	19891221
OTHER SOURCE(S):		CASREACT 112:138914; MARPAT 112:138914		
GI				




AB The title compds. I (X = H, lower alkyl, alkoxy, halo; Y = H, lower alkyl, halo; Z = H, lower alkyl, halo; R = H, lower alkyl, alkenyl, lower alkylcarbonyl, etc.), were prepd. A soln. of 9H-carbazol-9-amine and 4-chloropyridine-HCl in isopropanol was refluxed to give, after workup and treatment with maleic acid, N-(4-pyridinyl)-9H-carbazol-9-amine maleate (II). II inhibited tetrabenazine-induced ptosis in mice with ED50 of 2.3 mg/kg p.o.


IT 125529-86-4P 125529-87-5P 125529-88-6P
 125529-89-7P 125529-90-0P 125529-91-1P
 125529-92-2P 125529-93-3P 125529-94-4P
 125529-95-5P 125529-96-6P 125529-97-7P
 125529-98-8P 125529-99-9P 125530-00-9P
 125530-01-0P 125530-02-1P 125530-03-2P
 125530-04-3P 125530-05-4P 125530-06-5P
 125530-07-6P 125530-08-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of, as analgesic, anticonvulsant, antidepressant, and drug for memory dysfunction)


RN 125529-86-4 CAPLUS
 CN 9H-Carbazol-9-amine, N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 125529-87-5 CAPLUS
CN 9H-Carbazol-9-amine, N-ethyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 125529-88-6 CAPLUS
CN 9H-Carbazol-9-amine, N-2-propenyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 125529-89-7 CAPLUS
CN 9H-Carbazol-9-amine, N-butyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 125529-90-0 CAPLUS
CN 1,3-Propanediamine, N-9H-carbazol-9-yl-N',N'-dimethyl-N-4-pyridinyl- (9CI)
(CA INDEX NAME)



RN 125529-91-1 CAPLUS
CN 8-Azaspiro[4.5]decane-7,9-dione, 8-[4-(9H-carbazol-9-yl-4-pyridinylamino)butyl]- (9CI) (CA INDEX NAME)




RN 125529-92-2 CAPLUS
CN Propanamide, N-9H-carbazol-9-yl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 125529-93-3 CAPLUS

CN 9H-Carbazol-9-amine, N-(3-fluoro-4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 125529-94-4 CAPLUS

CN 9H-Carbazol-9-amine, N-(3-fluoro-4-pyridinyl)-N-propyl- (9CI) (CA INDEX NAME)




RN 125529-95-5 CAPLUS

CN 9H-Carbazol-9-amine, 3-bromo-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 125529-96-6 CAPLUS
CN 9H-Carbazol-9-amine, 3-bromo-N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 125529-97-7 CAPLUS
CN 9H-Carbazol-9-amine, N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 125529-86-4
CMF C17 H13 N3




CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.




RN 125529-98-8 CAPLUS
CN 9H-Carbazol-9-amine, N-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 125529-99-9 CAPLUS
CN 9H-Carbazol-9-amine, N-methyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1)
(9CI) (CA INDEX NAME)

CM 1


CRN 125529-98-8
CMF C18 H15 N3



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.




RN 125530-00-9 CAPLUS

CN 9H-Carbazol-9-amine, N-ethyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1)
(9CI) (CA INDEX NAME)

CM 1


CRN 125529-87-5
CMF C19 H17 N3




CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.




RN 125530-01-0 CAPLUS
CN 9H-Carbazol-9-amine, N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 125530-02-1 CAPLUS
CN 9H-Carbazol-9-amine, N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 125530-01-0
CMF C20 H19 N3




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 125530-03-2 CAPLUS

CN 9H-Carbazol-9-amine, N-2-propenyl-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 125529-88-6

CMF C20 H17 N3




CM 2


CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 125530-04-3 CAPLUS
CN 9H-Carbazol-9-amine, N-butyl-N-4-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 125530-05-4 CAPLUS
CN Propanamide, N-9H-carbazol-9-yl-N-4-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 125530-06-5 CAPLUS
CN 9H-Carbazol-9-amine, N-(3-fluoro-4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 125530-07-6 CAPLUS
CN 9H-Carbazol-9-amine, 3-bromo-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1)
(9CI) (CA INDEX NAME)

CM 1


CRN 125529-95-5
CMF C17 H12 Br N3



CM 2

CRN 110-16-7
CMF C4 H4 O4


Double bond geometry as shown.



RN 125530-08-7 CAPLUS
CN 9H-Carbazol-9-amine, 3-bromo-N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 125529-96-6
CMF C20 H18 Br N3



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



L9 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:637510 CAPLUS

DOCUMENT NUMBER: 137:163836

TITLE: N-(Pyridinyl)-1H-indol-1-amines for treatment of demyelinating diseases and other conditions

INVENTOR(S): ~~Smith, Craig P.~~ Rathbone, Michel P.; Petty, Margaret; ~~Ramsey, David~~

PATENT ASSIGNEE(S): Aventis Pharmaceuticals Inc., USA

SOURCE: PCT Int Appl., 60 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002064126	A2	20020822	WO 2002-US5501	20020214
WO 2002064126	A3	20030220		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-268846P P 20010215
GB 2001-19435 A 20010809

OTHER SOURCE(S): MARPAT 137:163836

AB N-(Pyridinyl)-1H-indol-1-amines are disclosed which provide a unique combination of blocking properties for both the potassium and sodium channels. These compds. are useful for the treatment of demyelinating diseases and conditions, e.g. multiple sclerosis, spinal cord injury, traumatic brain injury, and stroke. The compds. are also useful for stroke rehabilitation, the treatment of bladder irritation and dysfunction, and the treatment of neuropathic pain and chemokine-induced pain.


IT 119229-64-0, HP 184 119229-65-1

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pyridinylindolamines for treatment of demyelinating diseases and other conditions)

RN 119229-64-0 CAPLUS


CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl-N-propyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 119229-65-1 CAPLUS

CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl-N-propyl- (9CI) (CA INDEX NAME)




L9 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:174790 CAPLUS

DOCUMENT NUMBER: 137:352864

TITLE: Synthesis of carbon-14 labeled 1-(4-pyridinylamino)-1H-indol-5-ol-methylcarbamate, (Z)-2-butenedioate
([14C]HMR 2420)


AUTHOR(S): Gill, Harpal S.
CORPORATE SOURCE: Radiochemistry Section, Aventis Pharmaceuticals
Chemical Development, Cincinnati, OH, 45215, USA
SOURCE: Synthesis and Applications of Isotopically Labelled
Compounds, Proceedings of the International Symposium,
7th, Dresden, Germany, June 18-22, 2000 (2001),
Meeting Date 2000, 280-282. Editor(s): Pleiss,
Ulrich; Voges, Rolf. John Wiley & Sons Ltd.:
Chichester, UK.
CODEN: 69CIJC; ISBN: 0-471-49501-8
DOCUMENT TYPE: Conference
LANGUAGE: English
GI




AB A diazonium chem. route was developed to accomplish the synthesis of 1-(4-pyridinylamino)-1H-[2-14C]indol-5-ol-methylcarbamate, (Z)-2-butenedioate (I, [14C]MDL 106276G-02, [14C]HMR 2420) which is under development for treatment of Alzheimer's disease. The synthetic sequence provided I in seven steps from [14C]methyl iodide in an overall radiochem. yield of 7.2%, specific activity of 52.4 .mu.Ci/mg (20.9 mCi/mmol, 1938.8 MBq/g), radiochem. purity of 99.9% and chem. purity of 99.7%.

IT 474380-67-1P 474380-68-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of 14C-labeled (pyridinylamino)indole via diazotization of 14C-labeled hydroxystyrene with pyridinediazonium salt followed by carbamate formation and salt formation with maleic acid)

RN 474380-67-1 CAPLUS
CN 1H-Indol-5-ol-2-14C, 1-(4-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 474380-68-2 CAPLUS
CN 1H-Indol-5-ol-2-14C, 1-(4-pyridinylamino)-, methylcarbamate (ester) (9CI)
(CA INDEX NAME)



IT 474380-69-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of 14C-labeled (pyridinylamino)indole via diazotization of
14C-labeled hydroxystyrene with pyridinediazonium salt followed by
carbamate formation and salt formation with maleic acid)


RN 474380-69-3 CAPLUS

CN 1H-Indol-5-yl-2-14C, 1-(4-pyridinylamino)-, methylcarbamate (ester),
(2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 474380-68-2

CMF C15 H14 N4 O2




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 10 OF 51 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:314578 CAPLUS

DOCUMENT NUMBER: 132:318050

TITLE: Choline esterase inhibitors, alone or with other
agents, for treating restless legs syndrome and/or
periodic limb movements during sleep, and diagnostic
method

INVENTOR(S): Hedner, Jan; Kraiczi, Holger

PATENT ASSIGNEE(S): Swed.

SOURCE: PCT Int. Appl., 26 pp.

Searched by Barb O'Bryen, STIC 308-4291

DOCUMENT TYPE: CODEN: PIXXD2
LANGUAGE: Patent
FAMILY ACC. NUM. COUNT: 1 English
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000025821	A1	20000511	WO 1999-SE1979	19991103
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1154795	A1	20011121	EP 1999-957453	19991103
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.: SE 1998-3760 A 19981104
WO 1999-SE1979 W 19991103

AB A method for treating or preventing the restless legs syndrome and/or the periodic limb movements during sleep comprises administration of a choline esterase inhibitor (CEI) and, optionally, carbamazepine, clonidine, baclofen, hypnotic agent, opioid agonist, and dopaminergic agonist. Administration precedes the onset of sleep at night by from zero to three hours so as to make the CEI exert a therapeutic effect during a major portion of the sleep period. Also disclosed are corresponding pharmaceutical compns. and their use, including compns. comprising a combination of CEI with carbamazepine, clonidine, baclofen, hypnotic agent, opioid agonist, and dopaminergic agonist.

IT **119257-34-0**, Besipirdine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(choline esterase inhibitors, alone or with other agents, for treating restless legs syndrome and/or periodic limb movements during sleep, and diagnostic method)

RN 119257-34-0 CAPLUS
CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 11 OF 51 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:273553 CAPLUS
DOCUMENT NUMBER: 133:13034
TITLE: .alpha.1-Adrenoceptor subtypes mediating contractions of the rat mesenteric artery
AUTHOR(S): Hussain, M. B.; Marshall, I.
CORPORATE SOURCE: Department of Pharmacology, University College London, London, UK
SOURCE: European Journal of Pharmacology (2000), 395(1), 69-76
CODEN: EJPHAZ; ISSN: 0014-2999

PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The .alpha.1-adrenoceptor subtype(s) mediating contractions of the rat mesenteric artery were investigated using the agonists methoxamine, cirazoline, P 7480 and subtype-selective antagonists including BMY 7378. The pA2 or apparent pKB values of antagonists against methoxamine contractions correlated best with its pKi values at the cloned .alpha.1b-(0.88), with cirazoline, antagonists affinities correlated equally well with those at .alpha.1a-(0.79) or the .alpha.1b-(0.81) while with P 7480 antagonist affinities correlated best with the .alpha.1d-adrenoceptor subtype (0.94). The low affinity est. for 5-methylurapidil (7.5) against the .alpha.1a-selective cirazoline suggests an .alpha.1A-subtype mediating contraction is unlikely. Shallow Schild plot slopes of subtype selective antagonists against all three agonists are consistent with heterogeneity of .alpha.1-adrenoceptors. P 7480 (putative .alpha.1D-adrenoceptor-selective) acts primarily at this subtype and at another which is more likely to be an .alpha.1B- than an .alpha.1A-adrenoceptor. The results with both agonists and antagonists are consistent with contractions of the rat mesenteric artery being mediated via the .alpha.1D- and possibly .alpha.1B-adrenoceptor.


IT 138624-41-6, P 7480

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(.alpha.1-adrenoceptor subtypes mediating contractions of rat mesenteric artery and pharmacol. characterization thereof)

RN 138624-41-6 CAPLUS

CN 1H-Indol-1-amine, N-4-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 12 OF 51 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:403135 CAPLUS

DOCUMENT NUMBER: 131:208484

TITLE: Cholinergic therapies in Alzheimer's disease

AUTHOR(S): Siddiqui, Muhammad F.; Levey, Allan I.

CORPORATE SOURCE: Department of Neurology, Emory University School of Medicine, Atlanta, GA, 30322, USA

SOURCE: Drugs of the Future (1999), 24(4), 417-424

CODEN: DRFUD4; ISSN: 0377-8282


PUBLISHER: Prous Science

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

Searched by Barb O'Bryen, STIC 308-4291

AB A review, with 81 refs., on the cholinergic therapies in Alzheimer's disease.
IT **119257-34-0**, Besipirdine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cholinergic therapies in Alzheimer's disease)
RN 119257-34-0 CAPLUS
CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 13 OF 51 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:310654 CAPLUS
DOCUMENT NUMBER: 131:96826
TITLE: ~~Microbial models of mammalian metabolism of xenobiotics: an updated review~~
AUTHOR(S): ~~Abourashed, E. A.; Clark, A. M.; Hufford, C. D.~~
CORPORATE SOURCE: Department of Pharmacognosy and National Center for the Development of Natural Products, Research Institute for Pharmaceutical Sciences, The University of Mississippi, University, MS, ~~38677~~, USA
SOURCE: Current Medicinal Chemistry (1999), 6(5), 359-374
CODEN: CMCHE7; ISSN: 0929-8673
PUBLISHER: Bentham Science Publishers
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review with 77 refs. The utilization of microbes as models for mammalian metab. of ~~xenobiotics~~ has been well established since the concept was first introduced by Smith and Rosazza in the early seventies. The core assumption of this concept rests on the fact that fungi are eukaryotic organisms that possess metabolizing enzyme systems similar to those present in mammalian systems. Hence, the outcome of xenobiotic metab. in both systems is expected to be similar, if not identical, and, thus, fungi can be used to predict the outcome of mammalian metab. of various xenobiotics, including drugs. Utilizing microbial models offers a no. of advantages over the use of animals in metab. studies, mainly redn. in use of animals, ease of setup and manipulation, higher yield and diversity of metabolite prodn., and lower cost of prodn. In a continuation to our contribution to this field, this review will outline the results of studies that were conducted over the last seven years to emphasize the similarities between the microbial and mammalian metabolic pathways of xenobiotics through the endorsement of the concept of "microbial models of mammalian metab."

IT **119257-34-0**, Besipirdine
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(microbial models of mammalian metab. of xenobiotics)
RN 119257-34-0 CAPLUS
CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 77 THERE ARE 77 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 14 OF 51 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:552350 CAPLUS

DOCUMENT NUMBER: 129:269966

TITLE: 4-aminopyridine derivatives: a family of novel modulators of voltage-dependent sodium channels

AUTHOR(S): Tang, Lei; Huger, Francis P.; Klein, Joseph T.; Davis, Larry; Martin, Lawrence L.; Shimshock, Stephen; Effland, Richard C.; Smith, Craig P.; Kongsamut, Sathapana

CORPORATE SOURCE: Departments of Neuroscience Research and Chemistry, Bridgewater, NJ, 08807-0800, USA

SOURCE: Drug Development Research (1998), 44(1), 8-13
CODEN: DDREDK; ISSN: 0272-4391

PUBLISHER: Wiley-Liss, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The interactions of a family of aminopyridine derivs. with Site II of the voltage-dependent sodium channel were examd. by measuring the ability of these compds. to inhibit [3H]batrachotoxin binding and veratridine-induced increases in [Ca²⁺]_i. Aminopyridines substituted with indole, carbazole, and pyrrole rings were evaluated. All compds. that had an arom. ring linked to the amine group of 4-aminopyridine showed pos. results in both assays. For example, the most potent compd., besipirdine (N-(n-propyl)-N-(4-pyridinyl)-1H-indol-1-amine), had IC₅₀ values of 5 .mu.M and 23.8 .mu.M in the two assays, resp. Small substitutions on either the arom. ring or on 4-aminopyridine did not substantially change their potencies. Indoles linked to the amino group of 2- and 3-aminopyridine also showed pos. results. These results indicate that aminopyridine derivs. substituted with an arom. ring on the amino nitrogen are inhibitors of voltage-dependent sodium channels.

IT 119229-50-4 119229-54-8 119229-60-6

119229-65-1 119257-33-9 119257-34-0,

Besipirdine 119257-35-1 119257-43-1

125529-86-4 125529-89-7 125529-94-4

125529-96-6 141287-62-9 141287-65-2

141287-68-5 141287-72-1 159732-09-9

159732-26-0 159732-32-8 159732-38-4

159732-42-0 173341-09-8 173341-11-2

188028-69-5 188028-84-4 188028-89-9


188028-95-7 210237-02-8

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(4-aminopyridine derivs.: modulators of voltage-dependent sodium channels)


RN 119229-50-4 CAPLUS

CN 1H-Indol-1-amine, 5-bromo-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119229-54-8 CAPLUS

CN 1H-Indol-1-amine, 5-bromo-N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119229-60-6 CAPLUS

CN 1H-Indol-1-amine, 3-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119229-65-1 CAPLUS


CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl-N-propyl- (9CI) (CA INDEX NAME)




RN 119257-33-9 CAPLUS
CN 1H-Indol-1-amine, N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119257-34-0 CAPLUS
CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119257-35-1 CAPLUS
CN 1H-Indol-1-amine, 3-ethyl-N-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119257-43-1 CAPLUS
CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX NAME)



RN 125529-86-4 CAPLUS
CN 9H-Carbazol-9-amine, N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 125529-89-7 CAPLUS
CN 9H-Carbazol-9-amine, N-butyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 125529-94-4 CAPLUS

CN 9H-Carbazol-9-amine, N-(3-fluoro-4-pyridinyl)-N-propyl- (9CI) (CA INDEX NAME)




RN 125529-96-6 CAPLUS

CN 9H-Carbazol-9-amine, 3-bromo-N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 141287-62-9 CAPLUS


CN 1H-Indol-5-ol, 1-[(3-fluoro-4-pyridinyl)propylamino]- (9CI) (CA INDEX NAME)




RN 141287-65-2 CAPLUS
CN 1H-Indol-5-ol, 3-methyl-1-(4-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 141287-68-5 CAPLUS
CN 1H-Indol-5-ol, 3-methyl-1-(propyl-4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 141287-72-1 CAPLUS
CN 1H-Indol-5-ol, 1-[(3-fluoro-4-pyridinyl)propylamino]-3-methyl- (9CI) (CA INDEX NAME)




RN 159732-09-9 CAPLUS

CN 1H-Indol-1-amine, N-(3-methyl-4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 159732-26-0 CAPLUS

CN 1H-Indol-1-amine, N-(2-methylpropyl)-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 159732-32-8 CAPLUS


CN 1H-Indol-1-amine, N-(1-methylethyl)-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 159732-38-4 CAPLUS
CN 1H-Indol-1-amine, N-(3-chloro-4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 159732-42-0 CAPLUS
CN 1H-Indol-1-amine, N-(3-chloro-4-pyridinyl)-3-methyl-N-propyl- (9CI) (CA INDEX NAME)




RN 173341-09-8 CAPLUS
CN 1H-Indol-1-amine, 3-chloro-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 173341-11-2 CAPLUS

CN 1H-Indol-1-amine, 3-chloro-N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 188028-69-5 CAPLUS

CN 1H-Indol-1-amine, N-(3-chloro-4-pyridinyl)-N-propyl- (9CI) (CA INDEX NAME)




RN 188028-84-4 CAPLUS

CN 3,4-Pyridinediamine, N4-1H-indol-1-yl- (9CI) (CA INDEX NAME)




RN 188028-89-9 CAPLUS

CN 1H-Indole-3-methanamine, 1-(propyl-4-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 188028-95-7 CAPLUS


CN 1H-Indole-3-ethanamine, 1-(4-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 210237-02-8 CAPLUS

CN 1H-Indol-1-amine, N-(3-chloro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX NAME)

NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 15 OF 51 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1997:696754 CAPLUS

DOCUMENT NUMBER: 128:13198

TITLE: Preparation of pyridinylaminoisatin derivatives as acetylcholinesterase inhibitors and analgesics.

INVENTOR(S): ~~Shimshock, Stephen J.; Mutlib, Abdul E.~~; Chesson, Susan M.

PATENT ASSIGNEE(S): Hoechst Marion Roussel, Inc., USA

SOURCE: PCT Int. Appl. 16 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9738993	A1	199711023	WO 1997-US3598	19970307
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2252039	AA	199711023	CA 1997-2252039	19970307
AU 9720725	A1	199711107	AU 1997-20725	19970307
AU 716997	B2	20000316		
EP 892796	A1	19990127	EP 1997-908942	19970307
EP 892796	B1	20011024		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CN 1215399	A	19990428	CN 1997-193728	19970307
BR 9708655	A	19990803	BR 1997-8655	19970307
JP 2001508400	T2	20010626	JP 1997-537084	19970307
AT 207483	E	20011115	AT 1997-908942	19970307
ES 2165586	T3	20020316	ES 1997-908942	19970307
TW 426678	B	20010321	TW 1997-86104363	19970407
ZA 9702990	A	19971103	ZA 1997-2990	19970408
NO 9804740	A	19981009	NO 1998-4740	19981009
KR 2000005379	A	20000125	KR 1998-8105	19981012
KR 2000005379	A	20000125	KR 1998-708105	19981012
PRIORITY APPLN. INFO.: US 1996-631870 A 19960412				
WO 1997-US3598 W 19970307				

OTHER SOURCE(S): MARPAT 128:13198

GI




AB Title compds. (I; R = H, alkyl, hydroxyalkyl; X = H, OH, alkoxy phenylalkoxy, aminocarbonyloxy; Y = H, halo), were prepd. as acetylcholinesterase inhibitors and analgesics (no data). Thus, N-propyl-N-(4-pyridinyl)-N-(1-indolyl)amine was stirred 72 h with $\text{Ti}(\text{NO}_3)_3 \cdot 3\text{H}_2\text{O}$ in MeOH to give I (X, Y = H; R = Pr).

IT **119257-33-9 119257-34-0**
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (prepn. of pyridinylaminoisatin derivs. as acetylcholinesterase inhibitors and analgesics)


RN 119257-33-9 CAPLUS

CN 1H-Indol-1-amine, N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119257-34-0 CAPLUS

CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



L9 ANSWER 16 OF 51 CAPLUS COPYRIGHT 2003 ACS



ACCESSION NUMBER: 1997:224079 CAPLUS

DOCUMENT NUMBER: 126:212049

TITLE: Preparation of N-(pyrrol-1-yl)pyridinamines as

INVENTOR(S): anticonvulsant agents
 Huger, Francis P.; Kongsamut, Sathapana; Smith, Craig
 P.; Tang, Lei
 PATENT ASSIGNEE(S): Hoechst Marion Roussel, Inc., USA
 SOURCE: PCT Int. Appl., 103 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9704777	A1	19970213	WO 1996-US11408	19960708
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
CA 2225156	AA	19970213	CA 1996-2225156	19960708
AU 9664547	A1	19970226	AU 1996-64547	19960708
AU 696007	B2	19980827		
EP 840609	A1	19980513	EP 1996-923693	19960708
EP 840609	B1	20020605		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
CN 1191486	A	19980826	CN 1996-195780	19960708
JP 11510159	T2	19990907	JP 1996-507602	19960708
AT 218343	E	20020615	AT 1996-923693	19960708
ES 2174081	T3	20021101	ES 1996-923693	19960708
TW 464497	B	20011121	TW 1996-85109038	19960724
NO 9800334	A	19980326	NO 1998-334	19980126
PRIORITY APPLN. INFO.:				
			US 1995-508071	A 19950727
			WO 1996-US11408	W 19960708
OTHER SOURCE(S): MARPAT 126:212049				
GI				



AB The title compds. [I; R = H, C1-6 alkyl, C2-6 alkenyl, etc.; R1-R3 = H, halo, C1-6 alkyl, etc.; R1R2 = (un)substituted benzene ring fused to the pyrrole ring; R4 = H, halo, NH2, C1-6 alkyl; n = 0-1] and their salts, useful for treating a patient in need of relief from convulsions, were prepd. Thus, treatment of N-(4-pyridinyl)-1H-indol-1-amine with NaH in DMF followed by addn. of 1-bromopropane afforded II.HCl which showed IC50

of 5 .mu.M against [3H]Batrachotoxin binding.


IT 119229-38-8P 119229-43-5P 119229-46-8P
119229-50-4P 119229-57-1P 119257-33-9P
159732-16-8P 159732-18-0P 173341-09-8P
173677-77-5P 188028-92-4P 188028-98-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of N-(pyrrol-1-yl)pyridinamines as anticonvulsant agents)


RN 119229-38-8 CAPLUS

CN 1H-Indole-3-carboxaldehyde, 1-(methyl-4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 119229-43-5 CAPLUS

CN 1H-Indol-1-amine, 3-ethenyl-N-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119229-46-8 CAPLUS


CN 1H-Indol-1-amine, 5-chloro-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119229-50-4 CAPLUS
CN 1H-Indol-1-amine, 5-bromo-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119229-57-1 CAPLUS
CN 1H-Indol-1-amine, 5-nitro-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119257-33-9 CAPLUS
CN 1H-Indol-1-amine, N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 159732-16-8 CAPLUS
CN 1H-Indole-3-carboxaldehyde, 1-(propyl-4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 159732-18-0 CAPLUS
CN 1H-Indol-1-amine, 3-ethenyl-N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 173341-09-8 CAPLUS
CN 1H-Indol-1-amine, 3-chloro-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 173677-77-5 CAPLUS
CN 1H-Indole-3-carboxaldehyde, 1-(propyl-4-pyridinylamino)-, oxime (9CI) (CA INDEX NAME)



RN 188028-92-4 CAPLUS
CN 1H-Indole-3-acetonitrile, 1-(4-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 188028-98-0 CAPLUS
CN 1H-Indol-1-amine, N-(5-chloro-3-pyridinyl)- (9CI) (CA INDEX NAME)



IT 119229-37-7P 119229-39-9P 119229-40-2P
119229-41-3P 119229-44-6P 119229-45-7P
119229-47-9P 119229-48-0P 119229-49-1P
119229-51-5P 119229-52-6P 119229-53-7P
119229-54-8P 119229-55-9P 119229-56-0P
119229-58-2P 119229-59-3P 119229-60-6P
119229-61-7P 119229-62-8P 119229-63-9P
119229-64-0P 119229-65-1P 119229-68-4P
119229-69-5P 119257-32-8P 119257-34-0P
119257-35-1P 119257-36-2P 119257-37-3P
119257-38-4P 119257-39-5P 119257-40-8P
119257-41-9P 119257-43-1P 130953-69-4P
141287-61-8P 141287-62-9P 141287-65-2P
141287-68-5P 141287-69-6P 141287-72-1P
145660-10-2P 159732-08-8P 159732-09-9P
159732-10-2P 159732-14-6P 159732-20-4P
159732-22-6P 159732-24-8P 159732-26-0P
159732-28-2P 159732-30-6P 159732-32-8P
159732-34-0P 159732-38-4P 159732-41-9P
159732-42-0P 159732-43-1P 159732-44-2P
173341-10-1P 173341-11-2P 173341-12-3P
188028-38-8P 188028-65-1P 188028-69-5P
188028-74-2P 188028-77-5P 188028-84-4P
188028-89-9P 188028-95-7P 188029-00-7P


188029-02-9P 188029-52-9P 188029-56-3P

188029-59-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-(pyrrol-1-yl)pyridinamines as anticonvulsant agents)

RN 119229-37-7 CAPLUS

CN 1H-Indol-1-amine, 5-methoxy-N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119229-39-9 CAPLUS

CN 1H-Indole-3-carboxaldehyde, 1-(methyl-4-pyridinylamino)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119229-38-8

CMF C15 H13 N3 O




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.



RN 119229-40-2 CAPLUS

CN 1H-Indole-3-carboxaldehyde, 1-(ethyl-4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 119229-41-3 CAPLUS
CN 1H-Indole-3-carboxaldehyde, 1-(ethyl-4-pyridinylamino)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119229-40-2

CMF C16 H15 N3 O




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 119229-44-6 CAPLUS
CN 1H-Indol-1-amine, 3-ethenyl-N-methyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119229-43-5

CMF C16 H15 N3




CM 2


CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



RN 119229-45-7 CAPLUS

CN 1H-Indol-1-amine, 3-ethyl-N-methyl-N-4-pyridinyl-, monohydrochloride (9CI)
(CA INDEX NAME)

● HCl


RN 119229-47-9 CAPLUS

CN 1H-Indol-1-amine, 5-chloro-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 119229-46-8

CMF C13 H10 Cl N3




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.



RN 119229-48-0 CAPLUS

CN 1H-Indol-1-amine, 5-chloro-N-propyl-N-4-pyridinyl- (9CI). (CA INDEX NAME)




RN 119229-49-1 CAPLUS

CN 1H-Indol-1-amine, 5-chloro-N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119229-48-0

CMF C16 H16 Cl N3




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 119229-51-5 CAPLUS

CN 1H-Indol-1-amine, 5-bromo-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 119229-50-4

CMF C13 H10 Br N3




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.



RN 119229-52-6 CAPLUS

CN 1H-Indol-1-amine, 5-bromo-N-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119229-53-7 CAPLUS

CN 1H-Indol-1-amine, 5-bromo-N-methyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119229-52-6

CMF C14 H12 Br N3




CM 2


CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 119229-54-8 CAPLUS
CN 1H-Indol-1-amine, 5-bromo-N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119229-55-9 CAPLUS
CN 1H-Indol-1-amine, 5-bromo-N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 119229-54-8
CMF C16 H16 Br N3




CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.




RN 119229-56-0 CAPLUS
CN 1H-Indol-1-amine, 5-nitro-N-4-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 119229-58-2 CAPLUS
CN 1H-Indol-1-amine, N-methyl-5-nitro-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119229-59-3 CAPLUS
CN 1H-Indol-1-amine, N-methyl-5-nitro-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 119229-58-2
CMF C14 H12 N4 O2




CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.




RN 119229-60-6 CAPLUS
CN 1H-Indol-1-amine, 3-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119229-61-7 CAPLUS
CN 1H-Indol-1-amine, 3-methyl-N-4-pyridinyl-, ethanedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 119229-60-6
CMF C14 H13 N3




CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 119229-62-8 CAPLUS

CN 1H-Indol-1-amine, 3-methyl-N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119229-63-9 CAPLUS

CN 1H-Indol-1-amine, 3-methyl-N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119229-62-8

CMF C17 H19 N3




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.



RN 119229-64-0 CAPLUS


CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl-N-propyl-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 119229-65-1 CAPLUS

CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl-N-propyl- (9CI) (CA
INDEX NAME)



RN 119229-68-4 CAPLUS


CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-N-propyl-, monohydrochloride
(9CI) (CA INDEX NAME)



● HCl


RN 119229-69-5 CAPLUS

CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-N-propyl- (9CI) (CA INDEX NAME)




RN 119257-32-8 CAPLUS

CN 1H-Indol-1-amine, N-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119257-34-0 CAPLUS

CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119257-35-1 CAPLUS

CN 1H-Indol-1-amine, 3-ethyl-N-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN. 119257-36-2 CAPLUS

CN 1H-Indol-1-amine, N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119257-33-9

CMF C13 H11 N3




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 119257-37-3 CAPLUS

CN 1H-Indol-1-amine, N-methyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119257-32-8

CMF C14 H13 N3




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.



RN 119257-38-4 CAPLUS

CN 1H-Indol-1-amine, N-ethyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119257-39-5 CAPLUS

CN 1H-Indol-1-amine, N-ethyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 119257-38-4

CMF C15 H15 N3




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 119257-40-8 CAPLUS

CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 119257-34-0

CMF C16 H17 N3




CM 2

CRN 110-16-7

CMF C4 H4 O4


Double bond geometry as shown.



RN 119257-41-9 CAPLUS
CN 1H-Indol-1-amine, 5-methoxy-N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 119229-37-7
CMF C17 H19 N3 O




CM 2

CRN 110-16-7
CMF C4 H4 O4


Double bond geometry as shown.



RN 119257-43-1 CAPLUS
CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX
NAME)




RN 130953-69-4 CAPLUS
CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 141287-61-8 CAPLUS
CN 1H-Indol-5-ol, 1-[(3-fluoro-4-pyridinyl)propylamino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 141287-62-9 CAPLUS
CN 1H-Indol-5-ol, 1-[(3-fluoro-4-pyridinyl)propylamino]- (9CI) (CA INDEX NAME)



RN 141287-65-2 CAPLUS
CN 1H-Indol-5-ol, 3-methyl-1-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 141287-68-5 CAPLUS
CN 1H-Indol-5-ol, 3-methyl-1-(propyl-4-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 141287-69-6 CAPLUS
CN 1H-Indol-5-ol, 3-methyl-1-(propyl-4-pyridinylamino)-, ethanedioate (2:1) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 141287-68-5
CMF C17 H19 N3 O




CM 2

CRN 144-62-7
CMF C2 H2 O4




RN 141287-72-1 CAPLUS

CN 1H-Indol-5-ol, 1-[(3-fluoro-4-pyridinyl)propylamino]-3-methyl- (9CI) (CA INDEX NAME)




RN 145660-10-2 CAPLUS

CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 159732-08-8 CAPLUS

CN 1H-Indol-1-amine, 2-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 159732-09-9 CAPLUS


CN 1H-Indol-1-amine, N-(3-methyl-4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 159732-10-2 CAPLUS
CN 1H-Indol-1-amine, N-(3-methyl-4-pyridinyl)-N-propyl- (9CI) (CA INDEX NAME)




RN 159732-14-6 CAPLUS
CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 159732-20-4 CAPLUS
CN 1H-Indol-1-amine, 3-ethyl-N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 159732-22-6 CAPLUS
CN 1H-Indol-1-amine, N-butyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 159732-24-8 CAPLUS
CN 1H-Indol-1-amine, N-2-propynyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 159732-26-0 CAPLUS
CN 1H-Indol-1-amine, N-(2-methylpropyl)-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 159732-28-2 CAPLUS
CN 1H-Indol-1-amine, N-pentyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 159732-30-6 CAPLUS
CN 1H-Indol-1-amine, N-(1-methylpropyl)-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 159732-32-8 CAPLUS
CN 1H-Indol-1-amine, N-(1-methylethyl)-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 159732-34-0 CAPLUS

CN 1H-Indol-1-amine, 2-methyl-N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 159732-38-4 CAPLUS

CN 1H-Indol-1-amine, N-(3-chloro-4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 159732-41-9 CAPLUS


CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-2-methyl-N-propyl- (9CI) (CA INDEX NAME)



RN 159732-42-0 CAPLUS
CN 1H-Indol-1-amine, N-(3-chloro-4-pyridinyl)-3-methyl-N-propyl- (9CI) (CA
INDEX NAME)




RN 159732-43-1 CAPLUS
CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-N-2-propenyl-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 159732-44-2 CAPLUS
CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-N-2-propenyl- (9CI) (CA INDEX
NAME)




RN 173341-10-1 CAPLUS

CN Benzoic acid, 2-hydroxy-, compd. with 3-chloro-N-4-pyridinyl-1H-indol-1-amine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 173341-09-8


CMF C13 H10 C1 N3



CM 2'


CRN 69-72-7

CMF C7 H6 O3




RN 173341-11-2 CAPLUS

CN 1H-Indol-1-amine, 3-chloro-N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 173341-12-3 CAPLUS

1H-Indol-1-amine, 3-chloro-N-propyl-N-4-pyridinyl-, monohydrochloride
(9CI) (CA INDEX NAME)




● HCl


RN 188028-38-8 CAPLUS
CN 1H-Indol-1-amine, N-(3-chloro-4-pyridinyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 188028-65-1 CAPLUS
CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 188028-69-5 CAPLUS
CN 1H-Indol-1-amine, N-(3-chloro-4-pyridinyl)-N-propyl- (9CI) (CA INDEX NAME)




RN 188028-74-2 CAPLUS
CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-N-2-propynyl- (9CI) (CA INDEX NAME)




RN 188028-77-5 CAPLUS
CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl-N-2-propynyl- (9CI)
(CA INDEX NAME)




RN 188028-84-4 CAPLUS
CN 3,4-Pyridinediamine, N4-1H-indol-1-yl- (9CI) (CA INDEX NAME)




RN 188028-89-9 CAPLUS
CN 1H-Indole-3-methanamine, 1-(propyl-4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 188028-95-7 CAPLUS
CN 1H-Indole-3-ethanamine, 1-(4-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 188029-00-7 CAPLUS
CN 1H-Indol-1-amine, N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 188029-02-9 CAPLUS
CN 1H-Indol-1-amine, N-2-pyridinyl- (9CI) (CA INDEX NAME)



RN 188029-52-9 CAPLUS
CN 1H-Indole-3-carboxaldehyde, 1-(propyl-4-pyridinylamino)-, oxime,
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 173677-77-5
CMF C17 H18 N4 O




CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 188029-56-3 CAPLUS
CN 1H-Indole-3-methanamine, 1-(propyl-4-pyridinylamino)-, dihydrochloride
(9CI) (CA INDEX NAME)




● 2 HCl

RN 188029-59-6 CAPLUS
CN 1H-Indole-3-ethanamine, 1-(4-pyridinylamino)-, (2Z)-2-butenedioate (1:1)
(9CI) (CA INDEX NAME)

CM 1


CRN 188028-95-7
CMF C15 H16 N4




CM 2

CRN 110-16-7
CMF C4 H4 O4


Double bond geometry as shown.




IT 119229-75-3 141287-59-4 141287-64-1
141287-66-3 141287-71-0 188029-86-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of N-(pyrrol-1-yl)pyridinamines as anticonvulsant agents)
RN 119229-75-3 CAPLUS
CN 1H-Indol-1-amine, 5-methoxy-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 141287-59-4 CAPLUS
CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-5-(phenylmethoxy)-N-propyl-
(9CI) (CA INDEX NAME)




RN 141287-64-1 CAPLUS
CN 1H-Indol-1-amine, 3-methyl-5-(phenylmethoxy)-N-4-pyridinyl- (9CI) (CA
INDEX NAME)




RN 141287-66-3 CAPLUS
CN 1H-Indol-1-amine, 3-methyl-5-(phenylmethoxy)-N-propyl-N-4-pyridinyl- (9CI)
(CA INDEX NAME)



RN 141287-71-0 CAPLUS
 CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl-5-(phenylmethoxy)-N-propyl- (9CI) (CA INDEX NAME)



RN 188029-86-9 CAPLUS
 CN 1H-Indol-1-amine, N-(3-nitro-4-pyridinyl)- (9CI) (CA INDEX NAME)




L9 ANSWER 17 OF 51 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1997:545514 CAPLUS
 DOCUMENT NUMBER: 127:188033
 TITLE: Microbial models of mammalian metabolism:
biotransformations of HP 749 (Besipirdine) using
Cunninghamella elegans. [Erratum to document cited in
CA127:158856]
 AUTHOR(S): Rao, Geeta P.; Davis, Patrick J.
 CORPORATE SOURCE: Coll. Pharm., Univ. Texas, Austin, TX, USA
 SOURCE: Drug Metabolism and Disposition (1997), 25(8), 1016
 CODEN: DMDSAI; ISSN: 0090-9556
 PUBLISHER: Williams & Wilkins
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The figure no. in parentheses in the ref. on line 17, column 2, of page
 713 should be Fig. 5. Fig. 6 with its complete legend is given.
 IT 119257-34-0, Besipirdine
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL

(Biological study); PROC (Process)

(biotransformations of HP 749 (besipirdine) using Cunninghamella
elegans (Erratum))

RN 119257-34-0 CAPLUS

CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




IT 119257-33-9 141287-49-2 141287-55-0

193490-35-6

RL: BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL
(Biological study); FORM (Formation, nonpreparative)
(biotransformations of HP 749 (besipirdine) using Cunninghamella
elegans (Erratum))


RN 119257-33-9 CAPLUS

CN 1H-Indol-1-amine, N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 141287-49-2 CAPLUS

CN 1H-Indol-5-ol, 1-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 141287-55-0 CAPLUS

CN 1H-Indol-5-ol, 1-(propyl-4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 193490-35-6 CAPLUS
 CN 1H-Indolol, 1-(4-pyridinylamino)- (9CI) (CA INDEX NAME)



D1-OH

IT **193416-08-9P**
 RL: BSU (Biological study, unclassified); MFM (Metabolic formation); PUR (Purification or recovery); SPN (Synthetic preparation); BIOL (Biological study); FORM (Formation, nonpreparative); PREP (Preparation) (biotransformations of HP 749 (besipirdine) using Cunninghamella elegans (Erratum))
 RN 193416-08-9 CAPLUS
 CN 1H-Indol-1-amine, 5-propoxy-N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



L9 ANSWER 18 OF 51 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1997:281669 CAPLUS
 DOCUMENT NUMBER: 127:13310
 TITLE: Pharmacological activity and safety profile of P10358, a novel, orally active acetylcholinesterase inhibitor for Alzheimer's disease
 AUTHOR(S): Smith, Craig P., Bore, Gina M.; Petko, Wayne; Li, Mary; Selk, David E.; Rush, Douglas K.; Camacho, Fernando; Winslow, James T.; Fishkin, Rod; Cunningham, Dana M.; Brooks, Karen M.; Roehr, Joachim; Hartman, Harold B.; Davis, Larry; Vargas, Hugo M.
 CORPORATE SOURCE: Neuroscience Therapeutic Domain, Hoechst Marion Roussel, Inc., Bridgewater, NJ, USA
 SOURCE: Journal of Pharmacology and Experimental Therapeutics (1997) 280(2), 710-720
 CODEN: JPETAB; ISSN: 0022-3565

dis

PUBLISHER: Williams & Wilkins
DOCUMENT TYPE: Journal
LANGUAGE: English


AB P10358 [1-[(3-fluoro-4-pyridinyl)amino]-3-methyl-1(H)-indol-5-yl Me carbamate] is a potent, reversible acetylcholinesterase inhibitor that produces central cholinergic stimulation after oral and parental administration in rats and mice. P10358 is a 2.5 times more potent acetylcholinesterase inhibitor than THA in vitro ($IC_{50} = 0.10 \pm 0.02 \mu M$ vs. $IC_{50} = 0.25 \pm 0.03 \mu M$). It also inhibits butyrylcholinesterase activity as potently as THA ($IC_{50} = 0.08 \pm 0.05 \mu M$ vs. $IC_{50} = 0.07 \pm 0.01 \mu M$). Ex vivo, P10358 (0.2-20 mg/kg, p.o.) produced dose-dependent inhibition of brain acetylcholinesterase activity. At 10 and 20 mg/kg, it produced profound and long-lasting hypothermia in mice. P10358 enhanced performance in rats in a step-down passive avoidance task (0.62 and 1.25 mg/kg) and in a social recognition paradigm (0.32, 0.64 and 1.25 mg/kg) in mice. It reversed scopolamine-induced deficits in the Morris Water maze in rats (1.256 and 2.5 mg/kg) and a higher dose elevated striatal homovanillic acid levels. These behavioral and biochem. effects are consistent with central cholinergic stimulation. Hemodynamic studies in the rat demonstrated a 16-fold sepn. between behaviorally active doses (1.25 mg/kg) and those that elevated arterial pressure (20 mg/kg). Lethality in rats occurred at an oral dose of 80 mg/kg, but not at lower doses. Chem., P10358 is an N-aminoindole and may not have the hepatotoxic liability assocd. with aminoacridine structure of tacrine. P10358 had weak affinity ($>10 \mu M$) at a variety of aminergic and peptidergic receptors and uptake carriers. These properties suggest that P10358 may be a safe and promising symptomatic treatment of Alzheimer's disease.

IT 188240-59-7, P 10358

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacol. activity and safety of N-aminoindole P-10358 as orally active acetylcholinesterase inhibitor for Alzheimer's disease)

RN 188240-59-7 CAPLUS

CN 1H-Indol-5-ol, 1-[(3-fluoro-4-pyridinyl)amino]-3-methyl-, methylcarbamate (ester) (9CI) (CA INDEX NAME)



L9 ANSWER 19 OF 51 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1997:414966 CAPLUS

DOCUMENT NUMBER: 127:158856

TITLE: Microbial models of mammalian metabolism: biotransformations of RP 749 (besipirdine) using *Cunninghamella elegans*

AUTHOR(S): Rao, Geeta P.; Davis, Patrick J.

CORPORATE SOURCE: Coll. Pharm., Univ. Texas, Austin, TX, USA

SOURCE: Drug Metabolism and Disposition (1997), 25(6), 709-715


CODEN: DMDSAI; ISSN: 0090-9556

PUBLISHER: Williams & Wilkins


DOCUMENT TYPE: Journal

LANGUAGE: English

GI




I



II


AB HP 749 (besipirdine; I) and related analogs belonging to the N-(4-pyridinyl)-1H-indol-1-amine class of compds. have shown a potential to mitigate multiple biochem. deficits assocd. with Alzheimer's disease. I has demonstrated cholinergic and noradrenergic activities both in vitro and in vivo and has potential for the symptomatic treatment of Alzheimer's disease. The 3 primary metabolites of I in dogs, rats, and humans result from hydroxylation of the indole ring, N-dealkylation of the parent compd., and sequential hydroxylation and dealkylation. The fungus *C. elegans* (ATCC 36112) converts 25% of I in a dextrose broth to yield 4 metabolites, 3 of which have been reported in mammalian systems. Preparative scale fermn. allowed for the isolation of the major fungal metabolite (II) resulting from hydroxylation of the indole nucleus at position 5 (16%). Addnl. minor fungal metabolites were formed as a result of N-dealkylation (2%), and sequential N-dealkylation and arom. hydroxylation (2.5%). *C. elegans* is being used as a model to help predict and generate the logical mammalian metabolites of related structural analogs of I.

IT 119257-34-0, Besipirdine
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (biotransformations of HP 749 (besipirdine) using *Cunninghamella elegans*)
 RN 119257-34-0 CAPLUS
 CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




IT 119257-33-9 141287-49-2 141287-55-0
 193490-35-6
 RL: BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative)
 (biotransformations of HP 749 (besipirdine) using *Cunninghamella elegans*)
 RN 119257-33-9 CAPLUS


CN 1H-Indol-1-amine, N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 141287-49-2 CAPLUS
CN 1H-Indol-5-ol, 1-(4-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 141287-55-0 CAPLUS
CN 1H-Indol-5-ol, 1-(propyl-4-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 193490-35-6 CAPLUS
CN 1H-Indolol, 1-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




D1-OH

IT 193416-08-9P

RL: BSU (Biological study, unclassified); MFM (Metabolic formation); PUR (Purification or recovery); SPN (Synthetic preparation); BIOL (Biological study); FORM (Formation, nonpreparative); PREP (Preparation) (biotransformations of HP 749 (besipirdine) using *Cunninghamella elegans*)

RN 193416-08-9 CAPLUS

CN 1H-Indol-1-amine, 5-propoxy-N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



L9 ANSWER 20 OF 51 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1997:270846 CAPLUS

DOCUMENT NUMBER: 126:325417

TITLE: .alpha.-Adrenergic activity and cardiovascular effects of besipirdine HCl (HP 749) and metabolite P7480 in vitro and in the conscious rat and dog

AUTHOR(S): Hubbard, John W.; Nordstrom, Scott T.; Smith, Craig P.; Brooks, Karen M.; Laws-Ricker, Lynn; Zhou, Lily; Vargas, Hugo M.

CORPORATE SOURCE: Clinical Res. Dep., Hoechst Marion Roussel, Inc., Bridgewater, NJ, 08807-0800, USA

SOURCE: Journal of Pharmacology and Experimental Therapeutics (1997), 281(1), 337-346

CODEN: JPETAB; ISSN: 0022-3565

PUBLISHER: Williams & Wilkins

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Besipirdine displays potent adrenergic activity in a variety of pharmacol. and behavioral tests. Based on this property, the authors evaluated the effects of besipirdine and its N-despropyl metabolite N-despropyl-besipirdine (P7480) on cardiovascular function in rats and dogs. Besipirdine and P7480 bind alpha-2 adrenoceptors (KI: 380 and 10 nM, resp.) and facilitate the stimulated release of [3H]norepinephrine from rat cortical slices due to presynaptic autoreceptor blockade. In rat aorta rings and the pithed rat, P7480, but not besipirdine, also behaved as a postsynaptic alpha-1 adrenoceptor agonist. In conscious rats, besipirdine (2-10 mg/kg, p.o.) and P7480 (3-10 mg/kg, p.o.) produced dose-related increases in mean arterial pressure. Inhibition of hepatic cytochrome P 450 enzyme activity blocked the pressor effect of besipirdine, but not of P7480; therefore, P7480 mediated besipirdine's pressor effect. The bradycardia after either agent was unaffected. In conscious dogs, besipirdine (0.1-2 mg/kg, p.o.) also produced dose-related hypertension and bradycardia. The hypertension, but not the bradycardia, were sensitive to prazosin (3 mg/kg, p.o.), but not hexamethonium (10 mg/kg, p.o.). Muscarinic and beta-adrenergic receptor blockade studies in


anesthetized dogs demonstrated the bradycardia to be due to withdrawal of cardiac sympathetic tone. These findings suggest that besipirdine's peripheral hypertensive effect is primarily mediated by the pressor metabolite P7480, although facilitated norepinephrine release may contribute. Besipirdine's bradycardic action appears to be centrally mediated, because both compds. lacked direct neg. chronotropic activity on spontaneously beating guinea pig atria in vitro.

IT 130953-69-4, Besipirdine hydrochloride

RL: ADV (Adverse effect, including toxicity); BIOL (Biological study) (.alpha.-adrenergic activity and cardiovascular effects of besipirdine HCl (HP 749) and metabolite P7480 in vitro and in conscious rat and dog)

RN 130953-69-4 CAPLUS

CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

IT 138624-41-6, P7480

RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative) (.alpha.-adrenergic activity and cardiovascular effects of besipirdine HCl (HP 749) and metabolite P7480 in vitro and in conscious rat and dog)

RN 138624-41-6 CAPLUS

CN 1H-Indol-1-amine, N-4-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L9 ANSWER 21 OF 51 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1997:123307 CAPLUS

DOCUMENT NUMBER: 126:220296

TITLE: Synthesis and preliminary structure-activity

Searched by Barb O'Bryen, STIC 308-4291

relationships of 1-[(3-fluoro-4-pyridinyl)amino]-3-methyl-1H-indol-5-yl methyl carbamate (P10358), a novel acetylcholinesterase inhibitor

AUTHOR(S): Martin, Lawrence L.; Davis, Larry; Klein, Joseph T.; Nemoto, Peter; Olsen, Gordon E.; Bores, Gina M.; Camacho, Fernando; Petko, Wayne W.; Rush, Douglas K.; et al.

CORPORATE SOURCE: Hoechst Marion Roussel Inc., Neuroscience Therapeutic Area, Bridgewater, NJ, 08807-0800, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (1997), 7(2), 157-162
CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal


LANGUAGE: English

AB A series of carbamate analogs of besipirdine (HP 749) was synthesized as potential agents with enhanced cholinomimetic properties for the treatment of Alzheimer's disease. P10358, 1-[(3-fluoro-4-pyridinyl)amino]-3-methyl-1H-indol-5-yl Me carbamate, emerged as a potent, reversible acetylcholinesterase inhibitor that significantly enhanced performance on oral or parenteral administration in learning and memory paradigms.

IT 141287-70-9P 141287-72-1P 188240-58-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; synthesis and structure-activity relationships of besipirdine carbamate analogs as acetylcholinesterase inhibitors)


RN 141287-70-9 CAPLUS

CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 141287-72-1 CAPLUS

CN 1H-Indol-5-ol, 1-[(3-fluoro-4-pyridinyl)propylamino]-3-methyl- (9CI) (CA INDEX NAME)




RN 188240-58-6 CAPLUS
CN 1H-Indol-5-ol, 1-[(3-fluoro-4-pyridinyl)amino]-3-methyl- (9CI) (CA INDEX NAME)




IT 141287-42-5P 141287-43-6P 141287-44-7P
141287-45-8P 188240-59-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis and structure-activity relationships of besipirdine carbamate analogs as acetylcholinesterase inhibitors)


RN 141287-42-5 CAPLUS
CN 1H-Indol-5-ol, 1-[(3-fluoro-4-pyridinyl)propylamino]-3-methyl-, methylcarbamate (ester) (9CI) (CA INDEX NAME)



RN 141287-43-6 CAPLUS
CN Carbamic acid, butyl-, 1-[(3-fluoro-4-pyridinyl)propylamino]-3-methyl-1H-indol-5-yl ester (9CI) (CA INDEX NAME)




RN 141287-44-7 CAPLUS
CN Carbamic acid, heptyl-, 1-[(3-fluoro-4-pyridinyl)propylamino]-3-methyl-1H-indol-5-yl ester (9CI) (CA INDEX NAME)




RN 141287-45-8 CAPLUS

CN Carbamic acid, (phenylmethyl)-, 1-[(3-fluoro-4-pyridinyl)propylamino]-3-methyl-1H-indol-5-yl ester (9CI) (CA INDEX NAME)



RN 188240-59-7 CAPLUS

CN 1H-Indol-5-ol, 1-[(3-fluoro-4-pyridinyl)amino]-3-methyl-, methylcarbamate (ester) (9CI) (CA INDEX NAME)




IT 119257-34-0, Besipirdine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(synthesis and structure-activity relationships of besipirdine carbamate analogs as acetylcholinesterase inhibitors)

RN 119257-34-0 CAPLUS

CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



L9 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1996:300305 CAPLUS

DOCUMENT NUMBER: 125:1146

TITLE: Serotonergic activity of HP 184: does spontaneous release have a role?

AUTHOR(S): ~~Smith, Craig P.~~; Woods-Kettelberger, Ann T.; Corbett, Roy; Chesson, Susan M.; Bores, Gina M.; Petko, Wayne W.; Roehr, Joachim E.; Kongsamut, Sathapana

CORPORATE SOURCE: Neuroscience Therapeutic Domain, Somerville, NJ, 08876, USA

SOURCE: Neurochemical Research (1996), 21(5), 575-583

CODEN: NEREDZ; ISSN: 0364-3190

PUBLISHER: Plenum

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Examn. of HP 184, [N-n-propyl-N-(3-fluoro-4-pyridinyl)-1H-3-methylindol-1-amine hydrochloride], in a variety of tests for serotonergic activity revealed some unique properties of this compd. The authors report here that 100 .mu.M HP 184 enhanced spontaneous release of [3H]serotonin (5-HT) from rat hippocampal slices. This release was independent of the uptake carrier. In vivo assays confirmed that HP 184 (20 mg/kg, i.p.) lacked significant interactions at the norepinephrine (NE) or 5-HT uptake carrier itself. Notably, HP 184 (15 mg/kg, i.p.) reduced drinking behavior in schedule-induced polydipsic (SIP) rats (a behavioral model for obsessive compulsive disorder). The authors previously reported that some selective 5-HT reuptake inhibitors decrease SIP 30-40% after a 14-21 day treatment. In the current study, HP 184 decreased SIP beginning with the first treatment, and this redn. (30%) was maintained for 28 days. The authors further investigated HP 184 and serotonin metabolite levels. One hour after i.p. administration of 30 mg/kg HP 184, the ratio of whole brain 5-hydroxyindoleacetic acid (5-HIAA) to 5-HT was increased, suggesting serotonergic activation. Under these conditions, the brain-plasma ratio of HP 184 was approx. 2:1, with brain concns. of 1.6 .mu.g/g. The authors speculate that the spontaneous release effects of HP 184 may be responsible for the behavioral effects obsd.


IT 119229-64-0, HP 184

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(serotonergic activity of HP 184 in relation to serotonin release and treatment of obsessive compulsive disorder)

RN 119229-64-0 CAPLUS

CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl-N-propyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L9 ANSWER 23 OF 51 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1996:6887 CAPLUS

DOCUMENT NUMBER: 124:175740

TITLE: Synthesis and Structure-Activity Relationships of
N-Propyl-N-(4-pyridinyl)-1H-indol-1-amine
(Besipirdine) and Related Analogs as Potential
Therapeutic Agents for Alzheimer's Disease

AUTHOR(S): Klein, Joseph T.; Davis, Larry; Olsen, Gordon E.;
Wong, George S.; Huger, Francis P.; ~~Smith, Craig P.~~;
Petko, Wayne W.; Cornfeldt, Michael; Wilker, Jeffrey
C.; et al.

CORPORATE SOURCE: Hoechst-Roussel Pharmaceuticals Inc., Somerville, NJ,
NEW JERSEY 08876, USA

SOURCE: Journal of Medicinal Chemistry (1996), 39(2), 570-81
CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A series of novel N-(4-pyridinyl)-1H-indol-1-amines and other heteroaryl
analogs was synthesized and evaluated in tests to det. potential utility
for the treatment of Alzheimer's disease. From these compds.,
N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) was selected for
clin. development based on in-depth biol. evaluation. In addn. to
cholinomimetic properties based initially on in vitro inhibition of
[3H]quinuclidinyl benzilate binding, in vivo reversal of
scopolamine-induced behavioral deficits, and subsequently on other
results, besipirdine also displayed enhancement of adrenergic mechanisms
as evidenced in vitro by inhibition of [3H]clonidine binding and
synaptosomal biogenic amine uptake, and in vivo by reversal of
tetrabenazine-induced ptosis. The synthesis, structure-activity
relationships for this series, and the biol. profile of besipirdine are
reported.

IT 119229-61-7P 119257-33-9P 119257-34-0P,
Besipirdine 119257-36-2P 119257-40-8P
125529-97-7P 159732-16-8P 159732-17-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL
(Biological study); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and structure-activity relationship of N-(pyridinyl)indolamines
and analogs for treatment of Alzheimer's disease)


RN 119229-61-7 CAPLUS

CN 1H-Indol-1-amine, 3-methyl-N-4-pyridinyl-, ethanedioate (1:1) (9CI) (CA
INDEX NAME)

CM 1

CRN 119229-60-6


CMF C14 H13 N3



CM 2


CRN 144-62-7

CMF C2 H2 O4




RN 119257-33-9 CAPLUS

CN 1H-Indol-1-amine, N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119257-34-0 CAPLUS

CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119257-36-2 CAPLUS

CN 1H-Indol-1-amine, N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119257-33-9

CMF C13 H11 N3




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 119257-40-8 CAPLUS

CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119257-34-0

CMF C16 H17 N3




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 125529-97-7 CAPLUS

CN 9H-Carbazol-9-amine, N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA
INDEX NAME)

CM 1

CRN 125529-86-4

CMF C17 H13 N3




CM 2


CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 159732-16-8 CAPLUS
CN 1H-Indole-3-carboxaldehyde, 1-(propyl-4-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 159732-17-9 CAPLUS
CN 1H-Indole-3-carboxaldehyde, 1-(propyl-4-pyridinylamino)-, (Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 159732-16-8
CMF C17 H17 N3 O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



IT 119229-47-9P 119229-49-1P 119229-51-5P
119229-53-7P 119229-55-9P 119229-56-0P
119229-59-3P 119229-63-9P 119229-67-3P
119229-75-3P 119257-32-8P 119257-37-3P
119257-39-5P 119257-41-9P 125530-02-1P
128546-10-1P 159732-08-8P 159732-21-5P
159732-23-7P 159732-25-9P 159732-33-9P
159732-35-1P 173677-79-7P 173677-80-0P
173677-81-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. and structure-activity relationship of N-(pyridinyl)indolamines and analogs for treatment of Alzheimer's disease)


RN 119229-47-9 CAPLUS

CN 1H-Indol-1-amine, 5-chloro-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 119229-46-8

CMF C13 H10 Cl N3




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 119229-49-1 CAPLUS

CN 1H-Indol-1-amine, 5-chloro-N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119229-48-0

CMF C16 H16 Cl N3




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 119229-51-5 CAPLUS

CN 1H-Indol-1-amine, 5-bromo-N-(4-pyridinyl)-, (2Z)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 119229-50-4

CMF C13 H10 Br N3




CM 2

CRN 110-16-7

CMF C4 H4 O4


Double bond geometry as shown.



RN 119229-53-7 CAPLUS
CN 1H-Indol-1-amine, 5-bromo-N-methyl-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 119229-52-6
CMF C14 H12 Br N3



CM 2

CRN 110-16-7
CMF C4 H4 O4


Double bond geometry as shown.



RN 119229-55-9 CAPLUS
CN 1H-Indol-1-amine, 5-bromo-N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119229-54-8
CMF C16 H16 Br N3




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.



RN 119229-56-0 CAPLUS

CN 1H-Indol-1-amine, 5-nitro-N-4-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 119229-59-3 CAPLUS

CN 1H-Indol-1-amine, N-methyl-5-nitro-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119229-58-2

CMF C14 H12 N4 O2




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 119229-63-9 CAPLUS

CN 1H-Indol-1-amine, 3-methyl-N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119229-62-8

CMF C17 H19 N3




CM 2

CRN 110-16-7

CMF C4 H4 O4


Double bond geometry as shown.



RN 119229-67-3 CAPLUS
CN 1H-Indol-1-amine, N-2-propenyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1)
(9CI) (CA INDEX NAME)

CM 1


CRN 119229-66-2
CMF C16 H15 N3




CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.




RN 119229-75-3 CAPLUS
CN 1H-Indol-1-amine, 5-methoxy-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119257-32-8 CAPLUS

CN 1H-Indol-1-amine, N-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119257-37-3 CAPLUS

CN 1H-Indol-1-amine, N-methyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 119257-32-8

CMF C14 H13 N3




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 119257-39-5 CAPLUS

CN 1H-Indol-1-amine, N-ethyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 119257-38-4

CMF C15 H15 N3




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 119257-41-9 CAPLUS

CN 1H-Indol-1-amine, 5-methoxy-N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119229-37-7

CMF C17 H19 N3 O




CM 2

CRN 110-16-7

CMF C4 H4 O4


Double bond geometry as shown.



RN 125530-02-1 CAPLUS
CN 9H-Carbazol-9-amine, N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1)
(9CI) (CA INDEX NAME)

CM 1


CRN 125530-01-0
CMF C20 H19 N3



CM 2

CRN 110-16-7
CMF C4 H4 O4


Double bond geometry as shown.



RN 128546-10-1 CAPLUS
CN 4-Quinolinamine, 7-chloro-N-1H-indol-1-yl-N-propyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 128546-09-8
CMF C20 H18 Cl N3




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.



RN 159732-08-8 CAPLUS

CN 1H-Indol-1-amine, 2-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 159732-21-5 CAPLUS

CN 1H-Indol-1-amine, 3-ethyl-N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 159732-20-4


CMF C18 H21 N3




CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.

RN 159732-23-7 CAPLUS
CN 1H-Indol-1-amine, N-butyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)


CM 1

CRN 159732-22-6
CMF C17 H19 N3

CM 2

CRN 110-16-7
CMF C4 H4 O4


Double bond geometry as shown.



RN 159732-25-9 CAPLUS
CN 1H-Indol-1-amine, N-2-propynyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1)
(9CI) (CA INDEX NAME)

CM 1


CRN 159732-24-8
CMF C16 H13 N3



CM 2

CRN 110-16-7
CMF C4 H4 O4


Double bond geometry as shown.



RN 159732-33-9 CAPLUS
CN 1H-Indol-1-amine, N-(1-methylethyl)-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 159732-32-8
CMF C16 H17 N3




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 159732-35-1 CAPLUS

CN 1H-Indol-1-amine, 2-methyl-N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 159732-34-0

CMF C17 H19 N3




CM 2


CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 173677-79-7 CAPLUS
CN 1H-Indole-3-carbonitrile, 1-(propyl-4-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 173677-80-0 CAPLUS
CN 1H-Indole-3-carbonitrile, 1-(propyl-4-pyridinylamino)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 173677-79-7
CMF C17 H16 N4




CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 173677-81-1 CAPLUS
CN Ethanone, 1-[1-(propyl-4-pyridinylamino)-1H-indol-3-yl]- (9CI) (CA INDEX NAME)




IT 159732-18-0P 173677-77-5P 173677-78-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and structure-activity relationship of N-(pyridinyl)indolamines and analogs for treatment of Alzheimer's disease)


RN 159732-18-0 CAPLUS

CN 1H-Indol-1-amine, 3-ethenyl-N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 173677-77-5 CAPLUS

CN 1H-Indole-3-carboxaldehyde, 1-(propyl-4-pyridinylamino)-, oxime (9CI) (CA INDEX NAME)



RN 173677-78-6 CAPLUS

CN 1H-Indole-3-methanol, .alpha.-methyl-1-(propyl-4-pyridinylamino)- (9CI) (CA INDEX NAME)



L9 ANSWER 24 OF 51 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1996:304705 CAPLUS

DOCUMENT NUMBER: 125:1168

TITLE: Preliminary evaluation of besipirdine for the treatment of Alzheimer's diseaseAUTHOR(S): Huff, F. J.

CORPORATE SOURCE: Hoechst-Roussel Pharmaceuticals Inc., Somerville, NJ, 08876, USA

SOURCE: Annals of the New York Academy of Sciences (1996), 777 (Neurobiology of Alzheimers Disease), 410-414
CODEN: ANYAA9; ISSN: 0077-8923

PUBLISHER: New York Academy of Sciences

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Besipirdine hydrochloride (HP 749) is an indole-substituted analog of 4-aminopyridine. Besipirdine enhances both cholinergic and adrenergic neurotransmission in the central nervous system, and may have greater efficacy than purely cholinergic agents in treating dementia due to Alzheimer's disease.1. The present study examd. the efficacy and tolerability of two doses of besipirdine (5 and 20 mg BID) in 275 patients with Alzheimer's disease during 3 mo of treatment and during 3 mo after withdrawal of treatment. Besipirdine was generally well tolerated. The level of performance on a cognitive test was sustained during 3 mo of treatment with besipirdine, whereas the performance of patients treated with placebo deteriorated over the same time period. The results suggest a dose-response relationship, with greater efficacy after 3 mo of treatment and longer persistence after treatment withdrawal for besipirdine 20 mg BID than for 5 mg BID. A clin. global rating did not detect a besipirdine treatment effect. The full efficacy after 3 mo of treatment did not persist after withdrawal of treatment, suggesting that the benefit is primarily symptomatic. Treatment with higher doses and for longer periods may enhance efficacy on both cognitive and clin. global assessments.


IT 119257-34-0, Besipirdine

RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preliminary evaluation of besipirdine for Alzheimer's disease treatment)

RN 119257-34-0 CAPLUS

CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



L9 ANSWER 25 OF 51 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1996:478108 CAPLUS

DOCUMENT NUMBER: 125:158423

TITLE: .alpha.2-Adrenoceptor antagonists potentiate acetylcholinesterase inhibitor effects on passive


AUTHOR(S): avoidance learning in the rat
Camacho, Fernando; Smith, Craig P.; Vargas, Hugo M.;
Winslow, James T.
CORPORATE SOURCE: Neuroscience Therapeutic Domain, Somerville, NJ,
08876-1258, USA
SOURCE: Psychopharmacology (Berlin) (1996), 124(4), 347-354
CODEN: PSCHDL; ISSN: 0033-3158
PUBLISHER: Springer
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The ~~cholinergic hypothesis of Alzheimer's disease~~ (AD) has strongly influenced research on learning and memory over the last decade. However, there has been limited success treating AD dementia with cholinomimetics. Furthermore, there are indications that other neurotransmitter systems affected by this disease may be involved in cognitive processes. Animal studies have suggested that norepinephrine and acetylcholine may interact in learning and memory. The current expts. investigate this interaction in a step-down passive avoidance paradigm after coadministration of acetylcholinesterase inhibitors and .alpha.2-adrenoceptor antagonists. Administration of acetylcholinesterase inhibitors heptylphysostigmine (0.625-5.0 mg/kg, i.p.), tacrine (2.5-10.0 mg/kg, orally), velnacrine (0.312-2.5 mg/kg, s.c.), and galanthamine (0.312-2.5 mg/kg, i.p.) each enhanced retention of a passive avoidance response at selected moderate doses administered 30-60 min prior to training. The .alpha.2-adrenoceptor antagonists idazoxan (0.312-2.5 mg/kg, i.p.), yohimbine (.078-0.312 mg/kg, i.p.) and P 867480 (0.156-0.625 mg/kg, i.p.) alone failed to enhance learning in this paradigm. Coadministration of a subthreshold dose of heptylphysostigmine (0.625 mg/kg, i.p.) with doses of idazoxan, yohimbine or P 867480 enhanced passive avoidance learning. This synergistic interaction may represent effects of antagonism of presynaptic .alpha.2-adrenoceptor since coadministration of heptylphysostigmine and the selective postsynaptic .alpha.2-adrenoceptor antagonist SKF 104856 did not result in enhanced learning. Taken together these data suggest noradrenergic activation through pre-synaptic .alpha.2-adrenoceptor blockade may potentiate cholinergic activity in the formation of a long-term memory trace. These observation may have implications for the treatment of AD with cholinergic and adrenergic agents.

IT 119257-36-2, Despropylbesipirdine maleate
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(.alpha.2-adrenoceptor antagonists potentiate acetylcholinesterase inhibitor effects on passive avoidance learning in rats)
RN 119257-36-2 CAPLUS
CN 1H-Indol-1-amine, N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119257-33-9
CMF C13 H11 N3




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



L9 ANSWER 26 OF 51 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1996:600687 CAPLUS

DOCUMENT NUMBER: 125:238506

TITLE: Besipirdine (HP 749) reduces schedule-induced polydipsia in rats

AUTHOR(S): Woods-Kettelberger, A. T.; Smith, C. P.; Corbett, R.; Szewczak, M. R.; Roehr, J. E.; Bores, G. M.; Klein, J. T.; Kongsamut, S.

CORPORATE SOURCE: Neuroscience Therapeutic Domain, Hoechst Marion Roussel, Inc., Bridgewater, NJ, 08807-0800, USA

SOURCE: Brain Research Bulletin (1996), 41(2), 125-130

CODEN: BRBUDU; ISSN: 0861-9230

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English


AB Besipirdine inhibited the uptake of biogenic amines (norepinephrine and serotonin) by rat cortical synaptosomes in vitro. It prevented tetrabenazine-induced ptosis in mice and potentiated the 5-hydroxytryptophan-induced serotonin syndrome in rats. Furthermore, it decreased schedule-induced polydipsic behavior in rats. Schedule-induced polydipsia may be a model for obsessive compulsive disorder. Previous results have shown that certain selective serotonin reuptake inhibitors decrease schedule-induced polydipsia after 14-21 days of treatment. Besipirdine reduced schedule-induced polydipsic behavior immediately, and this redn. lasted throughout the duration of the expt. (29 days).

IT 119257-34-0, Besipirdine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(schedule-induced polydipsia inhibition by)

RN 119257-34-0 CAPLUS

CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



L9 ANSWER 27 OF 51 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1996:397829 CAPLUS

DOCUMENT NUMBER: 125:49175

TITLE: ~~A treatment and withdrawal trial of besipirdine in Alzheimer disease~~

AUTHOR(S): Huff, F. J.; Antuono, P. G.; Delagandara, J. E.; McDonald, M. A.; Cutler, N. R.; Cohen, S. R.; Green, R. C.; Zemlan, F. P.; Crismon, M. L.; et al.

CORPORATE SOURCE: University Medicine and Dentistry New Jersey, Piscataway, NJ, 08855, USA

SOURCE: Alzheimer Disease and Associated Disorders (1996), 10(2), 93-102

CODEN: ADADE2; ISSN: 0893-0341

PUBLISHER: Lippincott-Raven

DOCUMENT TYPE: Journal

LANGUAGE: English


AB Besipirdine hydrochloride (HP 749) is an indole-substituted analog of 4-aminopyridine. Besipirdine enhances both cholinergic and adrenergic neurotransmission in the central nervous system. The present study examd. the efficacy and tolerability of two doses of besipirdine (5 and 20 mg b.i.d.) in 275 patients with Alzheimer disease during 3 mo of treatment and for 3 mo after withdrawal of treatment. Assessment after withdrawal of treatment was used in an effort to distinguish persistent efficacy attributable to a neuroprotective mechanism from reversible symptomatic efficacy. Besipirdine was generally well tolerated. The level of performance on the cognitive subscale of the Alzheimer Disease Assessment Scale (ADAS-Cog) was sustained during 3 mo of treatment with besipirdine, whereas some deterioration in the performance of patients treated with placebo was obsd. over the same period. The small difference between active and placebo treatment groups approached, but did not reach statistical significance in the primary intent-to-treat anal. (p = 0.067); anal. of patients who completed all assessments was supportive (p = 0.031). Global ratings using the Clinician Interview-Based Impression of Change did not detect a besipirdine treatment benefit, possibly because of an adverse effect on mood and behavior in some patients. A high ratio of adrenergic to cholinergic potency may have resulted in the adverse effects of besipirdine and hence its failure to support the hypothesis that multiple neurotransmitter treatment may be more efficacious than monotherapy. The efficacy apparent on the ADAS-Cog after 3 mo of treatment did not persist 3 mo after withdrawal of treatment, suggesting that the benefit was symptomatic. This study provides a practical example of the use of treatment withdrawal assessment to distinguish neuroprotective from symptomatic efficacy.

IT 119257-34-0, Besipirdine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(treatment and withdrawal trial of besipirdine in Alzheimer disease)

RN 119257-34-0 CAPLUS
CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



L9 ANSWER 28 OF 51 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1996:234782 CAPLUS

DOCUMENT NUMBER: 124:307340

TITLE: Frequency-dependent inhibition of neurotransmitter release by besipirdine and HP 184

AUTHOR(S): Tang, Lei; Kongsamut, Sathapana

CORPORATE SOURCE: Neuroscience Therapeutic Domain, Hoechst Marion

Roussel, P.O. Box 2500, Somerville, USA

SOURCE: European Journal of Pharmacology (1996), 300(1/2), 71-4

CODEN: EJPHAZ; ISSN: 0014-2999

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Interaction of besipirdine (HP 749, N-(n-propyl)-N-(4-pyridinyl)-1H-indol-1-amine hydrochloride) with voltage-dependent Na⁺ channels has been described. Here we describe studies with besipirdine and a related compd., HP 184 ((N-(n-propyl)-3-fluoro-4-pyridinyl)-1H-3-methylindol-1-amine hydrochloride), showing that this interaction is voltage-dependent and leads to frequency-dependent inhibition of elec. stimulated neurotransmitter release. Thus, the inhibition of veratridine-induced increases in intracellular Ca²⁺ was enhanced by depolarization with KCl (IC₅₀ shifted from 23.8 .mu.M in 5 mM KCl to 7.3 .mu.M in 15 mM KCl for besipirdine and from 58.2 .mu.M to 14.1 .mu.M for HP 184). Moreover, the enhancement of elec. stimulated [3H]norepinephrine release by besipirdine was diminished at higher frequencies of stimulation. As has been previously suggested for such compds., we predict that besipirdine would act as a filter in the brain allowing signaling at low frequencies but blocking transmission at high frequencies.


IT 119229-64-0, HP 184 119257-34-0, Besipirdine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(frequency-dependent inhibition of neurotransmitter release by besipirdine and HP 184)


RN 119229-64-0 CAPLUS

CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl-N-propyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 119257-34-0 CAPLUS
CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



L9 ANSWER 29 OF 51 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1995:389845 CAPLUS
DOCUMENT NUMBER: 122:151393
TITLE: Central .alpha.2-adrenergic agonists for inhibition of
posttraumatic metabolism
INVENTOR(S): Goeters, Christine; Mertes, Nobert; Zander, Joseph;
Kuhmann, Martin; Brecht, Hans-Michael
PATENT ASSIGNEE(S): Boehringer Ingelheim KG, Germany
SOURCE: Ger. Offen., 12 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4325491	A1	19950202	DE 1993-4325491	19930729
WO 9503798	A2	19950209	WO 1994-EP2475	19940727
WO 9503798	A3	20010503		
W: AU, BG, BR, BY, CA, CH, CN, CZ, FI, HU, JP, KR, KZ, LV, NO, NZ, PL, RO, RU, SK, UA, US, UZ				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9475331	A1	19950228	AU 1994-75331	19940727
EP 719139	A1	19960703	EP 1994-925399	19940727
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				

PRIORITY APPLN. INFO.:

DE 1993-4325491 A 19930729

WO 1994-EP2475 W 19940727

OTHER SOURCE(S):

MARPAT 122:151393


AB Substituted aminoimidazolines, oxazoloazepines, and thiazoloazepines are proposed for treatment of the acute alterations in intermediary metab. subsequent to surgery, trauma, or burns. Thus, administration of clonidine to postoperative patients improved the cumulative N balance.

IT 130953-69-4, HP-749

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(central .alpha.2-adrenergic agonists for inhibition of posttraumatic metab.)

RN 130953-69-4 CAPLUS

CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L9 ANSWER 30 OF 51 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1995:933859 CAPLUS

DOCUMENT NUMBER: 124:689

TITLE: Effects of besipirdine at the voltage-dependent sodium channel

AUTHOR(S): Tang, L.; Smith, C. P.; Huger, F. P.; Kongsamut, S.

CORPORATE SOURCE: Department of Biological Research, Hoechst Roussel Pharmaceuticals, Inc., Somerville, NJ, 08876, USA

SOURCE: British Journal of Pharmacology (1995), 116(5), 2468-72

CODEN: BJPCBM; ISSN: 0007-1188


PUBLISHER: Stockton

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Besipirdine (HP 749) is a compd. undergoing clin. trials for efficacy in treating Alzheimer's disease. Among other pharmacol. effects, besipirdine inhibits voltage-dependent sodium and potassium channels. This paper presents a pharmacol. study of the interaction of besipirdine with voltage-dependent sodium channels. Besipirdine inhibited [3H]-batrachotoxin binding ($IC_{50} = 5.5 \pm 0.2 \mu M$) in a rat brain vesicular prepn. and concn.-dependently inhibited veratridine (25 μM)-stimulated increases in intracellular free sodium ($[Na^+]_i$) and calcium ($[Ca^{2+}]_i$) in primary cultured cortical neurons of rat. Besipirdine (30-100 μM) concn.-dependently inhibited (up to 100%) veratridine-stimulated release of [3H]-noradrenaline (NA) from rat cortical slices. When examd. in greater detail, besipirdine was found to inhibit [3H]-batrachotoxin binding in vesicular membranes competitively. However, when examd. in rat brain synaptosomes, we found that the antagonism by besipirdine was not competitive; i.e., the maximal stimulation of $[Ca^{2+}]_i$ induced by veratridine decreased with increasing concns. of besipirdine. These results show that besipirdine is an inhibitor of voltage-sensitive sodium channels and appears to bind to a site close to the batrachotoxin/veratridine binding site.

IT 130953-69-4, HP 749
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(besipirdine effect at voltage-dependent sodium channel in brain)
RN 130953-69-4 CAPLUS
CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

L9 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1995:760335 CAPLUS
DOCUMENT NUMBER: 123:188369
TITLE: A "bridging" (safety/tolerance) study of besipirdine hydrochloride in patients with Alzheimers disease
AUTHOR(S): Sramek, John J.; Viereck, Christopher; Huff, F. Jacob; Wardle, Thomas; Hourani, Jameel; Stewart, John A.; Cutler, Neal R.
CORPORATE SOURCE: California Clinical Trials, Beverly Hills, CA, 90211, USA
SOURCE: Life Sciences (1995), 57(12), 1241-8
CODEN: LIFSAB; ISSN: 0024-3205
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Besipirdine hydrochloride is a novel compd. with cholinergic and adrenergic activity being investigated as a treatment for Alzheimer's disease (AD). The pharmacodynamics of some anti-dementia drugs are known to differ in patients with AD as compared with elderly normals. The present study was designed to det. the max. tolerated dose (MTD) of multiple oral doses of besipirdine in AD patients. Twelve AD patients (NINCDS/ADRDA criteria; 7M, 5F, ages 58-75, mean age 65) were randomized to besipirdine (n=9) or placebo (n=3) in a double-blind, parallel-group, rising-dose design. Doses were 10, 20, 30, and 40 mg bid for 2 days each, followed by 50 and 60 mg bid for 5 days each. The most common adverse events were asymptomatic postural hypotension and asymptomatic bradycardia. Two patients on active drug developed severe adverse events: 1 after 3 days at 50 mg bid (nausea and vomiting); 1 after 3 days at 60 mg bid (angina). Due to the anginal episode, the study was terminated on Day 17. Plasma concns. increased linearly with dose for besipirdine and its major metabolite. The two patients who developed severe adverse events had the highest plasma concns. measured. Besipirdine 50 mg bid was considered the max. tolerated dose (MTD).

IT 130953-69-4, Besipirdine hydrochloride
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(safety and tolerance study of besipirdine hydrochloride in patients with Alzheimers disease)
RN 130953-69-4 CAPLUS
CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl-, monohydrochloride (9CI) (CA

INDEX NAME)



● HCl

L9 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1995:729270 CAPLUS

DOCUMENT NUMBER: 123:159988

TITLE: The pharmacokinetics and cardiovascular pharmacodynamics of HP 749 (besipirdine-HCl) and metabolite P86-7480 in the conscious monkey

AUTHOR(S): Hubbard, John W.; Hsu, Robert S.; Griffiths, Lynne; Natarajan, Chandra; Dean, Roosevelt; Dileo, Eva M.; Hintze, Thomas H.

CORPORATE SOURCE: Department of Clinical Research, Hoechst-Roussel Pharmaceuticals Inc., Somerville, NJ, 08876, USA

SOURCE: Journal of Clinical Pharmacology (1995), 35(7), 688-96
CODEN: JPCPBR; ISSN: 0091-2700

PUBLISHER: Lippincott

DOCUMENT TYPE: Journal

LANGUAGE: English

AB HP 749 was absorbed slowly in the conscious monkey after single oral doses (10, 20, and 40 mg/kg), with gradual metab. to the N-despropyl metabolite, P86-7480. The t_{max} was 2 to 4 h after dosing, with nonlinear increases in C_{max} and the AUC0-4h for HP 749. The calcd. elimination half life ($t_{1/2}$) after oral administration was 7.4 ± 2.1 h; however, absorption appeared to influence the terminal phase because the $t_{1/2}$ after i.v. administration of 10 mg/kg was 1.5 h. Plasma concn. of HP 749 2 min after i.v. bolus was 26.08 $\mu\text{g/mL}$. The HP 749 was rapidly distributed ($t_{1/2\alpha} = 0.064 \pm 0.033$ h) after i.v. administration, and displayed a V_z of 2.6 ± 0.85 L/kg. The CL of HP 749 was 20.8 ± 6.9 mL/min/kg, whereas renal clearance (CLR) of unchanged drug was only 0.13 ± 0.04 mL/min/kg. Thus, only about 1% of the administered dose was excreted unchanged by the kidney. The P86-7480 also was rapidly distributed and eliminated after an i.v. bolus, but was less extensively distributed than HP 749. HP 749 administered either as an i.v. bolus or orally caused a significant pressor effect soon after dosing. A significant tachycardia resulted from i.v. administration, but not after oral administration of the drug. An i.v. bolus of P86-7480 (0.1 mg/kg) resulted in an immediate increase in MAP and decreased heart rate. The duration of these cardiovascular events was significantly shorter after i.v. administration of P86-7480 than with i.v. or oral administration of the parent drug. These results support findings of previous studies in rats and dogs, demonstrating that high doses of HP 749 and its metabolite P86-7480 exert significant cardiovascular effects.


IT 119257-33-9, P 86-7480 130953-69-4, HP 749

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(HP 749 (besipirdine-HCl) and metabolite P86-7480 pharmacokinetics and cardiovascular pharmacodynamics)


RN 119257-33-9 CAPLUS

CN 1H-Indol-1-amine, N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 130953-69-4 CAPLUS

CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L9 ANSWER 33 OF 51 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1995:219495 CAPLUS

DOCUMENT NUMBER: 122:936

TITLE: HP 749 enhances calcium-independent release of [3H]norepinephrine from rat cortical slices and synaptosomes

AUTHOR(S): Smith, Craig P.; Huger, Francis P.; Petko, Wayne; Kongsamut, Sathapana

CORPORATE SOURCE: Neuroscience Strategic Business Unit, Hoechst-Roussel Pharmaceuticals, Inc., Somerville, NJ, 08876, USA

SOURCE: Neurochemical Research (1994) 19(10), 1265-70
CODEN: NEREDZ; ISSN: 0364-3190

PUBLISHER: Plenum

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Previous studies have shown that, at concns. of 1 .mu.M and 10 .mu.M, HP 749 increased elec.-stimulated release of [3H]norepinephrine (NE) from rat cortical slices. These effects were Ca²⁺-dependent, indicating an effect on release from vesicular stores. At 100 .mu.M, HP 749 had two effects. In addn. to enhancing the CA²⁺-dependent elec.-evoked release, it also induced a rise in the basal efflux (spontaneous release) of [3H]NE, which was obsd. in both cortical slices and synaptosomes. The spontaneous release effect was (1) not blocked by the reuptake inhibitor nomifensine, (2) not affected by removal of external calcium, (3) not blocked by vesicular depletion with reserpine, and (4) not inhibited by the sodium channel blocker tetrodotoxin (TTX). As would be expected, the spontaneous [3H]NE release induced by the cytoplasmic releaser tyramine and the sodium channel activator veratridine were blocked by nomifensine and TTX, resp. Notably, however, the Ca²⁺-independent veratridine-induced release was

completely blocked by 100 .mu.M HP 749. The mechanism of spontaneous release of [3H]NE caused by 100 .mu.M HP 749 is unresolved at present; however, the data are consistent with this release originating from a cytoplasmic source.


IT 130953-69-4, HP 749

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(HP 749 enhances calcium-independent release of [3H]norepinephrine from rat cortical slices and synaptosomes)

RN 130953-69-4 CAPLUS

CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L9 ANSWER 34 OF 51 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1995:265463 CAPLUS

DOCUMENT NUMBER: 122:46256

TITLE: Interaction of HP749 with erythrocyte and neocortical synaptosomal membranes

AUTHOR(S): Butterfield, D. Allan; Shrewsbury, Polly J.; Hensley, Kenneth

CORPORATE SOURCE: Center Membrane Sciences, University Kentucky, Lexington, KY, 40506-0055, USA

SOURCE: Biochemical Archives (1994), 10(4), 285-92

CODEN: BIAREM; ISSN: 0749-5331

DOCUMENT TYPE: Journal

LANGUAGE: English

AB N-(n-propyl)-N-(4-pyridinyl)-1H-indol-1-amine hydrochloride (HP749) is a pharmaceutical agent which demonstrates both cholinomimetic and noradrenergic properties. The interaction of HP749 with cytoskeletal proteins of erythrocyte and neocortical synaptosomal membranes was investigated employing ESR and spin labels specific for proteins or lipids. The in vitro addn. of HP749 to spin labeled erythrocyte membranes strengthened protein-protein interactions in the cytoskeleton. Spin labeling the membranes with a lipid-specific paramagnetic probe demonstrated that the cytoskeletal changes were not a secondary effect of lipid motion. In neocortical synaptosomal membranes, HP749 also increased interactions among cytoskeletal proteins, albeit not as extensively as in erythrocytes. These results are discussed with ref. to possible mol. mechanisms by which HP749 could affect both cholinergic and noradrenergic systems.

IT 130953-69-4, HP749


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(interaction of HP749 with erythrocyte and neocortical synaptosomal membranes in relation to Alzheimer's disease)

RN 130953-69-4 CAPLUS

CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl-, monohydrochloride (9CI) (CA

INDEX NAME)



● HCl

L9 ANSWER 35 OF 51 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1994:400788 CAPLUS

DOCUMENT NUMBER: 121:788

TITLE: Mechanisms for the increase in electrically stimulated [3H]norepinephrine release from rat cortical slices by N-(n-propyl)-N-(4-pyridinyl)-1H-indole-1-amine

AUTHOR(S): Smith, Craig P.; Petko, Wayne W.; Kongsamut, Sathapana; Roehr, Joachim E.; Effland, Richard C.; Klein, Joseph T.; Huger, Francis P.

CORPORATE SOURCE: Neurosci. Strategic Business Unit, Hoechst-Roussel Pharmaceuticals, Inc., Somerville, NJ, USA

SOURCE: Drug Development Research (1994), 32(1), 13-18
CODEN: DDREDK; ISSN: 0272-4391

DOCUMENT TYPE: Journal

LANGUAGE: English


AB N-(n-propyl)-N-(4-pyridinyl)-1H-indole-1-amine (HP 749) is currently in clin. trials for the treatment of Alzheimer's disease (AD). While HP 749 has many pharmacol. properties, the biochem. basis for its efficacy in animal models for AD remains unexplained. To this end, the authors have investigated some biochem. properties of HP 749 as they relate to its effect on elec. stimulated [3H]norepinephrine (NE) release. HP 749 was found to inhibit both [3H]NE uptake and [3H]yohimbine binding to cortical .alpha.2-adrenergic receptors. Consistent with this profile, HP 749 (1 and 10 .mu.M) enhanced elec. stimulated release of [3H]NE from rat cortical slices. Both clonidine (1 .mu.M) and nomifensine (10 .mu.M) inhibited the effect of HP 749 (1 .mu.M). The enhancement of [3H]NE release produced by the .alpha.2-adrenergic antagonist, idazoxan (0.1 .mu.M), was completely reversed by the .alpha.2-agonist, clonidine (1 .mu.M), but was not affected by the NE uptake inhibitor, nomifensine (10 .mu.M). These results indicate that the HP 749 enhancement of elec. stimulated [3H]NE release is due, at least in part, to a combination of presynaptic .alpha.2-adrenergic receptor antagonism and NE reuptake blockade. These mechanisms may contribute to some of the adrenergic effects of HP 749.

IT 130953-69-4, HP 749

RL: BIOL (Biological study)
(norepinephrine release from brain cortex stimulation by)

RN 130953-69-4 CAPLUS

CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L9 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1994:182846 CAPLUS

DOCUMENT NUMBER: 120:182846

TITLE: N-(n-propyl)-N-(3-fluoro-4-pyridinyl)-1H-3-methylindol-1-amine hydrochloride (HP 184): in vitro spontaneous release of acetylcholine and norepinephrine

AUTHOR(S): Smith, Craig P.; Brougham, Linda R.; Huger, Francis P.; Davis, Larry; Klein, Joseph T.; Effland, Richard C.

CORPORATE SOURCE: Neurosci. Strategic Bus. Unit, Hoechst-Roussel Pharm. Inc., Somerville, NJ, 08876 USA

SOURCE: Drug Development Research (1993), 30(4), 203-12

CODEN: DDREDK; ISSN: 0272-4391

DOCUMENT TYPE: Journal

LANGUAGE: English

AB It has been shown that a single injection of N-(n-propyl)-N-(3-fluoro-4-pyridinyl)-1H-3-methylindol-1-amine hydrochloride (HP 184) (0.6-4.8 mg/kg, or 2-15 .mu.moles/kg, s.c.) reversed passive avoidance deficits in rats with combined cholinergic and noradrenergic lesions. This report describes the effects of HP 184 on NE and ACh release from rat brain slices. In contrast to 4-aminopyridine (4-AP), tyramine, or veratridine, HP184 only enhanced spontaneous release and had no effect on elec. stimulation (ES). Chromatog. anal. showed that the spontaneous release from [3H]choline-loaded striatal slices correlated with increased release of ACh, not choline efflux. HP 184 also enhanced ACh spontaneous release in the absence of both extracellular calcium and functional vesicles (as defined by ES and vesamicol). In frontal cortical slices, HP 184 caused [3H]NE release in a calcium independent fashion different from that induced by veratridine, and was not affected by uptake blockers. In contrast to the cholinergic profile, the [3H]NE release induced by HP 184 required intact storage vesicles, since release was blocked by reserpine pretreatment. The results show that HP 184 can release both NE and ACh in vitro, and, coupled with the dual lesion results, suggest it may have use in diseases ~~involving cholinergic and noradrenergic deterioration.~~


IT 119229-64-0, HP 184

RL: BIOL (Biological study)

(acetylcholine and norepinephrine release by brain response to)

RN 119229-64-0 CAPLUS

CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl-N-propyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L9 ANSWER 37 OF 51 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1993:617294 CAPLUS

DOCUMENT NUMBER: 119:217294

TITLE: Effects of linopirdine, HP 749, and glycyL-prolyl-glutamate on transmitter release and uptake

AUTHOR(S): Zaczek, R.; Tinker, W. J.; Logue, A. R.; Cain, G. A.; Teleha, C. A.; Tam, S. W.

CORPORATE SOURCE: Cent. Nerv. Sys. Dis. Res., Du Pont Merck Pharm. Co., Wilmington, DE, 19880-0400, USA.

SOURCE: Drug Development Research (1993), 29(3), 203-8
CODEN: DDREDK; ISSN: 0272-4391

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Linopirdine, HP 749, and glycyL-prolyl-glutamate (GPE) are compds. that have been reported to alter the release of neurotransmitters. This study compares the potassium-stimulated neurotransmitter release enhancing properties of these compds. in parallel. While not affecting the apparent release of [3H]norepinephrine ([3H]NE), linopirdine at a concn. of 10 .mu.M enhanced the potassium evoked release of cerebral cortical and hippocampal [3H]acetylcholine ([3H]ACh) release by 143% and 200% over control, resp., and striatal [3H]dopamine ([3H]DA) and hippocampal [3H]d-aspartate ([3H]d-Asp) release by 236% and 65% over control, resp. The release enhancing effects of linopirdine were not due to inhibition of high-affinity uptake processes, since the drug did not inhibit neurotransmitter uptake at the concn. (10 .mu.M) which caused maximal release enhancement. HP 749 increased the extracellular concns. of the catecholamines, [3H]NE and [3H]DA, but not [3H]ACh or [3H]d-Asp. HP 749 was a potent inhibitor of both [3H]NE and [3H]DA uptake, and this may, in part, be responsible for the apparent release enhancing activity of the drug. GPE was devoid of release enhancing activity under the conditions used in the present study.


IT 130953-69-4, HP 749

RL: BIOL (Biological study)

(neurotransmitter release and uptake response to, in brain, Alzheimer's disease treatment in relation to)

RN 130953-69-4 CAPLUS


CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L9 ANSWER 38 OF 51 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1993:101970 CAPLUS
 DOCUMENT NUMBER: 118:101970
 TITLE: 4-(1H-indol-1-yl)pyrido[3,4-b]-1,4-oxazines, a method for their preparation and their use as antidepressants and memory enhancers
 INVENTOR(S): Effland, Richard Charles; Davis, Larry; Olsen, Gordon Edward
 PATENT ASSIGNEE(S): Hoechst-Roussel Pharmaceuticals Inc., USA
 SOURCE: Eur. Pat. Appl., 23 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 509400	A1	19921021	EP 1992-106160	19920409
EP 509400	B1	19960703		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, PT, SE				
US 5214038	A	19930525	US 1991-684758	19910415
AT 140006	E	19960715	AT 1992-106160	19920409
ES 2094840	T3	19970201	ES 1992-106160	19920409
FI 97544	B	19960930	FI 1992-1641	19920413
FI 97544	C	19970110		
NO 9201490	A	19921016	NO 1992-1490	19920414
CA 2065986	AA	19921016	CA 1992-2065986	19920414
AU 9214852	A1	19921022	AU 1992-14852	19920414
AU 643135	B2	19931104		
ZA 9202721	A	19921125	ZA 1992-2721	19920414
JP 05112572	A2	19930507	JP 1992-94177	19920414
RU 2042680	C1	19950827	RU 1992-5011168	19920414
PL 168671	B1	19960329	PL 1992-294221	19920414
IL 101589	A1	19961031	IL 1992-101589	19920414
CZ 282054	B6	19970514	CZ 1992-1135	19920414
HU 62588	A2	19930528	HU 1992-1290	19920415
US 5276156	A	19940104	US 1992-976778	19921116
US 5519131	A	19960521	US 1993-138645	19931020
PRIORITY APPLN. INFO.:			US 1991-684758	19910415
			US 1992-976778	19921116
OTHER SOURCE(S):		CASREACT 118:101970; MARPAT 118:101970		
GI				



AB Some 2,3-dihydro-4-(1H-indol-1-yl)pyrido[3,4-b]-1,4-oxazines are claimed. The use of these compds. for the prepn. of antidepressant pharmaceuticals or for the treatment memory dysfunction is claimed. A process which comprises the cyclocondensation of N-(2-hydroxyethyl)-N-(3-fluoro-4-pyridinyl)-1H-indol-1-amine (I) is claimed. Condensation of 4-chloro-2-fluoropyridine hydrochloride with 3-methyl-1H-indol-1-amine gave N-(3-fluoro-4-pyridinyl)-3-methyl-1H-indol-1-amine which was treated with Et chloroacetate and reduced to give I. Cyclocondensation of I (NaH/DMF) gave 2,3-dihydro-4-(3-methyl-1H-indol-1-yl)pyrido[3,4-b]-1,4-oxazine (II). II inhibited the uptake of 3H-norepinephrine in rat whole brain synaptosomes.


IT 119257-43-1P 145660-04-4P 145660-05-5P

145660-06-6P 145660-07-7P 145660-08-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as intermediate for dihydro(indolyl)pyridooxazine
(antidepressant and memory enhancer))


RN 119257-43-1 CAPLUS

CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 145660-04-4 CAPLUS

CN Glycine, N-(3-fluoro-4-pyridinyl)-N-(3-methyl-1H-indol-1-yl)-, ethyl ester
(9CI) (CA INDEX NAME)




RN 145660-05-5 CAPLUS

CN Ethanol, 2-[(3-fluoro-4-pyridinyl)(3-methyl-1H-indol-1-yl)amino]- (9CI)
(CA INDEX NAME)




RN 145660-06-6 CAPLUS

CN Ethanol, 2-[(3-fluoro-4-pyridinyl)[5-(phenylmethoxy)-1H-indol-1-yl]amino]-
(9CI) (CA INDEX NAME)




RN 145660-07-7 CAPLUS

CN Glycine, N-(3-fluoro-4-pyridinyl)-N-1H-indol-1-yl-, ethyl ester (9CI) (CA
INDEX NAME)



RN 145660-08-8 CAPLUS

CN Ethanol, 2-[(3-fluoro-4-pyridinyl)-1H-indol-1-ylamino]- (9CI) (CA INDEX NAME)




IT 145660-09-9 145660-10-2

RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant for dihydro(indolyl)pyridooxazine (antidepressant and memory enhancer))


RN 145660-09-9 CAPLUS

CN Glycine, N-(3-fluoro-4-pyridinyl)-N-[5-(phenylmethoxy)-1H-indol-1-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 145660-10-2 CAPLUS

CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)- (9CI) (CA INDEX NAME)



L9 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1992:235443 CAPLUS

DOCUMENT NUMBER: 116:235443

TITLE: Preparation of acetylcholinesterase-inhibiting
1-(substituted pyridinylamino)-1H-(indol-3-yl)carbamates as drugs for treatment of memory
dysfunctions

INVENTOR(S): Effland, Richard Charles; Davis, Larry; Olsen, Gordon
Edward; Klein, Joseph Thomas; Wettlaufer, David
Gordon; Nemoto, Peter Allen

PATENT ASSIGNEE(S): Hoechst-Roussel Pharmaceuticals, Inc., USA

SOURCE: Eur. Pat. Appl., 44 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 468401	A2	19920129	EP 1991-112237	19910722
EP 468401	A3	19920729		
EP 468401	B1	19980916		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 5102891	A	19920407	US 1990-555890	19900723
FI 9103502	A	19920124	FI 1991-3502	19910719
NO 9102866	A	19920124	NO 1991-2866	19910722
CA 2047531	AA	19920124	CA 1991-2047531	19910722
AU 9181216	A1	19920130	AU 1991-81216	19910722
AU 639581	B2	19930729		
HU 58317	A2	19920228	HU 1991-2450	19910722
ZA 9105723	A	19920429	ZA 1991-5723	19910722
JP 04243878	A2	19920831	JP 1991-181210	19910722
JP 2564714	B2	19961218		
IL 98920	A1	19950831	IL 1991-98920	19910722
CZ 283253	B6	19980218	CZ 1991-2281	19910722
AT 171176	E	19981015	AT 1991-112237	19910722
ES 2121761	T3	19981216	ES 1991-112237	19910722


PRIORITY APPLN. INFO.: US 1990-555890 19900723

OTHER SOURCE(S): MARPAT 116:235443

GI



I



II

AB The title compds. [I; R1 = H, (aryl)alkyl, alkenyl, alkynyl, (aryl)alkanoyl, heteroarylalkyl, heteroarylalkanoyl; R2 = H, alkyl, CHO, cyano; R3 = H, alkyl; R4 = (cyclo)alkyl, aralkyl, heteroaryl; NR3R4 = pyrrolidino, piperidino, morpholino, etc.; X, Y = H, halo, NO2, amino, CF3, alkyl, alkoxy; n = 0, 1], their optical and geometrical stereoisomers and racemates and pharmaceutically acceptable salts, useful for the treatment of memory dysfunctions such as Alzheimer's disease, were prepd., e.g. by addn. reaction of isocyanates with the appropriate indoles. Thus, 1-(N-propyl-4-pyridinylamino)-1H-indol-5-ol (prepn. from 5-phenylmethoxyindole given) in THF was stirred with K2CO3 and MeNCO to give title compd. II. II inhibited brain acetylcholinesterase with IC50 = 0.0023 .mu.M.


IT 141287-48-1P 141287-49-2P 141287-50-5P
 141287-51-6P 141287-52-7P 141287-53-8P
 141287-54-9P 141287-55-0P 141287-56-1P
 141287-57-2P 141287-58-3P 141287-59-4P
 141287-60-7P 141287-61-8P 141287-62-9P
 141287-64-1P 141287-65-2P 141287-66-3P
 141287-67-4P 141287-68-5P 141287-69-6P
 141287-70-9P 141287-71-0P 141287-72-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and reaction of, in prepn. of acetylcholinesterase inhibitors)


RN 141287-48-1 CAPLUS

CN 1H-Indol-1-amine, 5-(phenylmethoxy)-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 141287-49-2 CAPLUS

CN 1H-Indol-5-ol, 1-(4-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 141287-50-5 CAPLUS


CN 1H-Indol-1-amine, N-methyl-5-(phenylmethoxy)-N-4-pyridinyl-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 141287-51-6 CAPLUS

CN 1H-Indol-1-amine, N-methyl-5-(phenylmethoxy)-N-4-pyridinyl- (9CI) (CA
INDEX NAME)




RN 141287-52-7 CAPLUS

CN 1H-Indol-5-ol, 1-(methyl-4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 141287-53-8 CAPLUS
CN 1H-Indol-1-amine, 5-(phenylmethoxy)-N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 141287-54-9 CAPLUS
CN 1H-Indol-1-amine, 5-(phenylmethoxy)-N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 141287-53-8
CMF C23 H23 N3 O



CM 2


CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.




RN 141287-55-0 CAPLUS

CN 1H-Indol-5-ol, 1-(propyl-4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 141287-56-1 CAPLUS

CN Carbamic acid, cyclohexyl-, 1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester (9CI) (CA INDEX NAME)




RN 141287-57-2 CAPLUS

CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 141287-58-3 CAPLUS


CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-5-(phenylmethoxy)-N-propyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 141287-59-4 CAPLUS

CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-5-(phenylmethoxy)-N-propyl-, (9CI) (CA INDEX NAME)




RN 141287-60-7 CAPLUS

CN 1H-Indol-5-ol, 1-[(3-fluoro-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 141287-61-8 CAPLUS
CN 1H-Indol-5-ol, 1-[(3-fluoro-4-pyridinyl)propylamino]-, monohydrochloride
(9CI) (CA INDEX NAME)




● HCl


RN 141287-62-9 CAPLUS
CN 1H-Indol-5-ol, 1-[(3-fluoro-4-pyridinyl)propylamino]- (9CI) (CA INDEX NAME)




RN 141287-64-1 CAPLUS
CN 1H-Indol-1-amine, 3-methyl-5-(phenylmethoxy)-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 141287-65-2 CAPLUS
CN 1H-Indol-5-ol, 3-methyl-1-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 141287-66-3 CAPLUS
CN 1H-Indol-1-amine, 3-methyl-5-(phenylmethoxy)-N-propyl-N-4-pyridinyl- (9CI)
(CA INDEX NAME)



RN 141287-67-4 CAPLUS
CN 1H-Indol-1-amine, 3-methyl-5-(phenylmethoxy)-N-propyl-N-4-pyridinyl-,
(2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 141287-66-3
CMF C24 H25 N3 O




CM 2

CRN 110-17-8


CMF C4 H4 O4

Double bond geometry as shown.



RN 141287-68-5 CAPLUS

CN 1H-Indol-5-ol, 3-methyl-1-(propyl-4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 141287-69-6 CAPLUS

CN 1H-Indol-5-ol, 3-methyl-1-(propyl-4-pyridinylamino)-, ethanedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 141287-68-5


CMF C17 H19 N3 O



CM 2


CRN 144-62-7

CMF C2 H2 O4




RN 141287-70-9 CAPLUS

CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl-5-(phenylmethoxy)-(9CI) (CA INDEX NAME)




RN 141287-71-0 CAPLUS

CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl-5-(phenylmethoxy)-N-propyl- (9CI) (CA INDEX NAME)




RN 141287-72-1 CAPLUS
 CN 1H-Indol-5-ol, 1-[(3-fluoro-4-pyridinyl)propylamino]-3-methyl- (9CI) (CA INDEX NAME)



IT 141287-16-3P 141287-17-4P 141287-18-5P
 141287-19-6P 141287-20-9P 141287-21-0P
 141287-22-1P 141287-23-2P 141287-24-3P
 141287-25-4P 141287-26-5P 141287-27-6P
 141287-28-7P 141287-29-8P 141287-30-1P
 141287-31-2P 141287-32-3P 141287-33-4P
 141287-34-5P 141287-35-6P 141287-36-7P
 141287-37-8P 141287-38-9P 141287-39-0P
 141287-40-3P 141287-41-4P 141287-42-5P
 141287-43-6P 141287-44-7P 141287-45-8P
 141287-46-9P 141303-08-4P 141303-09-5P


RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, as acetylcholinesterase inhibitor)

RN 141287-16-3 CAPLUS
 CN 1H-Indol-5-ol, 1-(methyl-4-pyridinylamino)-, methylcarbamate (ester) (9CI)
 (CA INDEX NAME)



RN 141287-17-4 CAPLUS


CN Carbamic acid, butyl-, 1-(methyl-4-pyridinylamino)-1H-indol-5-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 141287-18-5 CAPLUS

CN Carbamic acid, (phenylmethyl)-, 1-(methyl-4-pyridinylamino)-1H-indol-5-yl ester (9CI) (CA INDEX NAME)




RN 141287-19-6 CAPLUS

CN 1H-Indol-5-ol, 1-(propyl-4-pyridinylamino)-, methylcarbamate (ester) (9CI) (CA INDEX NAME)



RN 141287-20-9 CAPLUS


CN Carbamic acid, ethyl-, 1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 141287-21-0 CAPLUS

CN Carbamic acid, propyl-, 1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester (9CI) (CA INDEX NAME)




RN 141287-22-1 CAPLUS

CN Carbamic acid, (1-methylethyl)-, 1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester (9CI) (CA INDEX NAME)




RN 141287-23-2 CAPLUS
CN Carbamic acid, butyl-, 1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 141287-24-3 CAPLUS
CN Carbamic acid, heptyl-, 1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester (9CI) (CA INDEX NAME)




RN 141287-25-4 CAPLUS
CN Carbamic acid, cyclohexyl-, 1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 141287-26-5 CAPLUS


CN Carbamic acid, (2-phenylethyl)-, 1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 141287-27-6 CAPLUS


CN Carbamic acid, (2-phenylethyl)-, 1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester (9CI) (CA INDEX NAME)



RN 141287-28-7 CAPLUS


CN Carbamic acid, (1-phenylethyl)-, 1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 141287-29-8 CAPLUS

CN Carbamic acid, dimethyl-, 1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester (9CI) (CA INDEX NAME)




RN 141287-30-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester (9CI) (CA INDEX NAME)




RN 141287-31-2 CAPLUS

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-, 1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester (9CI) (CA INDEX NAME)




RN 141287-32-3 CAPLUS

CN 1H-Indol-5-ol, 1-[(3-fluoro-4-pyridinyl)propylamino]-, methylcarbamate (ester) (9CI) (CA INDEX NAME)



RN 141287-33-4 CAPLUS


CN Carbamic acid, butyl-, 1-[(3-fluoro-4-pyridinyl)propylamino]-1H-indol-5-yl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 141287-34-5 CAPLUS

CN Carbamic acid, butyl-, 1-[(3-fluoro-4-pyridinyl)propylamino]-1H-indol-5-yl ester (9CI) (CA INDEX NAME)




RN 141287-35-6 CAPLUS
CN Carbamic acid, heptyl-, 1-[(3-fluoro-4-pyridinyl)propylamino]-1H-indol-5-yl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 141287-36-7 CAPLUS
CN Carbamic acid, heptyl-, 1-[(3-fluoro-4-pyridinyl)propylamino]-1H-indol-5-yl ester (9CI) (CA INDEX NAME)




RN 141287-37-8 CAPLUS
CN 1H-Indol-5-ol, 3-methyl-1-(propyl-4-pyridinylamino)-, methylcarbamate (ester) (9CI) (CA INDEX NAME)




RN 141287-38-9 CAPLUS

CN Carbamic acid, butyl-, 3-methyl-1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester (9CI) (CA INDEX NAME)




RN 141287-39-0 CAPLUS

CN Carbamic acid, heptyl-, 3-methyl-1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester (9CI) (CA INDEX NAME)




RN 141287-40-3 CAPLUS

CN Carbamic acid, (phenylmethyl)-, 3-methyl-1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester (9CI) (CA INDEX NAME)




RN 141287-41-4 CAPLUS

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-, 3-methyl-1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester (9CI) (CA INDEX NAME)




RN 141287-42-5 CAPLUS

CN 1H-Indol-5-ol, 1-[(3-fluoro-4-pyridinyl)propylamino]-3-methyl-, methylcarbamate (ester) (9CI) (CA INDEX NAME)




RN 141287-43-6 CAPLUS

CN Carbamic acid, butyl-, 1-[(3-fluoro-4-pyridinyl)propylamino]-3-methyl-1H-indol-5-yl ester (9CI) (CA INDEX NAME)




RN 141287-44-7 CAPLUS

CN Carbamic acid, heptyl-, 1-[(3-fluoro-4-pyridinyl)propylamino]-3-methyl-1H-indol-5-yl ester (9CI) (CA INDEX NAME)




RN 141287-45-8 CAPLUS

CN Carbamic acid, (phenylmethyl)-, 1-[(3-fluoro-4-pyridinyl)propylamino]-3-methyl-1H-indol-5-yl ester (9CI) (CA INDEX NAME)




RN 141287-46-9 CAPLUS

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-, 1-[(3-fluoro-4-pyridinyl)propylamino]-3-methyl-1H-indol-5-yl ester (9CI) (CA INDEX NAME)




RN 141303-08-4 CAPLUS

CN Carbamic acid, (phenylmethyl)-, 1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester (9CI) (CA INDEX NAME)



RN 141303-09-5 CAPLUS

CN Carbamic acid, [(4-chlorophenyl)methyl]-, 1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester (9CI) (CA INDEX NAME)



L9 ANSWER 40 OF 51 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1992:50748 CAPLUS


DOCUMENT NUMBER: 116:50748

TITLE: Determination of HP 749, a potential therapeutic agent for Alzheimer's disease, in plasma by high-performance liquid chromatography

AUTHOR(S): Hsu, Robert S.; DiLeo, Eva M.; Chesson, Susan M.; Klein, Joseph T.; Effland, Richard C.

Searched by Barb O'Bryen, STIC 308-4291

CORPORATE SOURCE: Chem. Res. Dep., Hoechst-Roussel Pharm., Inc.,
Somerville, NJ, 08876, USA
SOURCE: Journal of Chromatography (1991), 572(1-2), 352-9
CODEN: JOCRAM; ISSN: 0021-9673
DOCUMENT TYPE: Journal
LANGUAGE: English
GI




AB HP 749 (I), a non-receptor-dependent cholinomimetic agent with noradrenergic activity, is a potential agent for the treatment of Alzheimer's disease. Pharmacokinetic studies in animals and humans showed that I was well absorbed and metabolized primarily to the N-despropyl metabolite (P7480, II) after oral administration. To facilitate the kinetic studies, a sensitive and selective high-performance chromatog. assay was developed. I and II are extd. from plasma by a mixt. of cyclohexane-Et acetate and chromatographed on an isocratic reversed-phase high-performance liq. chromatog. system employing an anal. Ph column with acetonitrile-ammonium formate as mobile phase. The concns. of these two compds., quantitated by internal standardization, are monitored by UV detection. The method is linear in the plasma assay over a concn. range of 0.5-500 ng/mL for both compds. with a quantitation limit of 0.5 ng/mL. The precision and accuracy of the calibration curves and/or method are less than 10%. The recovery of I and II from plasma is 63-74 and 63-68%, resp., over a concn. range of 0.5-500 ng/mL.

IT 130953-69-4, HP 749 138624-41-6, P 7480
RL: ANT (Analyte); ANST (Analytical study)
(detn. of, in blood of humans by HPLC)

RN 130953-69-4 CAPLUS


CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 138624-41-6 CAPLUS


CN 1H-Indol-1-amine, N-4-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L9 ANSWER 41 OF 51 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1989:114690 CAPLUS
DOCUMENT NUMBER: 110:114690
TITLE: Preparation of N-(pyridyl)-1H-indol-1-amines as
medicaments
INVENTOR(S): Effland, Richard Charles; Klein, Joseph Thomas
PATENT ASSIGNEE(S): Hoechst-Roussel Pharmaceuticals, Inc., USA
SOURCE: Eur. Pat. Appl., 39 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 287982	A2	19881026	EP 1988-106121	19880418
EP 287982	A3	19910327		
EP 287982	B1	19941207		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 4880822	A	19891114	US 1988-171102	19880404
ES 2065324	T3	19950216	ES 1988-106121	19880418
FI 8801874	A	19881025	FI 1988-1874	19880421
FI 90978	B	19940114		
FI 90978	C	19940425		
ZA 8802810	A	19881130	ZA 1988-2810	19880421
DK 8802234	A	19881025	DK 1988-2234	19880422
DK 172153	B1	19971201		
NO 8801776	A	19881025	NO 1988-1776	19880422
NO 168104	B	19911007		
NO 168104	C	19920115		
AU 8815100	A1	19881027	AU 1988-15100	19880422
AU 594876	B2	19900315		
JP 63280079	A2	19881117	JP 1988-98467	19880422
IL 86154	A1	19920329	IL 1988-86154	19880422
CA 1330661	A1	19940712	CA 1988-564923	19880422
US 4970218	A	19901113	US 1989-405156	19890911
US 5039811	A	19910813	US 1990-571473	19900823
PRIORITY APPLN. INFO.:			US 1987-42079	19870424
			US 1988-171102	19880404
			US 1989-405156	19890911
OTHER SOURCE(S):			CASREACT 110:114690; MARPAT 110:114690	
GI				




AB Title compds. [I; R = H, halo, alkyl, OH, NO₂, etc.; R₁ = H, alkyl, alkenyl, alkylcarbonyl, etc.; R₂ H, alkyl, alkenyl, alkynyl, Ph, etc.; R₃ = H, NO₂, (substituted) NH₂, halo, alkyl; m, n = 1, 2; p = 0, 1] are prepd. from indoles II (R = H, halo, alkyl, alkoxy, NO₂, cyano, CHO, alkylthio, alkoxyalkylthio; R₁ = H, alkyl, halo, cyano; R₂ = H, alkyl; m, n = 1, 2) and pyridines III (X = Cl, F; R₃ = H, NO₂, halo, alkyl; p = 0, 1), followed by optional substitutions. A soln. of II (R_m = R_{1n} = R₂ = H), 4-chloropyridine.HCl, and pyridine in Me₂CHOH was stirred at 85.degree. for 1.5 h to give N-(4-pyridyl)-1H-indol-1-amine which was converted to its maleate salt. The latter, at 0.04 mg/kg s.c., reversed scopolamine-induced deficit in 53% of tested rats.

IT **119229-75-3**

RL: RCT (Reactant); RACT (Reactant or reagent)
(alkylation of, in prepn. of pharmaceuticals)

RN 119229-75-3 CAPLUS

CN 1H-Indol-1-amine, 5-methoxy-N-4-pyridinyl- (9CI) (CA INDEX NAME)




IT **119229-42-4**

RL: RCT (Reactant); RACT (Reactant or reagent)
(hydrogenation of, in prepn. of pharmaceuticals)

RN 119229-42-4 CAPLUS

CN 1H-Indol-1-amine, N-(4-nitro-1-oxido-3-pyridinyl)- (9CI) (CA INDEX NAME)




IT 119229-48-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as memory enhancer, antidepressant, and analgesic)

RN 119229-48-0 CAPLUS

CN 1H-Indol-1-amine, 5-chloro-N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




IT 119229-37-7P 119229-38-8P 119229-39-9P
119229-40-2P 119229-41-3P 119229-42-4P
119229-43-5P 119229-44-6P 119229-45-7P
119229-46-8P 119229-47-9P 119229-49-1P
119229-50-4P 119229-51-5P 119229-52-6P
119229-53-7P 119229-54-8P 119229-55-9P
119229-56-0P 119229-57-1P 119229-58-2P
119229-59-3P 119229-60-6P 119229-61-7P
119229-62-8P 119229-63-9P 119229-64-0P
119229-65-1P 119229-66-2P 119229-67-3P
119229-68-4P 119229-69-5P 119257-32-8P
119257-33-9P 119257-34-0P 119257-35-1P
119257-36-2P 119257-37-3P 119257-38-4P
119257-39-5P 119257-40-8P 119257-41-9P
119257-42-0P 119257-43-1P


RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, for enhancing memory, as analgesic, and antidepressant)

RN 119229-37-7 CAPLUS

CN 1H-Indol-1-amine, 5-methoxy-N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119229-38-8 CAPLUS
CN 1H-Indole-3-carboxaldehyde, 1-(methyl-4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 119229-39-9 CAPLUS
CN 1H-Indole-3-carboxaldehyde, 1-(methyl-4-pyridinylamino)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119229-38-8

CMF C15 H13 N3 O




CM 2


CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 119229-40-2 CAPLUS
CN 1H-Indole-3-carboxaldehyde, 1-(ethyl-4-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 119229-41-3 CAPLUS
CN 1H-Indole-3-carboxaldehyde, 1-(ethyl-4-pyridinylamino)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 119229-40-2
CMF C16 H15 N3 O



CM 2


CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.




RN 119229-42-4 CAPLUS

CN 1H-Indol-1-amine, N-(4-nitro-1-oxido-3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 119229-43-5 CAPLUS

CN 1H-Indol-1-amine, 3-ethenyl-N-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119229-44-6 CAPLUS

CN 1H-Indol-1-amine, 3-ethenyl-N-methyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119229-43-5

CMF C16 H15 N3




CM 2


CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 119229-45-7 CAPLUS

CN 1H-Indol-1-amine, 3-ethyl-N-methyl-N-4-pyridinyl-, monohydrochloride (9CI)
(CA INDEX NAME)

● HCl

RN 119229-46-8 CAPLUS


CN 1H-Indol-1-amine, 5-chloro-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119229-47-9 CAPLUS
CN 1H-Indol-1-amine, 5-chloro-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1


CRN 119229-46-8
CMF C13 H10 Cl N3



CM 2

CRN 110-16-7
CMF C4 H4 O4


Double bond geometry as shown.



RN 119229-49-1 CAPLUS
CN 1H-Indol-1-amine, 5-chloro-N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119229-48-0
CMF C16 H16 Cl N3




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.



RN 119229-50-4 CAPLUS

CN 1H-Indol-1-amine, 5-bromo-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119229-51-5 CAPLUS

CN 1H-Indol-1-amine, 5-bromo-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 119229-50-4

CMF C13 H10 Br N3




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.



RN 119229-52-6 CAPLUS

CN 1H-Indol-1-amine, 5-bromo-N-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119229-53-7 CAPLUS

CN 1H-Indol-1-amine, 5-bromo-N-methyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119229-52-6

CMF C14 H12 Br N3




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.



RN 119229-54-8 CAPLUS

CN 1H-Indol-1-amine, 5-bromo-N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119229-55-9 CAPLUS

CN 1H-Indol-1-amine, 5-bromo-N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119229-54-8

CMF C16 H16 Br N3




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.



RN 119229-56-0 CAPLUS


CN 1H-Indol-1-amine, 5-nitro-N-4-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 119229-57-1 CAPLUS

CN 1H-Indol-1-amine, 5-nitro-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119229-58-2 CAPLUS
CN 1H-Indol-1-amine, N-methyl-5-nitro-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119229-59-3 CAPLUS
CN 1H-Indol-1-amine, N-methyl-5-nitro-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 119229-58-2
CMF C14 H12 N4 O2




CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.




RN 119229-60-6 CAPLUS
CN 1H-Indol-1-amine, 3-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119229-61-7 CAPLUS
CN 1H-Indol-1-amine, 3-methyl-N-4-pyridinyl-, ethanedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 119229-60-6
CMF C14 H13 N3




CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 119229-62-8 CAPLUS

CN 1H-Indol-1-amine, 3-methyl-N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119229-63-9 CAPLUS

CN 1H-Indol-1-amine, 3-methyl-N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119229-62-8

CMF C17 H19 N3




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.




RN 119229-64-0 CAPLUS

CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl-N-propyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 119229-65-1 CAPLUS
CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl-N-propyl- (9CI) (CA INDEX NAME)




RN 119229-66-2 CAPLUS
CN 1H-Indol-1-amine, N-2-propenyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119229-67-3 CAPLUS
CN 1H-Indol-1-amine, N-2-propenyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119229-66-2
CMF C16 H15 N3




CM 2


CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 119229-68-4 CAPLUS

CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-N-propyl-, monohydrochloride
(9CI) (CA INDEX NAME)


● HCl

RN 119229-69-5 CAPLUS


CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-N-propyl- (9CI) (CA INDEX
NAME)




RN 119257-32-8 CAPLUS
CN 1H-Indol-1-amine, N-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119257-33-9 CAPLUS
CN 1H-Indol-1-amine, N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119257-34-0 CAPLUS
CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119257-35-1 CAPLUS

CN 1H-Indol-1-amine, 3-ethyl-N-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119257-36-2 CAPLUS

CN 1H-Indol-1-amine, N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119257-33-9

CMF C13 H11 N3




CM 2

CRN 110-16-7

CMF C4 H4 O4


Double bond geometry as shown.



RN 119257-37-3 CAPLUS
CN 1H-Indol-1-amine, N-methyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1


CRN 119257-32-8
CMF C14 H13 N3




CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 119257-38-4 CAPLUS
CN 1H-Indol-1-amine, N-ethyl-N-4-pyridinyl-, (9CI) (CA INDEX NAME)




RN 119257-39-5 CAPLUS
CN 1H-Indol-1-amine, N-ethyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 119257-38-4

CMF C15 H15 N3




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 119257-40-8 CAPLUS

CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 119257-34-0

CMF C16 H17 N3




CM 2

CRN 110-16-7

CMF C4 H4 O4


Double bond geometry as shown.



RN 119257-41-9 CAPLUS
CN 1H-Indol-1-amine, 5-methoxy-N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 119229-37-7
CMF C17 H19 N3 O




CM 2

CRN 110-16-7
CMF C4 H4 O4


Double bond geometry as shown.




RN 119257-42-0 CAPLUS
CN 3,4-Pyridinediamine, N3-1H-indol-1-yl-, 1-oxide (9CI) (CA INDEX NAME)



RN 119257-43-1 CAPLUS
CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX NAME)




L9 ANSWER 42 OF 51 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1983:453536 CAPLUS
DOCUMENT NUMBER: 99:53536
TITLE: 6-Substituted 1-hetarylamino-3-aryloxindoles
AUTHOR(S): Aydeev, V. B.; Berdinskii, I. S.; Belykh, Z. D.
CORPORATE SOURCE: Perm. Gos. Univ., Perm, 614600, USSR
SOURCE: Khimiya Geterotsiklicheskikh Soedinenii (1983), (4), 524-7
CODEN: KGSSAQ; ISSN: 0453-8234
DOCUMENT TYPE: Journal
LANGUAGE: Russian
OTHER SOURCE(S): CASREACT 99:53536
GI



AB The title compds. I (R = Ph, R1 = 2-pyridyl, 8-quinolyl; R = p-FC6H4, p-ClC6H4, R1 = 2-pyridyl, 2-, and 8-quinolyl) were prepd. in 43-79% yields by treating R1NHNHCOC(OH)R2 with concd. H2SO4 for 15 min at room temp. Acylation of I (R = Ph, R1 = 2-pyridyl) by BzCl gave the N,O-dibenzoyl deriv., which was treated with base to give 44% N-benzoyl deriv.

IT **86445-04-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and debenzoylation of)

RN 86445-04-7 CAPLUS
CN Benzoic acid, 4-bromo-, 1-[(4-bromobenzoyl)-2-pyridinylamino]-3-phenyl-1H-indol-2-yl ester (9CI) (CA INDEX NAME)



L9 ANSWER 43 OF 51 USPATFULL
 ACCESSION NUMBER: 2003:26436 USPATFULL
 TITLE: Preparation of 1H-indol-1-amines
 INVENTOR(S): Lee, Thomas B., Whitehouse Station, NJ, United States
 Goehring, Keith E., Nazareth, PA, United States
 PATENT ASSIGNEE(S): Aventis Pharmaceuticals Inc., Bridgewater, NJ, United States (U.S. corporation)


	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6512125	B1	20030128
APPLICATION INFO.:	US 1995-455469		19950531 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-242395, filed on 13 May 1994, now patented, Pat. No. US 5459274, issued on 17 Oct 1995		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Fan, Jane		
LEGAL REPRESENTATIVE:	Gupta, Balaram		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)		
LINE COUNT:	362		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The synthesis of memory enhancing, analgetic, and antidepressant N-alkyl-N-pyridinyl-1H-indol-1-amines is described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 173341-09-8P, 3-Chloro-N-4-pyridinyl-1H-indol-1-amine
 173341-10-1P 173341-11-2P, 3-Chloro-N-propyl-N-4-pyridinyl-1H-indol-1-amine 173341-12-3P
 (prepn. of N-alkyl-N-pyridinyl-1H-indol-1-amines via arylation of 1-amino-3-haloindoles with halopyridines followed by alkylation and dehalogenation)
 RN 173341-09-8 USPATFULL
 CN 1H-Indol-1-amine, 3-chloro-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 173341-10-1 USPATFULL

CN Benzoic acid, 2-hydroxy-, compd. with 3-chloro-N-4-pyridinyl-1H-indol-1-amine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 173341-09-8


CMF C13 H10 Cl N3



CM 2


CRN 69-72-7

CMF C7 H6 O3




RN 173341-11-2 USPATFULL

CN 1H-Indol-1-amine, 3-chloro-N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 173341-12-3 USPATFULL

CN 1H-Indol-1-amine, 3-chloro-N-propyl-N-4-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


IT 119257-34-0P, N-Propyl-N-4-pyridinyl-1H-indol-1-amine

130953-69-4P

(prepn. of N-alkyl-N-pyridinyl-1H-indol-1-amines via arylation of 1-amino-3-haloindoles with halopyridines followed by alkylation and dehalogenation)


RN 119257-34-0 USPATFULL

CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 130953-69-4 USPATFULL

CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L9 ANSWER 44 OF 51 USPATFULL

ACCESSION NUMBER: 97:56827 USPATFULL

TITLE: Preparation of N-alkyl-N-pyridinyl-1H-indol-1-amines

INVENTOR(S): Lee, Thomas B., Whitehouse Station, NJ, United States


Goehring, Keith E., Nazareth, PA, United States

PATENT ASSIGNEE(S): Hoechst Marion Roussel, Inc., Cincinnati, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5644062		19970701
APPLICATION INFO.:	US 1995-455468		19950531 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-242395, filed on 13 May 1994, now patented, Pat. No. US 5459274, issued on 17 Oct 1995		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Fan, Jane		
LEGAL REPRESENTATIVE:	Barney, Charlotte L.		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
LINE COUNT:	360		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
AB	The synthesis of memory enhancing, analgetic, and antidepressant N-alkyl-N-pyridinyl-1H-indol-1-amines is described.		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 173341-09-8P, 3-Chloro-N-4-pyridinyl-1H-indol-1-amine
173341-10-1P 173341-11-2P, 3-Chloro-N-propyl-N-4-pyridinyl-1H-indol-1-amine 173341-12-3P
(prepn. of N-alkyl-N-pyridinyl-1H-indol-1-amines via arylation of 1-amino-3-haloindoles with halopyridines followed by alkylation and dehalogenation)
RN 173341-09-8 USPATFULL
CN 1H-Indol-1-amine, 3-chloro-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 173341-10-1 USPATFULL
CN Benzoic acid, 2-hydroxy-, compd. with 3-chloro-N-4-pyridinyl-1H-indol-1-amine (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 173341-09-8
CMF C13 H10 Cl N3




CM 2

CRN 69-72-7
CMF C7 H6 O3




RN 173341-11-2 USPATFULL

CN 1H-Indol-1-amine, 3-chloro-N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 173341-12-3 USPATFULL

CN 1H-Indol-1-amine, 3-chloro-N-propyl-N-4-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


IT 119257-34-0P, N-Propyl-N-4-pyridinyl-1H-indol-1-amine

130953-69-4P

(prepn. of N-alkyl-N-pyridinyl-1H-indol-1-amines via arylation of 1-amino-3-haloindoles with halopyridines followed by alkylation and dehalogenation)

RN 119257-34-0 USPATFULL


CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 130953-69-4 USPATFULL

CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl-, monohydrochloride (9CI) (CA

INDEX NAME)



● HCl

L9 ANSWER 45 OF 51 USPATFULL

ACCESSION NUMBER: 96:43781 USPATFULL

TITLE: ~~Synthesis of pyridooxazinyl-indoles~~INVENTOR(S): Effland, Richard C., Bridgewater, NJ, United States
Davis, Larry, Sergeantsville, NJ, United States
Olsen, Gordon E., Somerset, NJ, United States

PATENT ASSIGNEE(S): Hoechst Marion Roussel Inc., Somerville, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5519131		19960521
APPLICATION INFO.:	US 1993-138645		19931020 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1992-976778, filed on 16 Nov 1992, now patented, Pat. No. US 5276156 which is a division of Ser. No. US 1991-684758, filed on 15 Apr 1991, now patented, Pat. No. US 5214038		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Datlow, Philip I.		
LEGAL REPRESENTATIVE:	Maurer, Barbara V.		
NUMBER OF CLAIMS:	2		
EXEMPLARY CLAIM:	1		
LINE COUNT:	645		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This application relates to a process for the preparation of indolylpyridooxazines of the formula ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 are as defined in the specification which comprises cyclizing compound of the formula ##STR2## in the presence of a strong base such as sodium hydride or potassium t-butoxide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 119257-43-1P 145660-04-4P 145660-05-5P

145660-06-6P 145660-07-7P 145660-08-8P

(prepn. of, as intermediate for dihydro(indolyl)pyridooxazine (antidepressant and memory enhancer))


RN 119257-43-1 USPATFULL

CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 145660-04-4 USPATFULL

CN Glycine, N-(3-fluoro-4-pyridinyl)-N-(3-methyl-1H-indol-1-yl)-, ethyl ester
(9CI) (CA INDEX NAME)




RN 145660-05-5 USPATFULL

CN Ethanol, 2-[(3-fluoro-4-pyridinyl)(3-methyl-1H-indol-1-yl)amino]- (9CI)
(CA INDEX NAME)




RN 145660-06-6 USPATFULL

CN Ethanol, 2-[(3-fluoro-4-pyridinyl)[5-(phenylmethoxy)-1H-indol-1-yl]amino]-
(9CI) (CA INDEX NAME)




RN 145660-07-7 USPATFULL

CN Glycine, N-(3-fluoro-4-pyridinyl)-N-1H-indol-1-yl-, ethyl ester (9CI) (CA INDEX NAME)



RN 145660-08-8 USPATFULL

CN Ethanol, 2-[(3-fluoro-4-pyridinyl)-1H-indol-1-ylamino]- (9CI) (CA INDEX NAME)




IT 145660-09-9 145660-10-2

(reactant for dihydro(indolyl)pyridooxazine (antidepressant and memory enhancer))


RN 145660-09-9 USPATFULL

CN Glycine, N-(3-fluoro-4-pyridinyl)-N-[5-(phenylmethoxy)-1H-indol-1-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 145660-10-2 USPATFULL

CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)- (9CI) (CA INDEX NAME)



L9 ANSWER 46 OF 51 USPATFULL

ACCESSION NUMBER: 94:1547 USPATFULL

TITLE: N-(halopyridin-4-yl)-N-substituted compounds as intermediates in the preparation of

1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles
 INVENTOR(S): Effland, Richard C., Bridgewater, NJ, United States
 Davis, Larry, Sergeantstown, NJ, United States
 Olsen, Gordon E., Somerset, NJ, United States
 PATENT ASSIGNEE(S): Hoechst-Roussel Pharmaceuticals Incorporated,
 Somerville, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5276156		19940104
APPLICATION INFO.:	US 1992-976778		19921116 (7)
RELATED APPLN. INFO.:	Division of Ser. No. US 1991-684758, filed on 15 Apr 1991, now patented, Pat. No. US 5214038		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Ford, John M.		
ASSISTANT EXAMINER:	Datlow, Philip		
LEGAL REPRESENTATIVE:	Korsen, Elliott		
NUMBER OF CLAIMS:	4		
EXEMPLARY CLAIM:	1		
LINE COUNT:	624		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles of the formula ##STR1## where R.sub.1 -R.sub.3 are as defined herein which are useful for alleviation of depression and various memory dysfunction characterized by a cholinergic or adrenergic deficit. This

invention also relates to intermediate compounds of the formula ##STR2## where R.sub.1, R.sub.2, R.sub.3, R.sub.7 and X are as defined herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 119257-43-1P 145660-04-4P 145660-05-5P

145660-06-6P 145660-07-7P 145660-08-8P

(prepn. of, as intermediate for dihydro(indolyl)pyridooxazine
(antidepressant and memory enhancer))


RN 119257-43-1 USPATFULL

CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX
NAME)




RN 145660-04-4 USPATFULL

CN Glycine, N-(3-fluoro-4-pyridinyl)-N-(3-methyl-1H-indol-1-yl)-, ethyl ester
(9CI) (CA INDEX NAME)




RN 145660-05-5 USPATFULL

CN Ethanol, 2-[(3-fluoro-4-pyridinyl)(3-methyl-1H-indol-1-yl)amino]- (9CI)
(CA INDEX NAME)




RN 145660-06-6 USPATFULL

CN Ethanol, 2-[(3-fluoro-4-pyridinyl)[5-(phenylmethoxy)-1H-indol-1-yl]amino]-
(9CI) (CA INDEX NAME)




RN 145660-07-7 USPATFULL

CN Glycine, N-(3-fluoro-4-pyridinyl)-N-1H-indol-1-yl-, ethyl ester (9CI) (CA
INDEX NAME)



RN 145660-08-8 USPATFULL

CN Ethanol, 2-[(3-fluoro-4-pyridinyl)-1H-indol-1-ylamino]- (9CI) (CA INDEX
NAME)




IT 145660-09-9 145660-10-2

(reactant for dihydro(indolyl)pyridooxazine (antidepressant and memory enhancer))


RN 145660-09-9 USPATFULL

CN Glycine, N-(3-fluoro-4-pyridinyl)-N-[5-(phenylmethoxy)-1H-indol-1-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 145660-10-2 USPATFULL

CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)- (9CI) (CA INDEX NAME)



L9 ANSWER 47 OF 51 USPATFULL

ACCESSION NUMBER: 93:42057 USPATFULL

TITLE: 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof

INVENTOR(S): Effland, Richard C., Bridgewater, NJ, United States
Davis, Larry, Sergeantsville, NJ, United States
Olsen, Gordon E., Somerset, NJ, United States

PATENT ASSIGNEE(S): Hoechst-Roussel Pharmaceuticals Inc., Somerville, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5214038		19930525
APPLICATION INFO.:	US 1991-684758		19910415 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Shah, Mukund J.		
ASSISTANT EXAMINER:	Datlow, Philip I.		
LEGAL REPRESENTATIVE:	Korsen, Elliott		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1,11,12		
LINE COUNT:	677		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to compounds of the formula ##STR1##

wherein

R.sub.1 is hydrogen or loweralkyl;

R.sub.2 is hydrogen or loweralkyl; and

R.sub.3 is hydrogen, loweralkyl, halogen, nitro, amino, hydroxy, loweralkoxy, benzyloxy or ##STR2##

where R.sub.4 is hydrogen or loweralkyl and R.sub.5 is loweralkyl, aryl or arylloweralkyl, or R.sub.4 and R.sub.5 taken together form a heterocyclic ring selected from the group consisting of ##STR3##

wherein

R.sub.6 is hydrogen, loweralkyl, aryl or arylloweralkyl or a pharmaceutically acceptable acid addition salt thereof.

The compounds of this invention are useful for alleviating depression and various memory dysfunctions characterized by a cholinergic or adrenergic deficit, such as Alzheimer's Disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 119257-43-1P 145660-04-4P 145660-05-5P

145660-06-6P 145660-07-7P 145660-08-8P

(prepn. of, as intermediate for dihydro(indolyl)pyridooxazine (antidepressant and memory enhancer))


RN 119257-43-1 USPATFULL

CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 145660-04-4 USPATFULL

CN Glycine, N-(3-fluoro-4-pyridinyl)-N-(3-methyl-1H-indol-1-yl)-, ethyl ester
(9CI) (CA INDEX NAME)




RN 145660-05-5 USPATFULL

CN Ethanol, 2-[(3-fluoro-4-pyridinyl)(3-methyl-1H-indol-1-yl)amino]- (9CI)
(CA INDEX NAME)




RN 145660-06-6 USPATFULL

CN Ethanol, 2-[(3-fluoro-4-pyridinyl)[5-(phenylmethoxy)-1H-indol-1-yl]amino]-
(9CI) (CA INDEX NAME)




RN 145660-07-7 USPATFULL

CN Glycine, N-(3-fluoro-4-pyridinyl)-N-1H-indol-1-yl-, ethyl ester (9CI) (CA
INDEX NAME)



RN 145660-08-8 USPATFULL

CN Ethanol, 2-[(3-fluoro-4-pyridinyl)-1H-indol-1-ylamino]- (9CI) (CA INDEX NAME)




IT 145660-09-9 145660-10-2

(reactant for dihydro(indolyl)pyridooxazine (antidepressant and memory enhancer))


RN 145660-09-9 USPATFULL

CN Glycine, N-(3-fluoro-4-pyridinyl)-N-[5-(phenylmethoxy)-1H-indol-1-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 145660-10-2 USPATFULL

CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)- (9CI) (CA INDEX NAME)



L9 ANSWER 48 OF 51 USPATFULL

ACCESSION NUMBER: 92:27536 USPATFULL

TITLE: 1-(substituted pyridinylamino)-1H-indol-5-yl
substituted carbamatesINVENTOR(S): Effland, Richard C., Bridgewater, NJ, United States
Davis, Larry, Sergeantsville, NJ, United States
Olsen, Gordon E., Somerset, NJ, United States
Klein, Joseph T., Bridgewater, NJ, United States
Wettlaufer, David G., Phillipsburg, NJ, United States
Nemoto, Peter A., Bound Brook, NJ, United States
PATENT ASSIGNEE(S): Hoechst-Roussel Pharmaceuticals Inc., Somerville, NJ,
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5102891		19920407
APPLICATION INFO.:	US 1990-555890		19900723 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Ivy, C. Warren		
ASSISTANT EXAMINER:	Turnipseed, James H.		
LEGAL REPRESENTATIVE:	Ikeda, Tatsuya		
NUMBER OF CLAIMS:	42		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1347		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There are disclosed various compounds of the formula below, ##STR1##
where n is 0 or 1;X is hydrogen, halogen, nitro, amino, trifluoromethyl, loweralkyl, or
loweralkoxy;Y is hydrogen, halogen, nitro, amino, trifluoromethyl, loweralkyl, or
loweralkoxy;R.sub.1 is hydrogen, loweralkyl, arylloweralkyl, loweralkenyl,
loweralkynyl, loweralkanoyl, arylloweralkanoyl, heteroarylloweralkyl or
heteroarylloweralkanoyl;

R.sub.2 is hydrogen, loweralkyl, formyl or cyano;

R.sub.3 is hydrogen or loweralkyl;

R.sub.4 is loweralkyl, arylloweralkyl, cycloalkyl, aryl or heteroaryl;
or alternatively, --NR.sub.3 R.sub.4 taken together constitutes ##STR2##
R.sub.5 being hydrogen, loweralkyl, aryl, arylloweralkyl, heteroaryl or
heteroarylloweralkyl,

which compounds are useful for the treatment of various memory dysfunctions characterized by a cholinergic deficit such as Alzheimer's disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 141287-48-1P 141287-49-2P 141287-50-5P

141287-51-6P 141287-52-7P 141287-53-8P

141287-54-9P 141287-55-0P 141287-56-1P

141287-57-2P 141287-58-3P 141287-59-4P

141287-60-7P 141287-61-8P 141287-62-9P

141287-64-1P 141287-65-2P 141287-66-3P


141287-67-4P 141287-68-5P 141287-69-6P

141287-70-9P 141287-71-0P 141287-72-1P

(prepn. and reaction of, in prepn. of acetylcholinesterase inhibitors)


RN 141287-48-1 USPATFULL

CN 1H-Indol-1-amine, 5-(phenylmethoxy)-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 141287-49-2 USPATFULL

CN 1H-Indol-5-ol, 1-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 141287-50-5 USPATFULL

CN 1H-Indol-1-amine, N-methyl-5-(phenylmethoxy)-N-4-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 141287-51-6 USPATFULL
CN 1H-Indol-1-amine, N-methyl-5-(phenylmethoxy)-N-4-pyridinyl- (9CI) (CA
INDEX NAME)



RN 141287-52-7 USPATFULL
CN 1H-Indol-5-ol, 1-(methyl-4-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 141287-53-8 USPATFULL
CN 1H-Indol-1-amine, 5-(phenylmethoxy)-N-propyl-N-4-pyridinyl- (9CI) (CA
INDEX NAME)




RN 141287-54-9 USPATFULL

CN 1H-Indol-1-amine, 5-(phenylmethoxy)-N-propyl-N-4-pyridinyl-,
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 141287-53-8

CMF C23 H23 N3 O




CM 2

CRN 110-16-7

CMF C4 H4 O4


CDES 2:Z

Double bond geometry as shown.




RN 141287-55-0 USPATFULL

CN 1H-Indol-5-ol, 1-(propyl-4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 141287-56-1 USPATFULL

CN Carbamic acid, cyclohexyl-, 1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester (9CI) (CA INDEX NAME)




RN 141287-57-2 USPATFULL

CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 141287-58-3 USPATFULL

CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-5-(phenylmethoxy)-N-propyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 141287-59-4 USPATFULL
CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-5-(phenylmethoxy)-N-propyl-
(9CI) (CA INDEX NAME)



RN 141287-60-7 USPATFULL
CN 1H-Indol-5-ol, 1-[(3-fluoro-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 141287-61-8 USPATFULL
CN 1H-Indol-5-ol, 1-[(3-fluoro-4-pyridinyl)propylamino]-, monohydrochloride
(9CI) (CA INDEX NAME)



● HCl


RN 141287-62-9 USPATFULL

CN 1H-Indol-5-ol, 1-[(3-fluoro-4-pyridinyl)propylamino]- (9CI) (CA INDEX NAME)




RN 141287-64-1 USPATFULL

CN 1H-Indol-1-amine, 3-methyl-5-(phenylmethoxy)-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 141287-65-2 USPATFULL

CN 1H-Indol-5-ol, 3-methyl-1-(4-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 141287-66-3 USPATFULL

CN 1H-Indol-1-amine, 3-methyl-5-(phenylmethoxy)-N-propyl-N-4-pyridinyl- (9CI)
(CA INDEX NAME)




RN 141287-67-4 USPATFULL

CN 1H-Indol-1-amine, 3-methyl-5-(phenylmethoxy)-N-propyl-N-4-pyridinyl-,
(2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 141287-66-3

CMF C24 H25 N3 O




CM 2

CRN 110-17-8

CMF C4 H4 O4


CDES 2:E

Double bond geometry as shown.



RN 141287-68-5 USPATFULL

CN 1H-Indol-5-ol, 3-methyl-1-(propyl-4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 141287-69-6 USPATFULL

CN 1H-Indol-5-ol, 3-methyl-1-(propyl-4-pyridinylamino)-, ethanedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 141287-68-5


CMF C17 H19 N3 O




CM 2

CRN 144-62-7


CMF C2 H2 O4




RN 141287-70-9 USPATFULL

CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl-5-(phenylmethoxy)-
(9CI) (CA INDEX NAME)

RN 141287-71-0 USPATFULL

CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl-5-(phenylmethoxy)-N-
propyl- (9CI) (CA INDEX NAME)

RN 141287-72-1 USPATFULL

CN 1H-Indol-5-ol, 1-[(3-fluoro-4-pyridinyl)propylamino]-3-methyl- (9CI) (CA
INDEX NAME)


IT 141287-16-3P 141287-17-4P 141287-18-5P
141287-19-6P 141287-20-9P 141287-21-0P
141287-22-1P 141287-23-2P 141287-24-3P
141287-25-4P 141287-26-5P 141287-27-6P
141287-28-7P 141287-29-8P 141287-30-1P
141287-31-2P 141287-32-3P 141287-33-4P

141287-34-5P 141287-35-6P 141287-36-7P
141287-37-8P 141287-38-9P 141287-39-0P
141287-40-3P 141287-41-4P 141287-42-5P
141287-43-6P 141287-44-7P 141287-45-8P
141287-46-9P 141303-08-4P 141303-09-5P

(prepn. of, as acetylcholinesterase inhibitor)


RN 141287-16-3 USPATFULL

CN 1H-Indol-5-ol, 1-(methyl-4-pyridinylamino)-, methylcarbamate (ester) (9CI)
(CA INDEX NAME)



RN 141287-17-4 USPATFULL


CN Carbamic acid, butyl-, 1-(methyl-4-pyridinylamino)-1H-indol-5-yl ester,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 141287-18-5 USPATFULL

CN Carbamic acid, (phenylmethyl)-, 1-(methyl-4-pyridinylamino)-1H-indol-5-yl
ester (9CI) (CA INDEX NAME)




RN 141287-19-6 USPATFULL

CN 1H-Indol-5-ol, 1-(propyl-4-pyridinylamino)-, methylcarbamate (ester) (9CI)
(CA INDEX NAME)



RN 141287-20-9 USPATFULL


CN Carbamic acid, ethyl-, 1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 141287-21-0 USPATFULL

CN Carbamic acid, propyl-, 1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester
(9CI) (CA INDEX NAME)




RN 141287-22-1 USPATFULL

CN Carbamic acid, (1-methylethyl)-, 1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester (9CI) (CA INDEX NAME)



RN 141287-23-2 USPATFULL


CN Carbamic acid, butyl-, 1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 141287-24-3 USPATFULL

CN Carbamic acid, heptyl-, 1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester (9CI) (CA INDEX NAME)



RN 141287-25-4 USPATFULL


CN Carbamic acid, cyclohexyl-, 1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 141287-26-5 USPATFULL


CN Carbamic acid, (2-phenylethyl)-, 1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 141287-27-6 USPATFULL


CN Carbamic acid, (2-phenylethyl)-, 1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester (9CI) (CA INDEX NAME)



RN 141287-28-7 USPATFULL


CN Carbamic acid, (1-phenylethyl)-, 1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 141287-29-8 USPATFULL

CN Carbamic acid, dimethyl-, 1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester (9CI) (CA INDEX NAME)




RN 141287-30-1 USPATFULL

CN 1-Piperidinecarboxylic acid, 1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester (9CI) (CA INDEX NAME)




RN 141287-31-2 USPATFULL

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-, 1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester (9CI) (CA INDEX NAME)




RN 141287-32-3 USPATFULL

CN 1H-Indol-5-ol, 1-[(3-fluoro-4-pyridinyl)propylamino]-, methylcarbamate (ester) (9CI) (CA INDEX NAME)



RN 141287-33-4 USPATFULL


CN Carbamic acid, butyl-, 1-[(3-fluoro-4-pyridinyl)propylamino]-1H-indol-5-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 141287-34-5 USPATFULL

CN Carbamic acid, butyl-, 1-[(3-fluoro-4-pyridinyl)propylamino]-1H-indol-5-yl ester (9CI) (CA INDEX NAME)



RN 141287-35-6 USPATFULL

CN Carbamic acid, heptyl-, 1-[(3-fluoro-4-pyridinyl)propylamino]-1H-indol-5-yl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 141287-36-7 USPATFULL

CN Carbamic acid, heptyl-, 1-[(3-fluoro-4-pyridinyl)propylamino]-1H-indol-5-


yl ester (9CI) (CA INDEX NAME)



RN 141287-37-8 USPATFULL


CN 1H-Indol-5-ol, 3-methyl-1-(propyl-4-pyridinylamino)-, methylcarbamate
(ester) (9CI) (CA INDEX NAME)

RN 141287-38-9 USPATFULL

CN Carbamic acid, butyl-, 3-methyl-1-(propyl-4-pyridinylamino)-1H-indol-5-yl
ester (9CI) (CA INDEX NAME)


RN 141287-39-0 USPATFULL

CN Carbamic acid, heptyl-, 3-methyl-1-(propyl-4-pyridinylamino)-1H-indol-5-yl
ester (9CI) (CA INDEX NAME)




RN 141287-40-3 USPATFULL

CN Carbamic acid, (phenylmethyl)-, 3-methyl-1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester (9CI) (CA INDEX NAME)




RN 141287-41-4 USPATFULL

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-, 3-methyl-1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester (9CI) (CA INDEX NAME)




RN 141287-42-5 USPATFULL

CN 1H-Indol-5-ol, 1-[(3-fluoro-4-pyridinyl)propylamino]-3-methyl-, methylcarbamate (ester) (9CI) (CA INDEX NAME)




RN 141287-43-6 USPATFULL

CN Carbamic acid, butyl-, 1-[(3-fluoro-4-pyridinyl)propylamino]-3-methyl-1H-indol-5-yl ester (9CI) (CA INDEX NAME)




RN 141287-44-7 USPATFULL

CN Carbamic acid, heptyl-, 1-[(3-fluoro-4-pyridinyl)propylamino]-3-methyl-1H-indol-5-yl ester (9CI) (CA INDEX NAME)




RN 141287-45-8 USPATFULL

CN Carbamic acid, (phenylmethyl)-, 1-[(3-fluoro-4-pyridinyl)propylamino]-3-methyl-1H-indol-5-yl ester (9CI) (CA INDEX NAME)




RN 141287-46-9 USPATFULL

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-, 1-[(3-fluoro-4-pyridinyl)propylamino]-3-methyl-1H-indol-5-yl ester (9CI) (CA INDEX NAME)




RN 141303-08-4 USPATFULL

CN Carbamic acid, (phenylmethyl)-, 1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester (9CI) (CA INDEX NAME)



RN 141303-09-5 USPATFULL

CN Carbamic acid, [(4-chlorophenyl)methyl]-, 1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester (9CI) (CA INDEX NAME)



L9 ANSWER 49 OF 51 USPATFULL

ACCESSION NUMBER: 91:64964 USPATFULL

TITLE: Preparation of N-(pyridinyl)-1H-indol-1-amines

INVENTOR(S): Effland, Richard C., Bridgewater, NJ, United States

Klein, Joseph T., Bridgewater, NJ, United State

Davis, Larry, Sergeantsville, NJ, United States

Olsen, Gordon E., Somerset, NJ, United States

PATENT ASSIGNEE(S): Hoechst-Roussel Pharmaceuticals Inc., Somerville, NJ.

United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5039811		19910813

APPLICATION INFO.: US 1990-571473 19900823 (7)

RELATED APPLN. INFO.: Division of Ser. No. US 1989-405156, filed on 11 Sep 1989, now patented, Pat. No. US 4970218 which is a continuation-in-part of Ser. No. US 1988-171102, filed on 4 Apr 1988, now patented, Pat. No. US 4880822 which is a continuation-in-part of Ser. No. US 1987-42079, filed on 24 Apr 1987, now abandoned

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

PRIMARY EXAMINER: Fan, Jane T.

LEGAL REPRESENTATIVE: Ikeda, Tatsuya

NUMBER OF CLAIMS: 1

EXEMPLARY CLAIM: 1

LINE COUNT: 1694

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There are disclosed compounds of the formula, ##STR1## wherein m, n, p, R, R.sub.1, R.sub.2 and R.sub.3 are as defined in the specification; which compounds are useful for enhancing memory and also as analgesic and antidepressant agents.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 119229-75-3

(alkylation of, in prepn. of pharmaceuticals)

RN 119229-75-3 USPATFULL

CN 1H-Indol-1-amine, 5-methoxy-N-4-pyridinyl- (9CI) (CA INDEX NAME)




IT 119229-42-4

(hydrogenation of, in prepn. of pharmaceuticals)

RN 119229-42-4 USPATFULL

CN 1H-Indol-1-amine, N-(4-nitro-1-oxido-3-pyridinyl)- (9CI) (CA INDEX NAME)




IT 119229-48-0P

(prepn. of, as memory enhancer, antidepressant, and analgesic)

RN 119229-48-0 USPATFULL

CN 1H-Indol-1-amine, 5-chloro-N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



IT 119229-37-7P 119229-38-8P 119229-39-9P

119229-40-2P 119229-41-3P 119229-42-4P

119229-43-5P 119229-44-6P 119229-45-7P

119229-46-8P 119229-47-9P 119229-49-1P

119229-50-4P 119229-51-5P 119229-52-6P

119229-53-7P 119229-54-8P 119229-55-9P

119229-56-0P 119229-57-1P 119229-58-2P

119229-59-3P 119229-60-6P 119229-61-7P


119229-62-8P 119229-63-9P 119229-64-0P

119229-65-1P 119229-66-2P 119229-67-3P
119229-68-4P 119229-69-5P 119257-32-8P
119257-33-9P 119257-34-0P 119257-35-1P
119257-36-2P 119257-37-3P 119257-38-4P
119257-39-5P 119257-40-8P 119257-41-9P
119257-42-0P 119257-43-1P

(prepn. of, for enhancing memory, as analgesic, and antidepressant)


RN 119229-37-7 USPATFULL

CN 1H-Indol-1-amine, 5-methoxy-N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119229-38-8 USPATFULL

CN 1H-Indole-3-carboxaldehyde, 1-(methyl-4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 119229-39-9 USPATFULL

CN 1H-Indole-3-carboxaldehyde, 1-(methyl-4-pyridinylamino)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119229-38-8

CMF C15 H13 N3 O




CM 2

CRN 110-16-7

CMF C4 H4 O4


CDES 2:Z

Double bond geometry as shown.



RN 119229-40-2 USPATFULL

CN 1H-Indole-3-carboxaldehyde, 1-(ethyl-4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 119229-41-3 USPATFULL

CN 1H-Indole-3-carboxaldehyde, 1-(ethyl-4-pyridinylamino)-, (Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119229-40-2

CMF C16 H15 N3 O




CM 2

CRN 110-16-7

CMF C4 H4 O4


CDES 2:Z

Double bond geometry as shown.




RN 119229-42-4 USPATFULL

CN 1H-Indol-1-amine, N-(4-nitro-1-oxido-3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 119229-43-5 USPATFULL

CN 1H-Indol-1-amine, 3-ethenyl-N-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119229-44-6 USPATFULL

CN 1H-Indol-1-amine, 3-ethenyl-N-methyl-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119229-43-5

CMF C16 H15 N3




CM 2

CRN 110-16-7

CMF C4 H4 O4


CDES 2:Z

Double bond geometry as shown.



RN 119229-45-7 USPATFULL


CN 1H-Indol-1-amine, 3-ethyl-N-methyl-N-4-pyridinyl-, monohydrochloride (9CI)
(CA INDEX NAME)



● HCl

RN 119229-46-8 USPATFULL

CN 1H-Indol-1-amine, 5-chloro-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119229-47-9 USPATFULL

CN 1H-Indol-1-amine, 5-chloro-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 119229-46-8


CMF C13 H10 Cl N3



CM 2

CRN 110-16-7
CMF C4 H4 O4
CDES 2:Z


Double bond geometry as shown.



RN 119229-49-1 USPATFULL
CN 1H-Indol-1-amine, 5-chloro-N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 119229-48-0
CMF C16 H16 Cl N3




CM 2

CRN 110-16-7
CMF C4 H4 O4
CDES 2:Z

Double bond geometry as shown.




RN 119229-50-4 USPATFULL
CN 1H-Indol-1-amine, 5-bromo-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119229-51-5 USPATFULL
CN 1H-Indol-1-amine, 5-bromo-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1


CRN 119229-50-4
CMF C13 H10 Br N3




CM 2

CRN 110-16-7
CMF C4 H4 O4
CDES 2:Z

Double bond geometry as shown.




RN 119229-52-6 USPATFULL
CN 1H-Indol-1-amine, 5-bromo-N-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119229-53-7 USPATFULL
CN 1H-Indol-1-amine, 5-bromo-N-methyl-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 119229-52-6
CMF C14 H12 Br N3



CM 2

CRN 110-16-7
CMF C4 H4 O4
CDES 2:Z


Double bond geometry as shown.



```

RN      119229-54-8  USPATFULL
CN      1H-Indol-1-amine, 5-bromo-N-propyl-N-4-pyridinyl- (9CI)  (CA INDEX NAME)


```



RN 119229-55-9 USPATFULL
CN 1H-Indol-1-amine, 5-bromo-N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 119229-54-8
CMF C16 H16 Br N3




CM 2

CRN 110-16-7
CMF C4 H4 O4
CDES 2:Z

Double bond geometry as shown.




RN 119229-56-0 USPATFULL
CN 1H-Indol-1-amine, 5-nitro-N-4-pyridinyl-, monohydrochloride (9CI) (CA
INDEX NAME)



● HCl


RN 119229-57-1 USPATFULL

CN 1H-Indol-1-amine, 5-nitro-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119229-58-2 USPATFULL

CN 1H-Indol-1-amine, N-methyl-5-nitro-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119229-59-3 USPATFULL

CN 1H-Indol-1-amine, N-methyl-5-nitro-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119229-58-2

CMF C14 H12 N4 O2




CM 2

CRN 110-16-7

CMF C4 H4 O4


CDES 2:Z

Double bond geometry as shown.



RN 119229-60-6 USPATFULL

CN 1H-Indol-1-amine, 3-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119229-61-7 USPATFULL

CN 1H-Indol-1-amine, 3-methyl-N-4-pyridinyl-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119229-60-6


CMF C14 H13 N3



CM 2


CRN 144-62-7

CMF C2 H2 O4



RN 119229-62-8 USPATFULL

CN 1H-Indol-1-amine, 3-methyl-N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119229-63-9 USPATFULL

CN 1H-Indol-1-amine, 3-methyl-N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119229-62-8

CMF C17 H19 N3




CM 2

CRN 110-16-7


CMF C4 H4 O4

CDES 2:Z

Double bond geometry as shown.




RN 119229-64-0 USPATFULL

CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl-N-propyl-,
monohydrochloride (9CI) (CA INDEX NAME)

● HCl


RN 119229-65-1 USPATFULL

CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl-N-propyl- (9CI) (CA
INDEX NAME)



RN 119229-66-2 USPATFULL

CN 1H-Indol-1-amine, N-2-propenyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119229-67-3 USPATFULL

CN 1H-Indol-1-amine, N-2-propenyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 119229-66-2

CMF C16 H15 N3




CM 2

CRN 110-16-7


CMF C4 H4 O4

CDES 2:Z

Double bond geometry as shown.




RN 119229-68-4 USPATFULL
CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-N-propyl-, monohydrochloride
(9CI) (CA INDEX NAME)




● HCl


RN 119229-69-5 USPATFULL
CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-N-propyl- (9CI) (CA INDEX
NAME)




RN 119257-32-8 USPATFULL
CN 1H-Indol-1-amine, N-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119257-33-9 USPATFULL
CN 1H-Indol-1-amine, N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119257-34-0 USPATFULL
CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119257-35-1 USPATFULL
CN 1H-Indol-1-amine, 3-ethyl-N-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119257-36-2 USPATFULL
CN 1H-Indol-1-amine, N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA
INDEX NAME)

CM 1


CRN 119257-33-9
CMF C13 H11 N3



CM 2

CRN 110-16-7
CMF C4 H4 O4
CDES 2:Z


Double bond geometry as shown.



RN 119257-37-3 USPATFULL
CN 1H-Indol-1-amine, N-methyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 119257-32-8
CMF C14 H13 N3




CM 2

CRN 110-16-7

CMF C4 H4 O4


CDES 2:Z

Double bond geometry as shown.



RN 119257-38-4 USPATFULL

CN 1H-Indol-1-amine, N-ethyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119257-39-5 USPATFULL

CN 1H-Indol-1-amine, N-ethyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 119257-38-4

CMF C15 H15 N3




CM 2

CRN 110-16-7

CMF C4 H4 O4

CDES 2:Z

Double bond geometry as shown.




RN 119257-40-8 USPATFULL

CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 119257-34-0

CMF C16 H17 N3




CM 2

CRN 110-16-7

CMF C4 H4 O4

CDES 2:Z


Double bond geometry as shown.



RN 119257-41-9 USPATFULL
CN 1H-Indol-1-amine, 5-methoxy-N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 119229-37-7
CMF C17 H19 N3 O




CM 2

CRN 110-16-7
CMF C4 H4 O4
CDES 2:Z


Double bond geometry as shown.



RN 119257-42-0 USPATFULL
CN 3,4-Pyridinediamine, N3-1H-indol-1-yl-, 1-oxide (9CI) (CA INDEX NAME)



RN 119257-43-1 USPATFULL
CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX NAME)



L9 ANSWER 50 OF 51 USPATFULL
ACCESSION NUMBER: 90:87350 USPATFULL
TITLE: N-(pyridinyl)-1H-indol-1-amines
INVENTOR(S): Effland, Richard C., Bridgewater, NJ, United States
Klein, Joseph T., Bridgewater, NJ, United States
Davis, Larry, Sergeantsville, NJ, United States
Olsen, Gordon E., Somerset, NJ, United States
PATENT ASSIGNEE(S): Hoechst-Roussel Pharmaceuticals Inc., Somerville, NJ,
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4970218		19901113
APPLICATION INFO.:	US 1989-405156		19890911 (7)
DISCLAIMER DATE:	20061114		
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1988-171102, filed on 4 Apr 1988, now patented, Pat. No. US 4880822 which is a continuation-in-part of Ser. No. US 1987-42079, filed on 24 Apr 1987, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Fan, Jane T.		
LEGAL REPRESENTATIVE:	Ikeda, Tatsuya		
NUMBER OF CLAIMS:	91		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1940		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB There are disclosed compounds of the formula, ##STR1## where m, n, p, R, R.sub.1, R.sub.2 and R.sub.3 are as defined in the specification; which compounds are useful for enhancing memory and also as analgesic and antidepressant agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 119229-75-3

(alkylation of, in prepn. of pharmaceuticals)

RN 119229-75-3 USPATFULL
CN 1H-Indol-1-amine, 5-methoxy-N-4-pyridinyl- (9CI) (CA INDEX NAME)




IT 119229-42-4

(hydrogenation of, in prepn. of pharmaceuticals)

RN 119229-42-4 USPATFULL

CN 1H-Indol-1-amine, N-(4-nitro-1-oxido-3-pyridinyl)- (9CI) (CA INDEX NAME)




IT 119229-48-0P

(prepn. of, as memory enhancer, antidepressant, and analgesic)

RN 119229-48-0 USPATFULL

CN 1H-Indol-1-amine, 5-chloro-N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



IT 119229-37-7P 119229-38-8P 119229-39-9P

119229-40-2P 119229-41-3P 119229-42-4P

119229-43-5P 119229-44-6P 119229-45-7P

119229-46-8P 119229-47-9P 119229-49-1P

119229-50-4P 119229-51-5P 119229-52-6P

119229-53-7P 119229-54-8P 119229-55-9P

119229-56-0P 119229-57-1P 119229-58-2P

119229-59-3P 119229-60-6P 119229-61-7P


119229-62-8P 119229-63-9P 119229-64-0P

119229-65-1P 119229-66-2P 119229-67-3P
119229-68-4P 119229-69-5P 119257-32-8P
119257-33-9P 119257-34-0P 119257-35-1P
119257-36-2P 119257-37-3P 119257-38-4P
119257-39-5P 119257-40-8P 119257-41-9P
119257-42-0P 119257-43-1P

(prepn. of, for enhancing memory, as analgesic, and antidepressant)


RN 119229-37-7 USPATFULL

CN 1H-Indol-1-amine, 5-methoxy-N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119229-38-8 USPATFULL

CN 1H-Indole-3-carboxaldehyde, 1-(methyl-4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 119229-39-9 USPATFULL

CN 1H-Indole-3-carboxaldehyde, 1-(methyl-4-pyridinylamino)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119229-38-8

CMF C15 H13 N3 O




CM 2

CRN 110-16-7

CMF C4 H4 O4


CDES 2:Z

Double bond geometry as shown.



RN 119229-40-2 USPATFULL

CN 1H-Indole-3-carboxaldehyde, 1-(ethyl-4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 119229-41-3 USPATFULL

CN 1H-Indole-3-carboxaldehyde, 1-(ethyl-4-pyridinylamino)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119229-40-2

CMF C16 H15 N3 O




CM 2

CRN 110-16-7

CMF C4 H4 O4


CDES 2:Z

Double bond geometry as shown.




RN 119229-42-4 USPATFULL

CN 1H-Indol-1-amine, N-(4-nitro-1-oxido-3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 119229-43-5 USPATFULL

CN 1H-Indol-1-amine, 3-ethenyl-N-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119229-44-6 USPATFULL

CN 1H-Indol-1-amine, 3-ethenyl-N-methyl-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119229-43-5

CMF C16 H15 N3




CM 2

CRN 110-16-7

CMF C4 H4 O4


CDES 2:Z

Double bond geometry as shown.



RN 119229-45-7 USPATFULL


CN 1H-Indol-1-amine, 3-ethyl-N-methyl-N-4-pyridinyl-, monohydrochloride (9CI)
(CA INDEX NAME)



● HCl

RN 119229-46-8 USPATFULL

CN 1H-Indol-1-amine, 5-chloro-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119229-47-9 USPATFULL

CN 1H-Indol-1-amine, 5-chloro-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 119229-46-8


CMF C13 H10 Cl N3



CM 2

CRN 110-16-7
CMF C4 H4 O4
CDES 2:Z


Double bond geometry as shown.



RN 119229-49-1 USPATFULL
CN 1H-Indol-1-amine, 5-chloro-N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 119229-48-0
CMF C16 H16 Cl N3




CM 2

CRN 110-16-7
CMF C4 H4 O4
CDES 2:Z

Double bond geometry as shown.




RN 119229-50-4 USPATFULL
CN 1H-Indol-1-amine, 5-bromo-N-4-pyridinyl-, (9CI) (CA INDEX NAME)



RN 119229-51-5 USPATFULL
CN 1H-Indol-1-amine, 5-bromo-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1


CRN 119229-50-4
CMF C13 H10 Br N3




CM 2

CRN 110-16-7
CMF C4 H4 O4
CDES 2:Z

Double bond geometry as shown.




RN 119229-52-6 USPATFULL
CN 1H-Indol-1-amine, 5-bromo-N-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119229-53-7 USPATFULL
CN 1H-Indol-1-amine, 5-bromo-N-methyl-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 119229-52-6
CMF C14 H12 Br N3




CM 2

CRN 110-16-7
CMF C4 H4 O4
CDES 2:Z

Double bond geometry as shown.




RN 119229-54-8 USPATFULL
CN 1H-Indol-1-amine, 5-bromo-N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119229-55-9 USPATFULL
CN 1H-Indol-1-amine, 5-bromo-N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 119229-54-8
CMF C16 H16 Br N3




CM 2

CRN 110-16-7
CMF C4 H4 O4
CDES 2:Z

Double bond geometry as shown.




RN 119229-56-0 USPATFULL
CN 1H-Indol-1-amine, 5-nitro-N-4-pyridinyl-, monohydrochloride (9CI) (CA
INDEX NAME)




● HCl

RN 119229-57-1 USPATFULL
CN 1H-Indol-1-amine, 5-nitro-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119229-58-2 USPATFULL
CN 1H-Indol-1-amine, N-methyl-5-nitro-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119229-59-3 USPATFULL
CN 1H-Indol-1-amine, N-methyl-5-nitro-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 119229-58-2
CMF C14 H12 N4 O2




CM 2

CRN 110-16-7
CMF C4 H4 O4
CDES 2:Z

Double bond geometry as shown.




RN 119229-60-6 USPATFULL
CN 1H-Indol-1-amine, 3-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119229-61-7 USPATFULL
CN 1H-Indol-1-amine, 3-methyl-N-4-pyridinyl-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 119229-60-6
CMF C14 H13 N3



CM 2


CRN 144-62-7

CMF C2 H2 O4



RN 119229-62-8 USPATFULL

CN 1H-Indol-1-amine, 3-methyl-N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119229-63-9 USPATFULL

CN 1H-Indol-1-amine, 3-methyl-N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119229-62-8

CMF C17 H19 N3




CM 2

CRN 110-16-7


CMF C4 H4 O4

CDES 2:Z

Double bond geometry as shown.




RN 119229-64-0 USPATFULL

CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl-N-propyl-,
monohydrochloride (9CI) (CA INDEX NAME)

● HCl


RN 119229-65-1 USPATFULL

CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl-N-propyl- (9CI) (CA
INDEX NAME)



RN 119229-66-2 USPATFULL

CN 1H-Indol-1-amine, N-2-propenyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119229-67-3 USPATFULL

CN 1H-Indol-1-amine, N-2-propenyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 119229-66-2

CMF C16 H15 N3




CM 2

CRN 110-16-7


CMF C4 H4 O4

CDES 2:Z

Double bond geometry as shown.




RN 119229-68-4 USPATFULL
CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-N-propyl-, monohydrochloride
(9CI) (CA INDEX NAME)




● HCl

RN 119229-69-5 USPATFULL
CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-N-propyl- (9CI) (CA INDEX
NAME)




RN 119257-32-8 USPATFULL
CN 1H-Indol-1-amine, N-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119257-33-9 USPATFULL

CN 1H-Indol-1-amine, N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119257-34-0 USPATFULL

CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119257-35-1 USPATFULL


CN 1H-Indol-1-amine, 3-ethyl-N-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119257-36-2 USPATFULL
CN 1H-Indol-1-amine, N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA
INDEX NAME)

CM 1


CRN 119257-33-9
CMF C13 H11 N3



CM 2

CRN 110-16-7
CMF C4 H4 O4
CDES 2:Z


Double bond geometry as shown.



RN 119257-37-3 USPATFULL
CN 1H-Indol-1-amine, N-methyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 119257-32-8
CMF C14 H13 N3




CM 2

CRN 110-16-7

CMF C4 H4 O4


CDES 2:Z

Double bond geometry as shown.



RN 119257-38-4 USPATFULL

CN 1H-Indol-1-amine, N-ethyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119257-39-5 USPATFULL

CN 1H-Indol-1-amine, N-ethyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 119257-38-4

CMF C15 H15 N3




CM 2

CRN 110-16-7

CMF C4 H4 O4

CDES 2:Z

Double bond geometry as shown.




RN 119257-40-8 USPATFULL

CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 119257-34-0

CMF C16 H17 N3




CM 2

CRN 110-16-7

CMF C4 H4 O4

CDES 2:Z

Double bond geometry as shown.




RN 119257-41-9 USPATFULL

CN 1H-Indol-1-amine, 5-methoxy-N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119229-37-7

CMF C17 H19 N3 O




CM 2

CRN 110-16-7

CMF C4 H4 O4


CDES 2:Z

Double bond geometry as shown.




RN 119257-42-0 USPATFULL

CN 3,4-Pyridinediamine, N3-1H-indol-1-yl-, 1-oxide (9CI) (CA INDEX NAME)



RN 119257-43-1 USPATFULL
CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX NAME)



L9 ANSWER 51 OF 51 USPATFULL
ACCESSION NUMBER: 89:92528 USPATFULL
TITLE: N-(pyridinyl)-1H-indol-1-amines
INVENTOR(S): Effland, Richard C., Bridgewater, NJ, United States
Klein, Joseph T., Bridgewater, NJ, United States
PATENT ASSIGNEE(S): Hoechst-Roussel Pharmaceuticals, Inc., Somerville, NJ,
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4880822		19891114
APPLICATION INFO.:	US 1988-171102		19880404 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1987-42079, filed on 24 Apr 1987, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Fan, Jane T.		
LEGAL REPRESENTATIVE:	Ikeda, Tatsuya		
NUMBER OF CLAIMS:	54		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1215		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB There are disclosed compounds of the formula ##STR1## where m, n, p, R, R.sub.1, R.sub.2 and R.sub.3 are as defined in the specification which compounds are useful for enhancing memory and also as analgesic and antidepressant agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 119229-75-3

(alkylation of, in prepn. of pharmaceuticals)

RN 119229-75-3 USPATFULL
CN 1H-Indol-1-amine, 5-methoxy-N-4-pyridinyl- (9CI) (CA INDEX NAME)




IT 119229-42-4

(hydrogenation of, in prepn. of pharmaceuticals)

RN 119229-42-4 USPATFULL

CN 1H-Indol-1-amine, N-(4-nitro-1-oxido-3-pyridinyl)- (9CI) (CA INDEX NAME)




IT 119229-48-0P

(prepn. of, as memory enhancer, antidepressant, and analgesic)

RN 119229-48-0 USPATFULL

CN 1H-Indol-1-amine, 5-chloro-N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




IT 119229-37-7P 119229-38-8P 119229-39-9P
119229-40-2P 119229-41-3P 119229-42-4P
119229-43-5P 119229-44-6P 119229-45-7P
119229-46-8P 119229-47-9P 119229-49-1P
119229-50-4P 119229-51-5P 119229-52-6P
119229-53-7P 119229-54-8P 119229-55-9P
119229-56-0P 119229-57-1P 119229-58-2P
119229-59-3P 119229-60-6P 119229-61-7P
119229-62-8P 119229-63-9P 119229-64-0P

119229-65-1P 119229-66-2P 119229-67-3P
119229-68-4P 119229-69-5P 119257-32-8P
119257-33-9P 119257-34-0P 119257-35-1P
119257-36-2P 119257-37-3P 119257-38-4P
119257-39-5P 119257-40-8P 119257-41-9P
119257-42-0P 119257-43-1P

(prepn. of, for enhancing memory, as analgesic, and antidepressant)


RN 119229-37-7 USPATFULL

CN 1H-Indol-1-amine, 5-methoxy-N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119229-38-8 USPATFULL

CN 1H-Indole-3-carboxaldehyde, 1-(methyl-4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 119229-39-9 USPATFULL

CN 1H-Indole-3-carboxaldehyde, 1-(methyl-4-pyridinylamino)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119229-38-8

CMF C15 H13 N3 O




CM 2

CRN 110-16-7

CMF C4 H4 O4


CDES 2:Z

Double bond geometry as shown.



RN 119229-40-2 USPATFULL

CN 1H-Indole-3-carboxaldehyde, 1-(ethyl-4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 119229-41-3 USPATFULL

CN 1H-Indole-3-carboxaldehyde, 1-(ethyl-4-pyridinylamino)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119229-40-2

CMF C16 H15 N3 O




CM 2

CRN 110-16-7

CMF C4 H4 O4


CDES 2:Z

Double bond geometry as shown.




RN 119229-42-4 USPATFULL

CN 1H-Indol-1-amine, N-(4-nitro-1-oxido-3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 119229-43-5 USPATFULL


CN 1H-Indol-1-amine, 3-ethenyl-N-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119229-44-6 USPATFULL
CN 1H-Indol-1-amine, 3-ethenyl-N-methyl-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 119229-43-5
CMF C16 H15 N3




CM 2

CRN 110-16-7
CMF C4 H4 O4
CDES 2:Z

Double bond geometry as shown.




RN 119229-45-7 USPATFULL
CN 1H-Indol-1-amine, 3-ethyl-N-methyl-N-4-pyridinyl-, monohydrochloride (9CI)
(CA INDEX NAME)



● HCl

RN 119229-46-8 USPATFULL

CN 1H-Indol-1-amine, 5-chloro-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119229-47-9 USPATFULL

CN 1H-Indol-1-amine, 5-chloro-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 119229-46-8


CMF C13 H10 Cl N3



CM 2

CRN 110-16-7
CMF C4 H4 O4
CDES 2:Z


Double bond geometry as shown.



RN 119229-49-1 USPATFULL
CN 1H-Indol-1-amine, 5-chloro-N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 119229-48-0
CMF C16 H16 Cl N3




CM 2

CRN 110-16-7
CMF C4 H4 O4
CDES 2:Z

Double bond geometry as shown.




RN 119229-50-4 USPATFULL
CN 1H-Indol-1-amine, 5-bromo-N-4-pyridinyl-, (9CI) (CA INDEX NAME)



RN 119229-51-5 USPATFULL
CN 1H-Indol-1-amine, 5-bromo-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1


CRN 119229-50-4
CMF C13 H10 Br N3




CM 2

CRN 110-16-7
CMF C4 H4 O4
CDES 2:Z

Double bond geometry as shown.




RN 119229-52-6 USPATFULL
CN 1H-Indol-1-amine, 5-bromo-N-methyl-N-4-pyridinyl-, (9CI) (CA INDEX NAME)



RN 119229-53-7 USPATFULL
CN 1H-Indol-1-amine, 5-bromo-N-methyl-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 119229-52-6
CMF C14 H12 Br N3




CM 2

CRN 110-16-7
CMF C4 H4 O4
CDES 2:Z

Double bond geometry as shown.




RN 119229-54-8 USPATFULL
CN 1H-Indol-1-amine, 5-bromo-N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119229-55-9 USPATFULL
CN 1H-Indol-1-amine, 5-bromo-N-propyl-N-(4-pyridinyl)-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 119229-54-8
CMF C16 H16 Br N3




CM 2

CRN 110-16-7
CMF C4 H4 O4
CDES 2:Z

Double bond geometry as shown.




RN 119229-56-0 USPATFULL
CN 1H-Indol-1-amine, 5-nitro-N-(4-pyridinyl)-, monohydrochloride (9CI) (CA
INDEX NAME)




● HCl

RN 119229-57-1 USPATFULL
CN 1H-Indol-1-amine, 5-nitro-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119229-58-2 USPATFULL
CN 1H-Indol-1-amine, N-methyl-5-nitro-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119229-59-3 USPATFULL
CN 1H-Indol-1-amine, N-methyl-5-nitro-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119229-58-2
CMF C14 H12 N4 O2




CM 2

CRN 110-16-7

CMF C4 H4 O4


CDES 2:Z

Double bond geometry as shown.



RN 119229-60-6 USPATFULL

CN 1H-Indol-1-amine, 3-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119229-61-7 USPATFULL

CN 1H-Indol-1-amine, 3-methyl-N-4-pyridinyl-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119229-60-6


CMF C14 H13 N3



CM 2


CRN 144-62-7

CMF C2 H2 O4



RN 119229-62-8 USPATFULL

CN 1H-Indol-1-amine, 3-methyl-N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119229-63-9 USPATFULL

CN 1H-Indol-1-amine, 3-methyl-N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119229-62-8

CMF C17 H19 N3




CM 2

CRN 1:10-16-7


CMF C4 H4 O4

CDES 2:Z

Double bond geometry as shown.




RN 119229-64-0 USPATFULL

CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl-N-propyl-,
monohydrochloride (9CI) (CA INDEX NAME)

● HCl


RN 119229-65-1 USPATFULL

CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl-N-propyl- (9CI) (CA
INDEX NAME)



RN 119229-66-2 USPATFULL

CN 1H-Indol-1-amine, N-2-propenyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119229-67-3 USPATFULL

CN 1H-Indol-1-amine, N-2-propenyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 119229-66-2

CMF C16 H15 N3




CM 2

CRN 110-16-7

CMF C4 H4 O4


CDES 2:Z

Double bond geometry as shown.



RN 119229-68-4 USPATFULL


CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-N-propyl-, monohydrochloride
(9CI) (CA INDEX NAME)



● HCl


RN 119229-69-5 USPATFULL

CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-N-propyl- (9CI) (CA INDEX
NAME)




RN 119257-32-8 USPATFULL

CN 1H-Indol-1-amine, N-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119257-33-9 USPATFULL

CN 1H-Indol-1-amine, N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119257-34-0 USPATFULL

CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 119257-35-1 USPATFULL

CN 1H-Indol-1-amine, 3-ethyl-N-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119257-36-2 USPATFULL

CN 1H-Indol-1-amine, N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119257-33-9

CMF C13 H11 N3




CM 2

CRN 110-16-7

CMF C4 H4 O4

CDES 2:Z

Double bond geometry as shown.




RN 119257-37-3 USPATFULL

CN 1H-Indol-1-amine, N-methyl-N-(4-pyridinyl)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119257-32-8

CMF C14 H13 N3




CM 2

CRN 110-16-7

CMF C4 H4 O4


CDES 2:Z

Double bond geometry as shown.



RN 119257-38-4 USPATFULL

CN 1H-Indol-1-amine, N-ethyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 119257-39-5 USPATFULL

CN 1H-Indol-1-amine, N-ethyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 119257-38-4

CMF C15 H15 N3




CM 2

CRN 110-16-7

CMF C4 H4 O4

CDES 2:Z

Double bond geometry as shown.




RN 119257-40-8 USPATFULL

CN 1H-Indol-1-amine, N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 119257-34-0

CMF C16 H17 N3




CM 2

CRN 110-16-7

CMF C4 H4 O4

CDES 2:Z

Double bond geometry as shown.




RN 119257-41-9 USPATFULL

CN 1H-Indol-1-amine, 5-methoxy-N-propyl-N-4-pyridinyl-, (2Z)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119229-37-7

CMF C17 H19 N3 O




CM 2

CRN 110-16-7

CMF C4 H4 O4


CDES 2:Z

Double bond geometry as shown.




RN 119257-42-0 USPATFULL

CN 3,4-Pyridinediamine, N3-1H-indol-1-yl-, 1-oxide (9CI) (CA INDEX NAME)



RN 119257-43-1 USPATFULL
CN 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl- (9CI) (CA INDEX NAME)



FILE 'CAOLD' ENTERED AT 10:34:40 ON 06 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

L1 STR
L3 225 SEA FILE=REGISTRY SSS FUL L1
L8 0 SEA FILE=CAOLD ABB=ON L3

FILE 'HOME' ENTERED AT 10:34:40 ON 06 MAY 2003

This Page Blank (uspto)